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Summary 
1 Summary 
Millions of people are highly exposed to arsenic, especially via contaminated drinking 
water. Once entered the human body, arsenic underlies (hepatic) metabolism leading 
to various methylated species, until it is either accumulated in skin and other tissues, 
or finally excreted via the renal pathway. Common health consequences are, among 
others, hyperkeratosis, vascular diseases, and cancer. Especially environmentally 
relevant doses of arsenic exhibit a highly carcinogenic potential. Arsenic-induced 
lung cancer, as well as skin, kidney, and bladder cancer have been reported. Bladder 
cancer in general was reported to occur very frequently with a high recurrence rate; it 
is in fifth place of the most commonly diagnosed cancer diseases and on second 
place of those observed in the urogenital tract (Zimbardi et al., 2012). Thus, this 
study was conducted to focus on the mechanisms of arsenic-induced bladder cancer. 
Since carcinogenesis is a very complex process with highly species- and tissue-
specific mechanisms, an in vitro test system was selected to assay molecular 
mechanisms during arsenic-induced bladder carcinognesis, taking advantage of an 
isolated cellular system instead of the complexicity of a whole living organism. 
The aim of the study was to give an overview over some of the most relevant key 
events during arsenic-induced carcinogenesis, occurring as a consequence of short-
term and chronic low-dose exposure by consolidating interdisciplinary research. To 
better understand the underlying mechanisms of arsenic carcinogenicity, studies 
were carried out to correlate arsenic metabolism and genotypic effects with 
epigenetic modifications and phenotypical alterations under chronic exposure 
conditions up to 90 weeks. Hence, it was important to detect and analyse intracellular 
arsenic species and their metabolic products. Therefore, the cellular uptake of 
arsenic species in non-methylating human urothelial cells (T24) in comparison to 
methylating human hepatic cells (HepG2) was investigated, and the intracellularly 
detected arsenic was speciated and quantified. Arsenic-induced genotoxic effects in 
T24 cells were measured by means of the Alkaline Comet Assay, and the malignant 
transformation after chronic arsenic treatment up to 90 weeks was assayed using the 
in vitro Mammalian Cell Transformation Assay, the Colony Formation Assay, and the 
Migration and Invasion Assay. MicroRNA analysis and examination of altered DNA 
methylation patterns were carried out to determine the arsenic-induced modulation of 
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epigenetic regulation systems. Moreover, COX-2 protein, which is frequently reported 
to be increased in malignant tissues and therefore considerd to be an important 
molecula marker, was analysed. Since the various arsenic species emerging from the 
hepatic biotransformation of arsenic exhibit distinctly different toxicity, this study 
focussed especially on effects induced by the methylated metabolite 
monomethylarsonous acid (MMA(III)), which was recently shown to be one of the 
most cyto-and genotoxic metabolites. The present study aims to enhance the 
understanding of arsenic-induced toxicity and carcinogenesis in the urinary bladder 
epithelium. 
The experiments conducted within the present study revealed a rapid cellular uptake 
of MMA(III) in both T24 and HepG2 cells, followed by subsequent conjugation to 
proteins and other cellular structures. While in HepG2 cells MMA(III) was further 
methylated to dimethylated arsenic due to the metabolic capacity of these cells, no 
such biotransformation was observed in T24 cells. Nevertheless, in both cellular 
systems oxidation to pentavalent species was observed, leading to the assumption 
that autophagy of affected cellular structures by utilising oxidative processes 
occurred. This was further confirmed by the presence of unconjugated trivalent 
arsenic species, but to a minor degree. 
Genotoxicity of the trivalent arsenic species, as well as arsenate was detected 
already after 30 min of exposure. Longer exposure durations revealed cytotoxicity, 
overlapping genotoxic effects. Genotoxicity was observed to be not only dependent 
on the oxidation state, but also on the methylation state, as genotoxicity of trivalent 
arsenic species increased with the number of methyl groups. As a consequence and 
due to their biomethylation capacity, HepG2 cells appeared to be more sensitive 
towards the genotoxic potential of arsenic species when compared to T24 cells. 
Additionally, the study revealed that primary cells such as human urothelial epithelial 
cells (HUEPC) are more susceptible to arsenic-induced genotoxicity than permanent 
cell lines. 
Furthermore, to investigate whether MMA(III) is only a genotoxic carcinogen or if it 
also exhibits non-genotoxic molecular changes, the epigenetic effects on T24 cells 
after chronic low-dose treatment were investigated. Key events such as modification 
of DNA methylation and miRNA profiles, as well as COX-2 protein activation were 
analysed. The experiment revealed that in T24 cells, under the chosen test 
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conditions, exposure to MMA(III) led to the alteration of miR-15a, -19a, 19b, 30a-3p, -
126, -128a, -139-5p, -146a, -200a, and -429; which are known to correlate with the 
occurrence of cancer diseases (Gregory et al., 2008; Hurst et al., 2009; Ichimi et al., 
2009; Lin te al., 2009). This indicates that altered miRNA profiles might play a pivotal 
role in MMA(III)-induced further malignant transformation of T24 cells, which was 
phenotypically verified in experiments described below. In contrast, altered DNA 
methylation was only observed for C1QTNF6 and CDH1. Nevertheless, since T24 
cells are transitional cell carcinoma cells of the urinary bladder, they show a distinctly 
altered DNA methylation background. Hence, it cannot conclusively be excluded that 
those changes overlay the effects caused by MMA(III) exposure. 
Elevated COX-2 protein levels were observed throughout the chronic low-dose 
exposure to MMA(III). It can be assumed from the results that the regulation of the 
COX-2 protein is not accomplished by the amount of mRNA, but presumably by the 
interaction of COX-2 mRNA with miR-26a and -26b. Further experiments are 
necessary to confirm this and to unveil the respective mechanism. 
Among the molecular effects of chronic low-dose exposure to MMA(III) also the 
development of altered phenotypic appearance was investigated. The determination 
of the in vitro Mammalian Cell Transformation Test, the Colony Formation Assay, and 
the Migration and Invasion Assay revealed further malignant transformatioin of T24 
cells after long-term exposure to MMA(III). In addition to morphological changes, the 
loss of contact inhibition and anchorage dependent growth were observed. Moreover, 
T24 cells chronically treated with MMA(III) developed the ability of migration and 
invasion, which can be concluded to be the basis for metastasizing properties in vivo. 
In summary, MMA(III) was shown to be rapidly taken up and to exhibit both 
genotoxicity, as well as tumour progression (i.e. non-genotoxic carcinogenic activities 
such as COX-2 protein activation, altered miRNA expression profiles, and altered 
DNA methylation), which resulted in a further malignant transformation of T24 
carcinoma cells after chronic low-dose exposure up to 90 weeks. This study indicated 
various molecular modes of action of MMA(III) in vitro, which only could be analysed 
and correlated to each other by consolidating interdisciplinary research. 
Nevertheless, the results must be further confirmed in vivo to be conclusively 
correlated to the MMA(III)-induced development of bladder cancer. 
3 
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2 Introduction 
2.1 The chemistry of arsenic 
Arsenic occasionally occurs elemental as “Scherbenkobalt”, but it can generally be 
found in anionic or cationic bindings. Arsenic presents its non-metallic character in 
the anionic compounds (metal-arsenides, e.g. “Arsenkies” FeAs2 · As2S3) and its 
metallic character in the cationic compounds (arsenic sulphides, e.g. “Auripigment” 
As2S3, or arsenic oxides, e.g. “Arsenolithe” As2O3). Arsenic can be isolated by 
heating “Arsenkies” in the absence of air, whereas arsenic is sublimated (Equation 1) 
(Hollemann & Wiberg, 1964). 
(1) FeAsS —• FeS + As 
The elemental arsenic occurs in three different modifications. The grey arsenic 
consists of undulated hexagons forming tight, interacting bilayers. The interaction 
between the atoms of the different layers results in an electroconductive property. 
This high-polymeric substance melts and vaporizes only under the loss of its 
structure (Hollemann & Wiberg, 1964). By heating under standard pressure at 633°C 
the grey arsenic sublimates without melting in the form of As4 molecules, at > 800°C 
the steam consists of As2. Yellow arsenic is prepared by rapidly cooling down the 
sublimated grey arsenic. It is metastable and consists of tetraedric As4 molecules. A 
fast transition into the grey arsenic can be observed. By condensation of gaseous 
arsenic on 100°C - 200°C warm surfaces black arsenic can be prepared. It exists in 
different amorphous forms, which are hard and brittle. Although black arsenic forms 
bilayers, it is non-conductive because the layers are of an irregular structure and of a 
lesser density than in grey arsenic, so there are no interactions. Arsine (AsH3) can be 
formed by nascent hydrogen reacting with soluble arsenic compounds (Equation 2) 
(Hollemann & Wiberg, 1964), e.g. 
(2) As(OH)3 + 6 H ^ AsH3 + 3 H2O. 
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This reaction became popular as the wet chemical analysis for arsenic and is known 
as the Marsh test. The most important halids are of the type AsX3 and AsX5 
(X = halogen), which can easily be obtained out of the elements (Hollemann & 
Wiberg, 1964). 
Organic arsenic compounds usually occur in plants and animals. Cacodyl was the 
first synthetically produced arsenic species, when Louis-Claude Cadet de Gassicourt 
1757 tried to synthesise invisible ink for the military. Hereby, Cacodyl was formed as 
a smoky and smelly fluid (Elschenbroich, 2008), but the structure was not explored 
until 1858, when Robert Bunsen described it as tetramethyldiarsenic ((CH3)2As-
As(CH3)2) (Seyferth, 2001). 
Trimethylarsine (Gosio-Gas) is the basic organic arsenic compound. Today there are 
many organo-arsenic species known (Garje & Jain, 1999). The bond between carbon 
and arsenic is generally stable against water and alkylated arsenic acids (RAsO(OH)2 
such as monomethylarsonic acid and R2AsO(OH) like dimethylarsinic acid or 
Cacodylic acid) can easily be prepared by reaction of sodium arsenite and alkyl 
halids (Meyer reaction). Analogue aryle arsenicals are generally synthesised using 
the Bart Reaction with sodium arsenite and diazonium salts (Goates et al., 1972). 
The trivalent arsenic species can be built by reduction of the homologous pentavalent 
compound using sulphur dioxide (SO2) (Styblo et al., 1997a). Arsenosugar 
(Arsinoylribosides) can be found in algae, whereas in fish and seafood predominantly 
Arsenobetaine and Arsenocholine as well as other methylated species can be 
detected (Edmonds & Francesconi, 2003; Kuehnelt & Goessler, 2003). 
2.2 Arsenic application and human exposure 
In the ancient world arsenic was the most famous murderous poison with a lethal 
dose of 100 – 200 mg. In the 19th century so called “Arsenic Eaters” consumed 
arsenic to keep well and fit and to increase their potency (Schäfer, 1861; Cullen, 
2008). Furthermore, arsenic was part of green pigments in tapestry (Schweinfurt 
green), but people were already warned of the use at that time (Chasteen et al., 
2002). 
100 years ago arsenic became famous as Salvarsan, which was developed by Paul 
Ehrlich as medicine against syphilis. It saved many lives until it was finally replaced 
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by penicillin. Additionally, sodium hydrogenarsanilate, known as Atoxyl, was applied 
in the therapy of sleeping sickness, and until today arsenic is used in Chinese 
medicine (Cullen, 2008). Today, in chemotherapy arsenic is of particular importance. 
For example, it is known as TRISENOX (arsenic trioxide) for the cure of leukaemia 
(Antmann, 2001), which was authorised in 2002 (EPAR, 2007). 
Arsenic is not only applied in medicine; elementary arsenic is used in alloys such as 
gallium arsenide GaAs) (Housecroft & Sharpe, 2006). Furthermore, it is part of wood 
preservatives in the form of chromated copper arsenate (Bringezu, 1990). In the USA 
the private application of arsenic containing wood preservatives is forbidden (U.S. 
EPA, 2002), and in the European Union the use is strongly regulated and limited 
(Amtsblatt der Europäischen Gemeinschaften, 2003). 
In the agriculture arsenic can be found in pesticides and herbicides (sodium 
methylarsenate, dimethylarsinic acid), and is applied as the product Roxarson in the 
porcine and poultry mast to stimulate the growth of the animals (Chapman & 
Johnson, 2002). 
The major source of exposure for human beings is arsenic contaminated 
groundwater. At many places on earth the drinking water contains concentrations 
above 10 µg/l, which significantly exceed the tolerable value recommended by the 
WHO (World health organization [WHO], 2001, as cited in Zdrenka et al., 20121). 
This is considered as a health threat for millions of people, especially in Bangladesh, 
Vietnam, and Latin America (Ng et al., 2003, as cited in Zdrenka et al., 2012), where 
the considerable arsenic occurrence is of geogenic origin (erosion), related to mining 
activities, and geothermal waters (Fig. 1) (Smedly & Kinniburgh, 2002, as cited in 
Zdrenka et al., 2012). 
1
 Available information on human exposure to arsenic was recently reviewed by Zdrenka et al. (2012). 
The respective information was interspersed into this chapter. 
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Fig. 1 Map of arsenic affected aquifers 
(Smedly & Kinniburgh, 2002) 
The main arsenic species detected in drinking water are arsenite and arsenate. But 
the geothermal waters (Hot Spots) in the Yellostone Nationalpark, USA, 
predominantly contain several mg/l of methylated thioarsenicals such as mono-, di-, 
tri-, and tetrathioarsenate, as well as methylated arsenoxy-, and -thioanions (Planer-
Friedrich et al., 2007, as cited in Zdrenka et al., 2012). In the surrounding 
atmosphere 0.5 – 200 mg/m3 of volatile arsenic species can be detected, which have 
been identified, among others, as (CH3)2AsCl, (CH3)3As, (CH3)2AsSCH3, and 
CH3AsCl2 (Planer-Friedrich et al., 2006, as cited in Zdrenka et al., 2012). 
A second important source of arsenic is the air, where only one third of the occurring 
arsenic is of natural origin. Further anthropogenic sources are ore mining, smelteries, 
and the combustion of fossil fuels (Lozna & Biernat, 2008, as cited in Zdrenka et al., 
2012). 
Among polluted air and contaminated drinking water also the human diet is of 
importance. For example, high doses of arsenic can be detected in fish, seafood, and 
algae, so that in 2004 the Food Agency of the UK warned against the consumption of 
Hijiki (hijikia fusiforme, black sea weed) (Food Standards Agency of the UK, 2004, as 
cited in Zdrenka et al., 2012) as it contains inorganic arsenic up to 100 mg/kg. High 
arsenic concentrations can be found in the urine of the consumers (Nakjima et al., 
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2006, as cited in Zdrenka et al., 2012). Francesconi (2010, as cited in Zdrenka et al., 
2012) published the detection of up to 50 different arsenic compounds in fish and 
seafood, whereas their toxicity still is widely unknown. Especially rice and rice 
products exhibit considerable noxious effects, as they contain high doses of toxic 
inorganic arsenic (Meharg et al., 2008; Signes-Pastor et al., 2009; Sun et al., 2009, 
as cited in Zdrenka et al., 2012) and form the nutrition base especially of the Asian 
people. But not only rice from Asia, but also rice from the middle of the USA is 
contaminated with arsenic, the latter sustaining its contaminant not basically from 
natural sources but from pesticides anciently used on the cotton plantations, until 
DDT (dichlorodiphenyltrichloroethane) was introduced to replace arsenic in biocides 
(Hirner & Hippler, 2011, as cited in Zdrenka et al., 2012). The following figure Fig. 2 
gives an overview of the main pathways of human exposure to arsenic: 
derma) 
^occupational exposure 
Fig. 2 Pathways of human exposure to arsenic 
(Dopp, 2007) 
2.3 Biodisposition and biomethylation of arsenic 
Chronic low-dose exposure may cause various diseases including bladder and other 
cancers. After ingestion arsenic is distributed to several organs, where it undergoes 
biotransformation (Zdrenka et al., 2012). Gosio was the first to observe the microbial 
conversion of inorganic arsenic to methylated species in 1891 (Gosio, 1892). He 
described the production of a gas with typical garlic odour. Later, Challenger and co-
workers identified this gas as trimethylarsine (Challenger et al., 1933). In 1945 
Challenger further postulated the first mechanism of arsenic biomethylation in yeast, 
and described it as based on repetitive reduction and oxidative methylation as shown 
in Fig. 2 (Challenger, 1945). 
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Fig. 3 Mechanism of arsenic biomethylation according to Challenger 
(Challenger, 1945) 
In 1997 Aposhian published that this biomethylation can also be performed by 
bacteria and animal tissue (Aposhian, 1997), and in 2005 Hayakawa et al. suggested 
a metabolic pathway for arsenic in rat liver tissue homogenate as shown in Fig. 4; 
hereby, arsenic-glutathione complexes are formed, which are then methylated by 
arsenic methyltransferase (Cyt19) and S-adenosyl-L-methionine (SAM) (Hayakawa 
et al., 2005, as cited in Zdrenka et al., 20122). 
This biotransformation of arsenic is generally regarded as a detoxifying process, 
since the toxicity of monomethylarsonic acid (MMA(V)) and dimethylarsinic acid 
(DMA(V)) is much lower than that of inorganic arsenic (Hirano et al., 2003; Hirano et 
al., 2004). Nevertheless, the trivalent arsenic intermediates and metabolites such as 
monomethylarsonous acid (MMA(III)) and dimethylarsinous acid (DMA(III)) are 
considered to be the most cyto- and genotoxic species (Dopp et al., 2010a, as cited 
in Zdrenka et al., 2012). 
2
 Available information on arsenic biodisposition and biomethylation was recently reviewd by Zdrenka 
et al. (2012). The respective information was interspersed into this chapter. 
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Fig. 4 Mechanism of arsenic biomethylation according to Hayakawa 
(Hayakawa et al., 2005, as cited in Zdrenka et al., 2012) GSH = reduced gluthatione, 
ATG = arsenic trigluthatione, MADG = monomethylarsonic digluthatione, 
DMAG = dimethylarsinic gluthatione, SAM = S-adenosyl-L-methionine, Cyt19 = arsenic 
methyltransferase 
The liver is the main site of arsenic metabolism, and the renal route is the most 
important excretion pathway. A number of human studies have revealed that 
predominantly MMA(V) and DMA(V) can be detected in urine samples of arsenic-
exposed individuals. Fillol et al. (2010, as cited in Zdrenka et al., 2012) reported that 
the main metabolites excreted in the urine were DMA(V) (84%) and MMA(V) (12%) 
and observed a significant correlation between the consumption of seafood and the 
excretion of arsenic metabolites in the urine. Furthermore, Aposhian et al. (2000, as 
cited in Zdrenka et al., 2012) detected concentrations of about 50 nM MMA(III) in the 
urine of an arsenic-exposed human population in Romania. In animals given the food 
additive Roxarson, arsenate was identified as the main metabolite present in the 
excrement; however the main part of the parent compound was found to be excreted 
as such, i.e., without any further conversion (Gabriano et al., 2003). Feldmann et al. 
(2000) analysed the urine of the seaweed-eating sheep living on an island in the 
north of Scotland. The author and his coworkers detected the metabolites of the 
ingested arsenosugar in the urine of these sheep and later also in the urine of human 
individuals. They showed, that arsenosugar is comparable to inorganic arsenic and 
accumulates in the different organs. Recently, the same group also demonstrated 
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that arsenobetaine is not as inert in the body, as it was expected to be so far 
(Newcombe et al., 2010). They corrected the misbelief that arsenobetaine is excreted 
without any metabolism and accumulation, and they showed that it can also be taken 
up by the body. Furthermore, they showed that arsenobetaine can also be formed out 
of DMA(V) and inorganic arsenic. 
In the rat, studies have shown that ingestion of DMA(V) causes bladder cancer after 
chronic exposure (Wei et al., 1999, as cited in Zdrenka et al., 2012). Subsequent 
experiments revealed that a large number of secondary arsenic metabolites are 
formed and excreted via urine; for example, thiolated arsenics such as 
dimethylmonothioarsonic acid (DMMTA(V)) could be detected in the urine of DMA(V)-
exposed rats (Yoshida et al, 1998, as cited in Zdrenka et al., 2012). 
The liver is the main site of arsenic metabolism, and the renal route is the most 
important excretion pathway. Although most of the ingested arsenic is excreted 
again, residues accumulate in tissue and skin as shown in Fig. 5 (Dopp, 2007). The 
impact of the arsenic circulation in the blood stream was specified by Naranmandura 
et al. (2006, as cited in Zdrenka et al., 2012); these authors published that the 
arsenic metabolites DMA(III) (dimethylarsinous acid) and (dimethylmonothioarsinic) 
DMMTA(V) can be taken up by red blood cells and transformed into DMDTA(V) 
(dimethyldithioarsinic). Furthermore, they found that DMA(III) is bound to 
haemoglobin in rat red blood cells, but not in human red blood cells, indicating 
species specific differences of arsenic toxicity. 
Tissue Skin 
Accumulation 
Fig. 5 Biodisposition of arsenic 
(Dopp, 2007) 
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It is still unknown, however, which of the various arsenic metabolites is responsible 
for the development of bladder cancer. The metabolism of arsenic is of great 
importance for toxicological studies. As summarized by Dopp et al. (2010b) and 
Hirner & Rettenmeier (2010), the cyto- and genotoxic effects are highly dependent on 
the particular arsenic species, its cellular uptake, and its intracellular metabolism 
(Zdrenka et al., 2012). For example, the toxicity of MMA(III) is 20 times higher than 
that of As(III) (Styblo et al., 2002; Bredfeldt et al., 2006, as cited in Zdrenka et al., 
2012). 
2.4 Toxicity of Arsenic 
The availbale data on arsenic toxicity was recently reviewed and summarised by 
Zdrenka et al (2012). The following chapter recites this information. 
Acute arsenic toxicity causes abdominal pain, nausea and faintness, vomiting, 
diarrhoea, and seizures (Gorby & Albuquerque, 1988, as cited in Zdrenka et al., 
2012). In contrast, chronic arsenic toxicity is less conspicuous. Characteristic 
symptoms are Mees' lines and hyperkeratosis predominantly at palms and soles of 
the feet. Furthermore, vascular diseases and peripheral neuropathy, as well as, 
diabetes mellitus may occur (Smith et al., 2000, as cited in Zdrenka et al., 2012). 
Until now, more than 60 Mio people in Bangladesh and India are still at risk of 
arsenic-induced diseases due to arsenic concentrations of 10 - 50 µg/l or even higher 
(Chakraborti et al., 2004, as cited in Zdrenka et al., 2012). The mechanisms of 
arsenic toxicity are only poorly understood. The structural likeness of arsenate and 
phosphate (Fig. 6), which is called molecular mimicry, results for example in the use 
of the same cellular transporters. Furthermore, there are plenty of biomolecules 
known, in which arsenate replaces phosphate, such as arsenosugars, arsenolipids, 
and arsenobetaine (Rosen et al., 2011, as cited in Zdrenka et al., 2012). 
A 
Fig. 6 Molecular mimicry of phosphate (A) and arsenate (B) 
(Rosen et al., 2011) 
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The relevance of this molecular mimicry is pointed out in the study of Wolfe-Simon et 
al. (2011, as cited in Zdrenka et al., 2012), reporting that phosphate can be 
substituted by arsenate in macromolecules of a bacterium, strain GFAJ-1 of the 
Halomonadaceae, isolated from Mono Lake, CA. However, these data were 
controversially discussed in the literature lately. Hereby, some points have to be 
considered: first the rapid hydrolysis of arsenate esters, and second the notably 
altered three dimensional structure of macromolecules like DNA (Rosen et al., 2011, 
as cited in Zdrenka et al., 2012). 
In addition to acute effects of arsenic toxicity, chronic arsenic exposure is also 
associated with an increased risk of cancer, especially at environmentally relevant 
doses. In contrast to the temporary administration of high doses of arsenic in cancer 
therapy, chronic exposure to only small amounts can cause cancer. Especially 
arsenic-induced lung cancer, as well as skin, kidney, and bladder cancer were 
reported (Chiou et al, 1995; Chen et al., 2010; Tseng, 2007, as cited in Zdrenka et 
al., 2012). Hence, the following chapters will focus on the mechanisms of 
carcinogenesis in general, and the effects of chronic low dose exposure to arsenic 
and its influence of carcinogenesis. 
2.5 Cancer and carcinogenesis 
According to the WHO, cancer diseases are with 7.6 Mio fatalities (13%) part of the 
most common causes of death worldwide (WHO, 2006). Cancer diseases are 
multifaceted and can involve every organ or tissue. The frequency is, among others, 
dependent on age, gender, lifestyle, and diet (Fig. 7). The basis of cancer is the 
accumulation of aberrant and growth disinhibited cells depending on evolution and 
selection (Cahill et al., 1999). 
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Fig. 7 Incidence of malignant neoplasms in Germany in the year 2004 
(Hiddemann et al., 2010, modified) 
2.5.1 Fundamentals of carcinogenesis 
One of the multiple models of carcinogenesis is the graduation into initiation, 
promotion, and progression (Schulte-Hermann 1985; Pitot et al., 1989). The initiation 
describes the development of potential tumour cells, whose morphology is 
indistinguishable from normal cells. The following development of morphologically 
recognisable preneoplastic cells by clonal growth is called tumour promotion, and the 
formation of clinically manifested tumours by further mutation of one of the 
preneoplastic cells and its selective growth is known as progression. The further 
transformation of one cell of the benign tumour can lead to malignant lesions (Fig. 8). 
Fig. 8 Multistage process of carcinogenesis 
(Schulte-Hermann & Parzefall, 2010, modified) The development of tumour lesions can be 
divided into initiation, promotion, and progression. 
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Research over decades has revealed that tumours are more than just masses of 
proliferating cancer cells; they are complex tissues containing multiple distinct cell 
types and extracellular matrix (Fig. 9), whose composition has developed with 
processes comparable to those used by developing organs, although their 
architecture and functionality is abnormal. This is why tumours cannot be understood 
just by figuring out the characteristics of the cancer cells, but also by taking into 
consideration the microenvironment of the tumoral cells (Egeblad et al., 2010; 
Hanahan & Weinberg, 2011). 
Fig. 9 The cells of the tumour microenvironment 
(Hanahan & Weinberg, 2011) Tumours are complex tissues containing multiple distinct cell 
types and extracellular matrix that collectively enable tumour growth and progression. 
In the following table (Tab. 1), a series of noncancerous cells present in tumours and 
their respective role within tumour development are presented in order to reflect, how 
versatile the cell composition of a tumour can be (Egeblad et al., 2010, modified). 
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Tab. 1 Noncancerous cells of the 
(Egeblad 
tumour organ and their effects on the tumour 
et al., 2010, modified) 
Cell Type 
Normal epithelial cells 
Myoepithelial cells 
Fibroblasts 
Mesenchymal stem cells 
Adipocytes 
Endothelial cells 
Perivascular cells 
Bone marrow-derived cells 
Dendritic cells 
Effect on Tumors 
inhibit 
inhibit (invasion, growth) 
promote (proliferation, angiogenesis, invasion) 
promote (metastasis) 
promote (tumor growth, survival, angiogenesis) 
promote (angiogenesis, niche?) 
promote (vascularization) 
promote (proliferation, invasion, angiogenesis) 
inhibit (stimulate antitumor immunity) 
Myeloid-derived suppressor cells and 
immature myeloid cells 
promote (angiogenesis, metastasis,reduce 
antitumor immunity) 
Macrophages, M1-like 
Macrophages, M2-like 
Mast cells 
Neutrophils, N1 
Neutrophils, N2 
T cells, CD4+, T helper 2 
T cells, CD8+, cytotoxic 
T cells, CD4+CD25+ regulatory 
T cells, gamma/delta 
T cells, Th17 
B cells 
B cells, immunoglobulins 
inhibit 
promote (invasion, angiogenesis) 
promote (angiogenesis) 
inhibit (stimulate antitumor immunity) 
promote (angiogenesis, reduce antitumor 
immunity) 
promote (metastasis) 
inhibit (tumoricidal) 
promote (reduce antitumor immunity) 
inhibit (stimulate antitumor immunity) 
promote (proliferation, angiogenesis) 
inhibit (stimulate T-cell antitumor immunity) 
promote (reduce antitumor immunity) 
promote (stimulate inflammation-associated 
progression) 
Platelets promote (metastasis) 
Cancer cells are known to sustain chronic proliferation, whereas normal tissues 
maintain their cell homeostasis by carefully controlling the release of growth factors in 
order to preserve the normal architecture and function of the organ. In normal tissue 
growth factors bind to cell-surface receptors, which mostly have intracellular tyrosine 
kinase domains activating the cellular pathways (mitogenic signals) for the regulation 
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of the cell cycle and cell growth. Theses mitogenic signals further influence cell 
survival and the energy metabolism. The growth factors control cell number and 
position in the tissues. In general, they are released by neighbouring cells (paracrine) 
into the extracellular matrix, where they are activated by a complex network of 
proteases, sulphatases, and other enzymes (Hanahan & Weinberg, 2011). In 
contrast, cancer cells deregulate the release of these growth-factors. Some cancer 
cells exhibit autocrine proliferative signalling by producing the growth factors 
themselves, or they stimulate other normal cells to supply these (Bhowmick et al., 
2004; Cheng et al., 2008, Hanahan & Weinberg, 2011). A further mechanism of 
cancer cells is the increase of cell receptor proteins to enhance the ligand binding. 
Moreover, structural alterations of receptors or constitutive activation of proteins in 
the signalling pathway reveal ligand-independent signalling. Negative feedback loops 
are also of certain importance: once activated, proteins are inactivated again to stop 
the signal and avoid sustaining stimulus. A prominent example is the RAS 
oncoprotein. Replacing GDP by GTP activates the RAS protein, and hence, 
mutations in the Ras gene deplete the GTPase activity of RAS, resulting in the 
inhibition of GTP. Consequently, RAS stays in its activated form and accumulates in 
the cell. The signal is now no longer transitory (Hanahan & Weinberg, 2011). 
Recent research revealed that excessive cell proliferation caused by oncoprotein 
stimulation (such as RAS) can trigger cell death or senescence (Lowe et al. 2004; 
Evan & d’Adda di Fagagna, 2009; Collado & Serrano, 2010, Hanahan & Weinberg, 
2011). Cultured cells receive a nonproliferative, but viable state after expressing high 
levels of RAS; other cells expressing less of the oncoprotein can avoid senescence 
and continue proliferation. The mechanism is considered to be a defence 
mechanism, as cells exhibiting excessive stimulation of a certain signalling pathway 
are eliminated. Cancer cells either yield a compromise between increased maximal 
stimulation and antiproliferative defences, or they can adapt to the excessive 
stimulation by disabling the apoptosis- or senescence features (Hanahan & 
Weinberg, 2011). 
Furthermore, cancer cells can disable negative cell proliferation regulation systems 
such as tumour suppressor genes. A prominent example is the retinoblastoma-
associated protein (RB protein), which responds to various extracellular signals and 
regulates the proceeding in the cell cycle. Cancer cells with defects in the RB protein 
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pathway miss an important control function, and persistent cell proliferation occurs 
(Hanahan & Weinberg, 2011). 
Another important mechanism to suppress inappropriate cell proliferation is known as 
contact inhibition. This phenomenon can easily be observed in two-dimensional cell 
cultures, with cell proliferation arrest observed as soon as a confluent cell monolayer 
is built up (Hanahan & Weinberg, 2011). One of the multiple mechanisms related to 
contact inhibition involves the protein Merlin, which is a gene product of NF2. It 
connects cell surface molecules such as E-cadherin with receptors like the EGF 
receptor (a transmembrane tyrosine kinase receptor), and by doing so it first 
enhances the cell-cell attachments, and second, it disables ligand binding into growth 
factor receptors (Okada et al., 2005; Curto et al., 2007, Hanahan & Weinberg, 2011). 
In neoplasia, cells lose the ability of contact inhibition, which can be demonstrated in 
numerous in vitro such as the Cell Transformation Assay. In fact, non-malignant cells 
grown to confluence in general stop proliferation, but after transformation and a loss 
of contact inhibition they continue proliferation and form clearly recognisable colonies 
(Ch.3.3.6) (Hanahan & Weinberg, 2011). 
A famous defence mechanism against the transformation of cells into cancer cells is 
the principle of the programmed cell death by apoptosis. As soon as a cell enters the 
apoptotic programme, the cell components are packed into vesicles and the cell is 
decomposed into so called apoptotic bodies. These bodies are either eliminated by 
neighboured cells or by special phagocytes. There are two major pathways to induce 
apoptosis: the extrinsic programme in response to extracellular signals and the 
intrinsic programme triggered by intracellular stimuli. The latter was found to be more 
widely involved in the physiological cancer defence. Most notable is the identification 
of DNA damages via the p53 tumour suppressor, which increases the expression of 
proteins of the Bcl-2 family, dependent on the occurrence of DNA breaks or other 
chromosomal abnormalities to finally induce the apoptotic programme. A defect in the 
p53 function means the loss of one of the most important damage sensors. A 
mechanism to prevent damaged, precancerous cells from elimination is autophagy. 
The autophagic programme leads to the breakdown and catabolism of cellular 
molecules and organelles by encompassing them with vesicles (autophagosomes). 
Following fusion with lysosomes, the content is degraded (Hanahan & Weinberg, 
2011). In general, the autophagic programme is induced as a response to cellular 
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stresses such as nutrient deficiency (Hanahan & Weinberg, 2011), but was also 
described for the sequestering of toxicants and is believed to be a kind of “first-
response reaction” to delay apoptosis (Kundu & Thompson, 2008; Yang et al., 2008). 
The treatment of cancer cells with cytotoxic drugs might lead to increased autophagy, 
which is apparently cytoprotective rather than lethal (Hanahan & Weinberg, 2011). 
In contrast to apoptosis, necrosis is a cell breakdown, which leads to a blow up of the 
affected cells, followed by disintegration, and the release of cellular components and 
proinflammatory signals into the surrounding tissue microenvironment. Hence, 
inflammatory cells are attracted and activated to induce angiogenesis, cancer cell 
proliferation, and invasiveness. Moreover, IL-1 α, released by necrotic cells, 
stimulates neighbour cell proliferation, followed up by neoplastic progression. 
Consequently, the tolerance of necrotic cell death and the recruiting of inflammatory 
cells provides an advantage for neoplasias because of growth stimulation to the 
surviving cells and, as a consequence, tumour promotion (Hanahan & Weinberg, 
2011). 
For the development of cancer, excessive proliferation requires the interaction with 
immortalisation. In normal cells chromosomes exhibit non-coding DNA material 
(telomers) at their ends, which is shortened with every cell division due to limited 
replication of the intermittent DNA strand. The limitation is based on the fact that the 
replication can only be processed as long as a primer still can attach to the DNA 
strand. Hence, small pieces of the DNA strand (up to 100 nucleotides) are lost with 
every replication. Consequently, the number of cell divisions is limited to the length of 
the telomers, and the cells finally enter the state of senescence. In cells, where 
nearly unlimited replication is of importance, such as germ cells and stem cells, an 
enzyme called telomerase is expressed, which elongates the telomers to protect the 
cells from chromosomal end-to-end fusion, which results in the destabilisation of 
chromosomes and a change of the karyotype. The telomerase activity is almost 
absent in normal cells, but in about 90% of the cancer cells the enzyme is expressed. 
As a consequence, the cells circumvent senescence and gain the chance to 
immortalise (Shay & Wright, 2000; Blasco, 2005; Hanahan & Weinberg, 2011). 
The induction of angiogenesis in tumour tissue is also one of the most important 
steps in carcinogenesis, as the tumour will be provided with nutrients and O2, and 
can emit metabolic wastes and CO2. The process of angiogenesis is physiologically 
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observed in embryogenesis and female reproductive cycling, as well as during wound 
healing, but always transiently. In tumour progression angiogenesis is almost always 
observed. A prominent group of angiogenic regulators are the vascular endothelial 
growth factors (VEGF), whose genes are upregulated by both hypoxia and oncogenic 
signalling (Hanahan & Weinberg, 2011). 
2.5.2 Migration, invasion and metastasis 
Tumour metastasis is generally described as a multistep process (Fig. 10). After the 
primary tumour has been established by cellular transformation, tumour growth, 
angiogenesis, and the development of a complex tumour microenvironment, local 
invasion of some cancer cells is observed in malignant tumour tissues. 
Especially the thin-walled vessels such as lymphatic channels are easy to penetrate 
and exhibit only poor resistance for intravastation. Hence, they are the most common 
entry route for cancer cells into the circulation. The detachment of tumour cells or cell 
aggregates, respectively, is the next step in metastasis. Nevertheless, most of the 
circulating tumour cells are rapidly eliminated. The surviving cells get stuck in the 
capillary system of distant organs and adhere to the capillary endothelium. 
Extravastation is presumably based on similar mechanisms like invasion and is 
followed by proliferation and colonisation. A secondary tumour, the metastasis, 
establishes at the new location by the same mechanisms as utilised in the primary 
tumour (Fidler, 2003). 
To undergo epithelial-mesenchymal transition (EMT), a developmental regulation 
programme, has been reported as a main tool for transformed epithelial cells to gain 
the ability of invasion, resistance of apoptosis, and dissemination (Hanahan & 
Weinberg, 2011). EMT is known as a multifaceted process and can either be 
transitory or permanent, as well as activated to a different degree during invasion and 
metastasis. During embryogenesis EMT is initiated and controlled by transcriptional 
factors such as Snail, Slug, Twist, and Zeb 1/2. Those initiators were observed in 
various combinations in numerous of malignant tumour types, as well as their mode 
of action was analysed in cancer models and they were casually associated with 
invasion and metastasis when overexpressed (Micalizzi et al., 2010; Taube et al., 
2010; Schmalhofer et al., 2009; Yang & Weinberg, 2008). Characteristics such as the 
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loss of adherens junctions, expression of matrix-degrading enzymes, increased 
motility, and the resistance to apoptosis are common consequences of EMT induced 
by those transcription factors and are generally associated with the process of 
invasion and metastasis. Some of these transcription factors for example, can directly 
suppress E-cadherin, a key cell-to-cell adhesion molecule, and hence, a key 
suppressor of motility and invasiveness in neoplastic epithelial lesions (Peinado et 
al., 2004). 
Fig. 10 Invasion Metastasis Cascade 
(Fidler, 2003) Tumour metastasis is generally described as a multistep process. 
The regulation of the transcription factors included in EMT and their interaction has 
not yet been fully understood. Research on developmental genetics revealed that 
also signals are received from neighboured cells, which are involved in the 
stimulation of those transcription factors. Analogously, it is likely that cancer cells also 
receive their stimulus for the expression of transcriptional regulators, which 
subsequently leads to the malignant phenotype, by means of interaction with the cells 
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of the tumour microenvironment. For example, macrophages can support 
invasiveness by supplying matrix-degrading enzymes such as metalloproteinases. 
Although the question has not yet been fully solved, it is likely that the invasion-
metastasis cascade and the following development of secondary tumours is 
controlled by EMT-inducing transcription factors. Nevertheless, further research has 
to be done to answer the question, whether invasive cancer cells necessarily have to 
pass EMT during development of their malignant state, or if alternative processes 
also lead to this capability. 
2.5.3 Cyclooxygenase 2 (COX-2) activation 
The COX-2 protein catalyses the biosynthesis of prostaglandines from arachidonic 
acid, which are known to enhance cell proliferation, angiogenesis, and metastasis, as 
well as to control apoptosis (Trifan & Hla, 2003). In general, there is no COX-2 
activity in the tissues. However, a single stimulus enhances the protein level for only 
a few hours (Vane et al., 1998). COX-2 is stimulated by factors associated with 
inflammation, such as bacterial lipopolysaccharide, cytokines, and TNF α. The 
protein itself further activates inflammatory cells and induces the secretion of growth 
factors like TGF-ß, which are, among others, important for wound healing and 
angiogenesis (Vane et al., 1998). COX-2 is known to be an essential factor for the 
survival of human and mammalian cells under stress conditions, as it protects the 
cells from stress -induced apoptosis, for example caused by DNA damaging agents 
(Chai et al., 2007). On the other hand, the induction, expression, and activity of COX-
2 is an essential step in the development of colon cancer due to the decrease of 
apoptosis and the survival of the epithelial cells beyond normal lifetimes, allowing the 
development of a malignant phenotype. Therefore, COX-2 activity is correlated with 
the progression of pro-cancerous epihelial cells to fully malignant phenotypes (Vane 
et al., 1998). The pro-carcinogenic property of COX-2 was demonstrated in 
experimental animal models, showing that inhibitors of COX-2 reduced the formation 
of intestinal, breast, skin, lung, bladder, and tongue tumours (Vainio, 2001). In 
malignant tissues from colorectal cancer and polyp tissues from patients, as well as 
in human gastric and breast tumours, COX-2 protein levels were elevated as 
compared to the surrounding tissue (Vane et al., 1998). In Apc mice, which serve as 
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a model for human familial adenomatous polyposis, the deletion of the COX-2 gene 
(official gene name PTGS2) or the treatment with a selective COX-2 inhibitor led to 
decreased intestinal polyposis. Rat epithelial cells infected with cDNA of COX-2 
showed consequently increased prostaglandine synthesis and decreased apoptosis 
rates (Vane et al., 1998). Xiong et al. (2005) determined the clinicopathologic 
significance of COX-2 expression in human colorectal cancer. They reported that 
67.9% of the colorectal cancer cases were detected positive for COX-2 protein when 
they were immunohistochemically analysed with anti-COX-2 antibodies. 86.7% of the 
cases with lymphnode metastasis had elevated COX-2 levels in the primary lesions, 
and 100% of these patients were analysed positive for COX-2 in the cancer cells of 
the metastatic lesions. Furthermore, the positive expressions of VEGF and MMP-2 
were closely correlated with that of COX-2. This is the reason why the latter is 
discussed to alter the invasive potential of colorectal cancer cells through the 
activation of MMP-2. Hence, COX-2 is associated with tumour progression by 
modulating angiogenesis, cancer cell motility, and the invasive potential in colorectal 
cancer. Phenotypic changes of rat intestinal epithelial cells, including increased 
adhesion to extracellular matrix, decreased apoptosis, and enhanced tumourigenic 
potential, were related to COX-2 overexpression (Xiong et al., 2005). Endothelial cell 
migration and vessel tube formation, as well as activated collagenase levels induced 
by COX-2 were reported by Masferrer et al. (2000). Because of the significant 
correlation of COX-2 with the depth of invasion, the state of disease, and the 
occurrence of metastasis, COX-2 is suggested to be a possible biomarker (Xiong et 
al., 2005). 
2.5.4 The role of miRNAs in carcinogenesis 
MicroRNAs (miRNAs) are about 22 nucleotide long RNA molecules with regulatory 
function. There are more than 500 miRNA genes known so far. In the nucleus miRNA 
genes are first transcribed into several hundred base pair (bp) long RNAs containing 
a hairpin structure (pri-miRNA), which are then further processed to about 70 bp long 
pre-miRNAs (Fig. 11). 
The processing is executed by the RNases III Drosha and Pasha. The prä-miRNAs 
are then excreted into the cytoplasm, where the RNases Dicer and Loqs transform 
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them into 22 bp long duplices. Only one strand of the duplices can be incorporated 
into a large protein complex (RNA -induced silencing complex, RISC) and guide it to 
its complementary target segment of the mRNAs. The aim is to regulate the target 
mRNA either by blocking further translation, or by its degradation. It is estimated that 
at least 30% of all human genes are regulated by miRNAs, and one miRNA can 
regulate the expression of up to 1,000 genes by either direct interaction with the 
respective mRNA, or by further indirect mechanisms: so called epi-miRNAs were 
recently found to regulate epigenetic enzymes, such as DNA methyltransferases and 
histone deacetylases (Bartram, 2010; Zimbardi et al., 2012). 
Fig. 11 miRNA sythesis und function 
(Bartram, 2010, modified) 
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In tumour tissue the regulation via miRNAs is of great relevance. Among classically 
known cancer genes miRNAs are known as molecular switches. They were 
described as essential components of fundamental signal transduction of 
carcinogenesis (Dalmay & Edwards, 2006; Sotiropoulou et al., 2009). Comparable to 
protein-coding genes, miRNAs can also be downregulated by DNA hypermethylation 
of the promoter regions in cancer cells (Zimbardi et al., 2012). 
Altered miRNA profiles in bladder cancer tissues were recently reported (Catto et al., 
2009; Dyrskjot et al., 2009; Ichimi et al., 2009; Lin et al., 2009; Veerla et al., 2009; 
Hanke et al., 2010); among them miR-200a (Lin et al., 2009) and miR-205 (Dyrskjot 
et al., 2009; Gottardo et al., 2007). miR-139 was detected to be decreased in bladder 
tumours (Ichimi et al., 2009), possibly targeting CXCR4 and resulting in metastasis. 
CXCR4 was described to be increased in invasive bladder tumours (Retz et al. 2005; 
Dalmay & Edwards 2006). Gregory et al. (2008) described miR-200-family (miR-
200a, -200b, -200c, -141, and -429) in combination with miR-205 regulating 
epithelial-mesenchymal transition (EMT). EMT is known to be closely correlated with 
invasion and migration of tumour cells, as well as metastasis of tumours. MiR-200-
miRNAs inhibit the expression of the proteins Zeb 1 and Zeb 2, which suppress the 
transcription of CDH1. Decreased levels of miR-200-miRNAs are correlated with 
progression in breast cancer and reveal poor prognosis for ovarian carcinoma 
(Gregory et al., 2008; Hu et al., 2009). miR-146a was detected to play a role in 
suppression of metastasis in breast cancer (Hurst et al., 2009), among others, by 
decreasing protein levels of MMP9, which is important for the invasion of tumour cells 
(Bhaumik et al., 2008). ROCK1 was identified to be a target of miR-146a in prostate 
carcinoma cell lines, as well as CXCR4 in leukaemia cells (Labbaye et al., 2008; Lin 
et al., 2008). Nevertheless, care has to be taken when the relevance of altered 
miRNA profiles is interpreted in carcinogenesis, as their expression patterns are 
highly specific for cell-type and cellular differentiation status. Hence, it is likely that 
altered expression patterns are not conclusively the reason for malignant 
transformation, but a secondary consequence of the loss of the normal cell identity 
accompanied by malignant transformation (Kent & Mendell, 2006). 
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2.5.5 DNA methylation 
The genetic information flow is not only dependent on the primary DNA sequence, 
but also on the fact that the functional structures of the transcriptional system, such 
as the RNA-polymerase II, gain access to the relevant gene loci. Specific 
modifications of the DNA sequence and the surrounding chromatin regulate genetic 
programs by either inhibition or activation. These modifications are tissue specific 
and dependent on the developmental stage. Hence, they are inherited to the 
following cell generations. This regulatory system is generally reversible and 
independent from the primary DNA sequence. Modifications in the so-called 
epigenetic system can reveal consequences of similar concern like mutations in the 
genetic information itself (Bartram, 2010; Zimbardi et al., 2012). 
DNA methylation is generally performed by DNA methyltransferases (DNMTs), which 
transfer a methyl group from S-adenosyl methionine (SAM) to the cytosine nucleotide 
(Ren et al., 2011). Hereby, the most relevant modification is the methylation of 
cytosine at CpG sites. These are dinucleotides consisting of a cytosine and a 
guanine in direct neighbourhood. In CpG islands these dinucleotides are found at 
higher frequencies, and about 37% of the approximately 38,000 CpG islands can be 
found in the promoter region of about 50% of the genes. Their methylation leads to 
the silencing of the respective gene (Bartram, 2010). Hence, DNA methylation 
patterns are a crucial part of the epigenetic gene regulation to maintain the normal 
homeostasis of gene expression (Zeimet et al., 2010). 
De novo methylation is catalysed by the DNA methyltransferases DNMT3A and 
DNMT3B. Both have similar functions but also different tissue and DNA-target 
structure specifications (Reik et al., 1999). The DNA methyltransferase DNMT1 
organises the maintenance of the DNA methylation patterns in the context of cell 
proliferation and modifies the daughter strands to avoid passive demethylation. 
Following methylation, methyl-CpG-binding domain proteins (e.g. MeCP2) are 
associated and mask the recognition sequence of transcription factors. Hence, the 
transcriptional activation system is blocked (Bartram, 2010). 
Global DNA hypomethylation is correlated with chromosomal instability, like it is 
observed for example in colon carcinoma (Matsuzaki et al., 2005).The majority of 
hypomethylation occurs at repetitive elements such as long interspersed nuclear 
elements (LINEs). There are about 500,000 copies of LINE1, and most of them have 
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lost their functionality during human evolution. However, genome wide 
hypomethylation of LINE1 may initiate the clonal expansion of premalignant cells in 
early stages of cancer development, is presumed to contribute crucially to 
chromosomal instability, and may lead to structural changes in chromosomes 
(Wilhelm et al., 2010; Zeimet et al., 2010). Choi et al. (2009) reported that LINE1 
methylation was very consistent from individual to individual and from tissue to tissue. 
There was a clear hypomethylation of LINE1 in bladder cancer, but not in leukaemia, 
leading to the assumption that DNA methylation of repetitive elements such as LINE1 
can serve as biomarkers. 
Oncogene activation due to DNA hypomethylation is rarely reported (Ehrlich, 2002). 
One example is the abnormal gene expression of BCL2 in patients suffering from B-
cell chronic lymphocytic leukaemia (Hanada et al., 1993). In contrast, there are 
numerous tumour suppressor genes inactivated by DNA hypermethylation in various 
kinds of tumours (Bartram, 2010). One prominent example of misleading epigenetic 
regulation is related to the P16 protein, which is a cyclin-dependent kinase (CDK) 
inhibitor. P16 is known to block the cyclin-D mediated activation of the protein 
kinases CDK4/6 and enable the retinoblastoma protein (RB) to prevent the cell from 
replicating damaged DNA by preventing its progression along the cell cycle through 
the first gap phase G1 into the synthesis phase S. Most of the tumours in man exhibit 
disruptions in this signal transduction pathway, because of the functional loss of 
either P16 or RB (Sherr 1996; Baylin et al. 1998). Notably, the loss of function of P16 
can be based on both, gene deletion or mutation, as well as on promoter 
hypermethylation, whose frequency varies between the different tumour forms. In 
colon carcinomas hypermethylation is the major mode of action for the inactivation of 
P16 (Bartram, 2010). 
Promoter hypermethylation of the gene coding for the cell adhesion molecule E-
cadherin (CDH1), is often found in epithelial tumours and results in the loss of 
inhibition of cell invasion (Yoshiura et al., 1995; Conacci-Sorrell et al., 2002). 
Nevertheless, Chim et al. (2003) reported only poor hypermethylation of CDH1 in 
patients suffering from acute promyelocytic leukaemia, in contrast to acute myeloid 
leukaemia. In bladder specimens CDH1 was reported to have similar methylation 
patterns in both benign and malignant tumours and was found to be no suitable 
biomarker (Pu et al., 2006). 
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A further prominent gene in tumourigenesis is the retinoic acid receptor, beta gene, 
RARB, which codes the retinoic acid receptor ß (RAR ß). Retionids are vitamin A 
derivates with effects on growth control, epithelial differentiation, and embryonic 
development. There are three isoforms of RAR (α, ß, γ), which all are nuclear 
receptors and transcription factors. They bind to the promoter of their target genes as 
heterodimers together with retinoid X receptors (RXR) and repress or activate the 
transcription depending on the presence or absence of their ligand hormone. Both 
retinoic acid and the three RARs are closely linked to cancer and are known to have 
tumour suppressive properties. Several alterations in the expression of RAR ß were 
reported for various kinds of tumours. The major mode of action is believed to be the 
loss of repressive function on the activator protein 1 (AP-1), which itself controls a 
number of cellular processes including differentiation, proliferation, and apoptosis (Lei 
& Thé, 2003). In bladder cancer, altered methylation of RARB was reported in 
several studies (Chan et al., 2002; Hoque et al., 2006, Negraes et al., 2008). 
In lung and breast cancer Ras Association Domain family 1 gene (RASSF1) was 
detected to undergo epigenetic inactivation by hypermethylation of the promoter 
region. There are two major transcripts, RASSF1A and RASSF1C, which are 
produced by alternative promoter selection and mRNA splicing. RASSF1A was 
reported to be a potential tumour suppressor gene. It is known to inhibit proliferation 
by negatively regulating cell cycle progression through G1 into S phase and inducing 
cell death as a negative Ras effector (Dammann et al., 2005; Burbee et al., 2011). 
Promoter hypermethylation of RASSF1A was detected in more than 50% of the 
bladder cancer cases analysed, but in none of the controls. Furthermore, RASSF1A 
was associated with invasive bladder cancer, the more advanced and fatal form of 
this disease (Dulaimi et al., 2004; Dammann et al., 2005). 
In recent scientific publications C1qTNF6, a protein with an unique molecular 
structure including, among others, a collagen-like domain, has come into focus. 
Initially, this protein was reported to be involved in fatty acid metabolism and to play a 
role in the energy balance (Lee et al., 2010). Additionally, C1qTNF6 was reported to 
induce the expression of IL10 and thus, be a potential pharmacological target in 
inflammatory diseases (Kim et al., 2010). Lately, the expression of C1qTNF6 was 
detected in hepatocellular cancer, and moreover, its possible support of tumour 
angiogenesis in this cancer type was discussed (Takeuchi et al., 2011). This is in 
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accordance with the findings of Wong et al. (2008), who reported endocrine actions 
of C1qTNF6. However, the pathologic role of this protein and its expression status in 
carcinogenesis still remains unclear and is of further interest. Up to now no 
information is available on the epigenetic regulation of the protein expression. 
The inhibition of DNA repair by promoter methylation of genes coding for DNA repair 
proteins is another well-known mechanism in tumourigenesis. One prominent 
example is O6-methylguanine-DNA methyltransferase (MGMT), which transfers the 
alkyl groups from the O6-position of guanine onto itself. This protein is not a true 
enzyme, since the protein is not regenerated after the reaction but degraded. 
Aberrant MGMT promoter methylation leads to aberrant protein amounts and 
decreased defence against genotoxicity. Many immortalised and tumour cell lines 
lack this protein; in contrast, it was detected in primary tumour samples. The levels of 
this protein vary in human tumoral and normal tissues. Nevertheless, some studies 
presume a correlation between MGMT methylation status and the susceptibility of 
tumour development (Ekim et al., 2011; Pegg, 2011). 
Inactivation of apoptotic factors by aberrant promoter hypermethylation was also 
observed in cancers such as therapy resistant melanomas, where the inactivated 
apoptotic protease activating factor - 1 (Apaf-1) was detected. Aberrant methylation 
of tumour suppressor genes can also be of prognostic relevance, as it was reported 
for the acute lymphoblastic leukaemia: the more genes are affected by aberrant 
methylation, the poorer is the prognosis (Bartram, 2010). 
Finally, misleading epigenetic regulation of miRNAs can also lead to tumorigenesis. 
Hypermethylation of miR-124a was observed in various neoplasia and was correlated 
with the activation of CDK6 and the repression of RB (Lujambio et al., 2007). 
There are numerous further genes, whose altered methylation patterns were 
described in bladder tumours that were suggested as possible biomarkers. But as 
cancer development is a complex process, only analysis of a panel of multiple genes 
could lead to valuable results in non-invasive cancer diagnosis (Zimbardi et al., 
2012). 
29 
Introduction 
2.5.6 Arsenic-induced carcinogenesis 
Chronic arsenic exposure is associated with an increased risk of cancer. Especially 
inorganic arsenic is a well known group I carcinogen recognised by the International 
Agency for Research on Cancer (IRAC) and the World Health Organization (WHO) 
(Zhang et al., 2007; Ren et al., 2011). Arsenic-induced lung cancer, as well as skin, 
kidney, and bladder cancer were reported (Chiou et al., 1995; Tseng, 2007; Chen et 
al., 2010; Ren et al., 2011). A detailed report on an epidemiological study over 
50 years showed that in a Chilean population a significant increase in bladder cancer 
mortality was correlated with higher arsenic concentrations in drinking water 
(Marshall et al., 2007). Moreover, indications are given that the biological behaviour 
of urothelial carcinomas in areas highly contaminated with arsenic, such as the 
southwest coast of Taiwan, are more aggressive than urothelial carcinomas from a 
non-contaminated area (Chen et al., 2007). As arsenic is metabolised after uptake, 
research has also been focussed on the toxicity and carcinogenicity of the 
metabolites. Especially the trivalent arsenicals are known to exhibit strong genotoxic 
effects (Dopp et al., 2010a). Furthermore, studies in rats have shown that ingestion of 
DMA(V) causes bladder cancer after chronic exposure (Wei et al., 1999). 
One generally accepted mechanism for arsenic toxicity and presumably also arsenic-
induced carcinogenesis is the generation of reactive oxygen species (ROS). While 
ROS physiologically occur during cellular respiration or aerobic metabolism they also 
can result from exposure to oxidants. Already low levels of As(III) and MMA(III) are 
reported to generate ROS and therefore cause oxidative stress (Eblin et al., 2008; 
Wnek et al., 2009, as cited in Zdrenka et al., 20123). These highly reactive radicals 
are discussed to exhibit their toxicity via induction of DNA damage, formation of DNA 
adducts, or alteration of DNA methylation and histone modifications (Wnek et al., 
2009), finally leading to carcinogenesis (Kitchin & Ahmad, 2003; Huang et al., 2004, 
as cited in Zdrenka et al., 2012). In addition, arsenic is known to interfere with 
nucleotide and base excision repair at very low, non-cytotoxic concentrations and 
was observed for both trivalent and pentavalent metabolites. Hereby, MMA(III) and 
DMA(III) were found to exhibit the strongest effects (Hartwig et al., 2003, as cited in 
Zdrenka et al., 2012). One key mechanism is the inactivation of poly (ADP-ribose) 
3
 Available information on the mechanisms discussed for arsenic-induced carcinogenesis was recently 
reviewd by Zdrenka et al. (2012). The respective information was interspersed into this chapter. 
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polymerase (PARP) already at extremely low, environmentally relevant 
concentrations (Hartwig et al., 2002; Hartwig et al., 2003, as cited in Zdrenka et al., 
2012). Wnek et al. (2009) reported that the relative PARP activity was significantly 
reduced during chronic exposure of immortalised human urothelial cells (UROtsa) to 
50 nM MMA(III). After removal of MMA(III) PARP activity increased again. Trivalent 
arsenic species are known to attach to zinc-binding structures generally found in 
DNA repair enzymes, leading to alteration or inhibition of these proteins and finally 
the loss of genomic integrity (Kitchin & Wallace, 2008, as cited in Zdrenka et al., 
2012). In contrast, former studies report the insensitivity of isolated and purified DNA 
repair enzymes against inhibition by arsenic (Hu et al., 1998, as cited in Zdrenka et 
al., 2012). This leads to the assumption that there are different modes of action for 
arsenic inhibited DNA repair, on the one hand by directly targeting DNA repair 
proteins, and on the other hand by altering signal transduction or gene expression 
(Zdrenka et al., 2012). 
Another mechanism of arsenic-induced carcinogenesis is the altered cytoplasmic and 
nuclear signal transduction, modifying proteins involved in cell proliferation, 
differentiation, and apoptosis (Wnek et al., 2009, as cited in Zdrenka et al., 2012). 
Hereby, ROS were detected to be one key mechanism for the influence of As(III) and 
MMA(III) on the mitogen-activated protein kinase (MAPK) signalling pathway leading 
to consistent changes in cellular signalling (Eblin et al., 2008, as cited in Zdrenka et 
al., 2012). The persistence of MMA(III)-induced altered cellular functions even after 
the termination of arsenic exposure point to lasting genomic or epigenetic changes, 
and thus the highly carcinogenic potential of arsenic and its metabolites (Zdrenka et 
al., 2012). 
Elevated mRNA levels of COX-2 were detected in arsenite exposed normal human 
epidermal keratinocytes at concentrations comparable to arsenic exposed 
populations (Hamadeh et al., 2002). In addition, chronic exposure to 50 nM MMA(III) 
for 12, 24, and 52 weeks led to time dependent increases of COX-2 and epidermal-
growth-factor-receptor (EGFR) activation (Eblin et al., 2009), which was correlated 
with phenotypic alterations and the development of malignancy. The authors also 
report the induction of COX-2 via the mitogen-activated protein kinase (MAPK) 
signalling, which is activated by the increase of reactive oxygen species (ROS). 
Previous studies showed increased COX-2 protein levels and increased intracellular 
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ROS in UROtsa cells exposed to MMA(III) for 52 weeks (Eblin et al., 2007). Both 
studies report the increased steady state mRNA of COX-2. In contrast, exposure to 
1 µM As(III) for 52 weeks led to statistically significant decreased COX-2 protein 
levels. The authors concluded that MMA(III) has more influence on the MAPK 
signalling than As(III) (Eblin et al., 2009). The authors reported that COX-2 is 
dependent on the continuous generation of ROS, as ROS inhibition resulted in a 
decrease of COX-2 in a comparable manner as with a specific COX-2 inhibitor. 
Furthermore, depletion of ROS in UROtsa cells treated with MMA(III) for 52 weeks 
led to colony formation results similar to those of non-treated UROtsa cells, whereas 
MMA(III)-treated UROtsa cells without ROS depletion showed stronger tumourigenity 
by an increased colony formation in soft agar. Based on the fact that COX-2 is 
important for a sustaining anchorage-independent growth, the protein was concluded 
to be required for the arsenic-induced transformation process (Eblin et al., 2009). 
A connection between arsenic-induced carcinogenesis and altered DNA methylation 
patterns is currently discussed, because both, arsenic biomethylation and DNA 
methylation, utilise the same methyl donor SAM, which is also involved in many 
further metabolic reactions. As SAM is the unique methyl donor in arsenic 
metabolism, it is proposed that chronic arsenic exposure might deplete SAM, 
especially in combination with methionin insufficient diet leading to decreased SAM 
synthesis. Many studies report hypomethylation after arsenite exposure both in vitro 
and in vivo. Reichard et al. (2006) report a depletion of SAM in human HaCaT cells 
after treatment with sub- to low-micro molar concentrations of arsenite. In addition, 
arsenite repressed the expression of DNMT1 and DNMT3A. Based on these results 
the authors conclude that long-term exposure to arsenite might lead to DNA 
hypomethylation. Moreover, only very few data for the human system report that 
arsenic exposure, e.g. via contaminated drinking water, leads to global DNA 
hypomethylation (Ren et al., 2011). Especially, the hypomethylation of LINE1 was 
observed in subjects suffering from bladder cancer. A strong correlation between the 
risk of non-invasive bladder cancer and LINE1 hypomethylation was observed, but in 
contrast, there was no significant association to invasive bladder cancer cases. The 
authors suggested that LINE1 hypomethylation is an independent risk factor for 
bladder cancer and might serve as an excellent biomarker. However, a dose-
dependency between LINE1 methylation extent and the risk of bladder cancer was 
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not observed (Wilhelm et al., 2010). Further studies have to be performed to assay 
whether LINE1 methylation patterns are directly targeted by arsenic. 
Among global DNA hypomethylation, promoter hypermethylation was also observed 
in human skin and bladder cancer, in animals in vivo, as well as in human and animal 
cell lines in vitro (Ren et al., 2011). In patients suffering from bladder cancer after 
arsenic exposure, promoter hypermethylation of RASSF1A was observed. The 
excess of arsenic incorporation was measured from toenail arsenic content, and the 
authors detected a correlation between arsenic exposure, RASSF1A promoter 
methylation, and bladder cancer occurrence (Marsit et al., 2006b). Moreover, in A/J 
mice arsenic exposure resulted in promoter hypermethylation of RASSF1A and was 
associated with the development of lung cancer (Ren et al., 2011). 
Only very poor information is available on the effect of arsenic treatment on miRNA 
profiles, especially in bladder cancer. Marsit et al. (2006a) detected generally 
increased miRNA profiles after arsenic exposure in human lymphoblastoid cells. The 
results were similar to those received from cells cultured under folate deficiency, 
which is known to result in altered SAM levels and altered global genomic 
methylation. Both, exposure to arsenic as well as folate deficiency, induced 
significantly different miRNA profiles than those from cells grown under normal 
control conditions, where arsenic-induced a less dramatic increase as compared to 
folate deficiency. In detail, hsa-miRNA-22, hsa-miRNA-34a, hsa-miRNA-221, hsa-
miRNA-222,and hsa-miRNA-210 were affected by both treatments. Importantly, the 
latter miRNA was the only one whose expression was decreased. Due to similar 
effects of arsenic exposure and folate deficiency the authors conclude that altered 
miRNA expression is based on SAM depletion and, as a consequence, changes in 
DNA methylation patterns. Hence, arsenic is believed to operate by altering the one-
carbon metabolism and thus exhibit downstream epigenetic effects. Aberrant 
phenotypes during tumourigenesis were suggested to result from alterations in key 
miRNA expression at critical points in development. Nevertheless, the induced 
changes in miRNA expression were not stable and returned to baseline levels upon 
removal of stress conditions, suggesting that chronic exposure may be necessary to 
permanently alter the expression of miRNAs. 
There are few data available concerning arsenic-induced angiogenesis. Kao et al. 
(2003) reported bilateral effects of arsenic exposure concerning angiogenesis in vitro. 
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0.1 µM sodium arsenite significantly increased tube lengths of Human Umbilical Vein 
Endothelial Cells (HUVEC) seeded on Matrigel (1.54 fold as compared to control), 
whereas at concentrations of 5 µM and above tubing integrity was disrupted. 
Furthermore, sodium arsenite treatment of HUVEC cells induced expression of 
VEGF121 by 2.8 fold as compared to control at concentration of no more than 0.1 µM. 
Similar results were obtained after As2O3 treatment in HeLa cells at high 
concentrations of 5 and 10 µM, which indicated on a dose dependent inhibition of 
CD44v6, VEGF-C, and MMP-9 mRNA synthesis (Tab. 2; Du et al., 2009). 
Tab. 2 Results of the semi-quantitative RT-PCR analysis in HeLa cells after 48 h exposure to 
As2O3 
(Du et al., 2009, modified) 
Gene 
CD44v6 
VEGF-C 
MMP-9 
untreated control 
0.386 ± 0.049 
0.605 ± 0.166 
0.966 ± 0.205 
5 µM As2O3 
0.244 ± 0.120 
0.344 ± 0.038 
0.466 ± 0.121 
10 µM As2O3 
0.177 ± 0.030 
0.150 ± 0.036 
0.220 ± 0.098 
These findings are further supported by data from Soucy et al. (2003). As(III) induced 
a dose dependent increase in vessel density in the chicken chorioallantoic-
membrane (CAM) assay, but at concentrations above 1 µM inhibition of vessel 
growth was observed. The authors concluded a threshold concentration of 0.33 µM 
arsenite for arsenic-induced angiogenesis in the CAM assay. Taken together, in vitro 
assays gave strong indications for arsenic-induced angiogenesis at low, 
environmentally relevant concentrations. As angiogenesis is a very important step in 
the development of solid tumours, this data is very concerning. Further in vivo data 
are needed to determine, whether arsenic exhibits a direct influence on angiogenesis 
in arsenic-induced cancer diseases, or if this is just a secondary effect during 
carcinogenesis. 
Among molecular markers of arsenic-induced tumourigenesis also the resulting 
malignant phenotypical changes in vitro were assayed. Wen et al. (2008) observed 
increased population doubling times, enhanced motility and invasiveness, as well as 
the development of anchorage-independent growth of immortalised human small 
airway epithelial cells (SAEC) after subchronic treatment with 0.5 µg/mL sodium 
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arsenite for 6 months. These findings were furthermore correlated with an increase in 
micronuclei formation and the increased expression of oncoproteines such as c-myc, 
c-Ha-ras, and c-fos. The authors conclude that long-term arsenite treatment has 
caused an oncogenic cell transformation. These findings are supported by the results 
obtained in mouse skin epidermal cells JB6 Cl14, which developed anchorage-
independent growth after arsenic treatment (Huang et al., 1999). More recent studies 
with UROtsa cells came to comparable results after chronic low-dose transformation 
with arsenic. Interestingly, both As(III) and MMA(III) caused increased anchorage-
independent growth after up to 52 weeks of exposure (Bredfeldt et al., 2006; Jensen 
et al., 2009). Moreover, xenografts of UROtsa cells treated with 50 nM As(III) for 
52 weeks into SCID mice resulted in significantly increased subcutaneous tumour 
formation as compared to the untreated control (Bredfeldt et al., 2006). Furthermore, 
already 12 weeks of exposure to 50 nM MMA(III) were sufficient to cause enhanced 
tumourigenesis after injection (Wnek et al., 2010). Similar results were observed in 
earlier studies. Low-dose arsenite (0.5 µM) induced malignant transformation of rat 
liver epithelial cells TRL 1215 and led to metastatic tumour growth after injection into 
nude mice (Zhao et al., 1997). 
In summary, all these studies revealed that carcinogenesis in general, but especially 
arsenic-induced (bladder) cancer has multifaceted modes of action. Despite cytotoxic 
effects of arsenic treatment at concentrations of 1 µM and above, environmentally 
relevant low doses revealed cytotoxic tolerance in combination with diverse cellular 
effects such as genotoxicity and epigenetic modifications, leading to e.g. inhibited 
DNA repair, altered cell cycle progression, and morphological changes. In addition, 
not only inorganic arsenic itself, but also its metabolites originating from 
biomethylation processes, exhibit tumourigenic effects. Further studies are urgently 
needed to connect those manifold results and develop a complete model of arsenic-
induced (bladder) cancer. Only a better understanding of these mechanisms 
undergone during arsenic-induced (bladder) carcinogenesis can be the basis for 
more effective diagnostic methods at earlier disease stages by utilising biomarkers, 
finally leading to a more successful medical treatment. 
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2.6 Aim of the present work 
The aim of the present work was to contribute to a better understanding of the 
mechanisms behind arsenic-induced cancer, especially regarding bladder cancer. 
For this purpose, a series of studies was undertaken, to correlate arsenic metabolism 
and genotypic effects with epigenetic modifications and phenotypical alterations 
under chronic exposure conditions in vitro: 
1 . The cellular uptake and intracellular biotransformation of arsenic species in 
non-methylating human urothelial cells (T24) in comparison to methylating 
human hepatic cells (HepG2) was investigated, and the detected intracellular 
arsenic was speciated and quantified. 
2. Induced genotoxic effects in T24 cells were measured with the Alkaline Comet 
Assay. To investigate the impact of metabolic capacitiy of the affected tissue 
on the extend of genotoxicity, both non-methylating T24 cells and methylating 
HepG2 cells served as a cellular model. Furthermore, primary human 
uroepithelial cells (HUEPC) were utilised in this test to estimate differences in 
susceptibility against genotoxicity of primary and permanent cell culture 
systems. 
3. MiRNA analysis and examination of altered DNA methylation patterns were 
carried out in T24 cells to determine the arsenic-induced modulation of 
epigenetic regulation systems. Additionally, COX-2 protein, an important 
molecular markers, was analysed. The tests were carried out throughout the 
course of chronic low dose treatment with arsenic and aimed to investigate a 
possible time dependency. 
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4. The malignant transformation following chronic arsenic treatment was assayed 
using the Mammalian Cell Transfomation Assay, the Colony Formation Assay, 
and the Migration and Invasion Assay. The tests were carried out to 
investigate the influence of arsenic on a malignant phenotype and addressed 
endpoints such as loss of growth inhibition and the acquirement of three-
dimensional growth abilities and enhanced motility, as well as invasive 
properties. 
Since the various arsenic species emerging from the hepatic biotransformation of 
arsenic exhibit distinctly different toxicity, this study focussed especially on effects 
induced by methylated metabolites such as MMA(III). 
The study was conducted to enhance the understanding of the mechanisms behind 
arsenic-induced toxicity and carcinogenesis in the urinary bladder epithelium. 
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3 Material and Methods 
For detailed information on applied chemicals and solutions please refer to Annex 
7.1. 
3.1 Cells and culture conditions 
3.1.1 Human urothelial cells: UROtsa and T24 cells 
The UROtsa cell line was immortalised by introduction of the SV40 large T-antigen 
into human urothelial cells (Petzold et al., 1995, Johnen et al, 2013), thus having a 
stable karyotype without developing anchorage-independent growth properties in 
later passages, as compared to cells immrotalised with the live SV40 (Christian et al., 
1987, Johnen et al,. 2013). UROtsa cells were further described to be non-tumorous 
in immuno-compromised mice, therfore serve as a model for normal human urothelial 
cells and are considered to be a suitable test sytem to explore the mechanisms of 
bladder carcinogenesis in vitro (Rossi et al., 2001; Eblin et al., 2008; Johnen et al., 
2013). When maintained in serum-coontaining cell culture medium, UROtsa cells are 
relatively undifferentiated and only form monolayers instead of stratified layers like 
those observed from primary cells. In contrast, when maintained under serum-free 
conditions, UROtsa cells were reported to form structures comparable to the 
intermediate layer of the bladder epithelium in vivo (Rossi et al., 2001; Johnen et al., 
2013). 
UROtsa cells used in the present study were a generous gift from Prof. M. Styblo 
(University of North Dakota, USA). However, experiments conducted in this 
laboratory after the present study revealed uncertanities about the identity of the 
UROtsa cells used. A full analysis to investigate this question was recently performed 
by G. Johnen and colleagues (Institute for Prevention and Occupational Medicine of 
the German Social Accident Insurance, Institute of the Ruhr-University Bochhum, 
Germany). The data exhibited that the UROtsa cells used in this laboratory actualy 
are T24 cells (transitional cell carcinoma of the urinary bladder), which was proven by 
means of RNA expression, DNA methylation, and genomic analyses (short tandem 
repeat (STR) profiling). It is assumed that cross-contamination might have occurred 
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already before 2004, however, the time and place of the contamination could not be 
determined (Johnen et al., 2013). 
As early as 1973 the T24 cell line was derived from an invasive human transitional 
cell carcinoma from the bladder of a female patient (Gildea et al., 2000). The cell line 
was characterised by its non-tumourigenicity when injected into SCID mice. However, 
it became apparent that over time variants of the T24 cell line have established 
exhibiting evidently higher tumourigenicity than the original cell line, which is why one 
of these was named T24T (Gildea et al., 2000). The authors investigated a study to 
characterise the differences between T24 and T24T cells, showing that in contrast to 
T24, the latter cell line lost the property of contact inhibition (as indicated by means of 
the Colony Formation Assay and the in vitro Mammalian Cell Transformation Test), 
are more motile at higher cell densities in the cell migration assay, and form tumours 
when injected into SCID mice. On the other hand, both cell lines showed the ability to 
degrade matrigel, which simulates extracellular matrix, and were therefore proven to 
exhibit proteolytic activities. Observations made in the present study indicate that the 
cell line contaminating the UROtsa stocks actually is the non-tumourigenic T24 cell 
line rather than the tumourigenic T24T cell line. 
T24 cells contaminating the UROtsa stocks showed varying chromosome numbers, 
but only relatively moderate alterations of gene expression and gene methylation 
paterns during long-term culturing. The data show that our cells slightly differ from the 
ACC376 T24 cells registered at the STR database of the German Collection of 
Microorganisms and Cell Cultures (DSMZ) and the HBT-4 T24 cells distributed by the 
American Type Culture Collection (ATCC) (Johnen et al., 2013): the STR analysis of 
our T24 cells was 100% identical with the HBT-4 data of the DSMZ database and 
differed in only one allel from the ACC376 serving as concurrent control for the 
analyses. Among this, DNA methylation patterns of AC374 and our T24 cells are 
similar but not identical. The karyotype reported for all three T24 stocks is slightly 
different: ATTC data show 86 chromosomes for HBT-4 cells, the DSMZ reports 70-77 
chromosomes, and our T24 cell line exhibited varying chromosome numbers 
between 55 and 83. Whether our T24 cell line evolved so far from the known T24 
stocks that it could be considered to represent a new variant could not be confirmed 
so far (Johnen et al., 2013). Therefore, the cell line used in our laboratory will in the 
following only be named as T24 cell line. 
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The T24 cells were maintained in Earle’s minimal essential medium (MEM) enriched 
with 10% foetal bovine serum (FBS), 0.5% Gentamycin, and 1 % L - glutamine. They 
were incubated at 37 °C and 5% CO2 atmosphere in 75 cm² flasks. The T24 cells 
were observed to grow adherent and in a monolayer (Fig. 12) (Zdrenka et al., 2012). 
Fig. 12 T24 cells grown as a monolayer in a 75 cm² flask 
3.1.2 Human urothelial epithelial cells HUEPC 
Human urothelial epithelial cells (HUEPC) (Fig. 13) were obtained from Provitro 
(Cat.-No.: 1210721; Provitro GmbH, Berlin, Germany). They were produced on the 
base of human tissues and isolated according to known procedures (Provitro GmbH, 
2012). The primary cells were maintained in the serum-free urothelial cell growth 
medium supplemented with < 0.5% BPE (bovine pituitary extract), < 0.5 µg/ml 
Hydrocortisone, 10 ng/ml epidermal growth factor (EGF), 0.5 µg/ml Epinephrine, 
5 µg/ml Transferrin and 4 ng/ml T3 (3,5,3’-triiodothyronine). Furthermore, 50 ng/ml 
Amphotericin B and 50 µg/ml Gentamycin were added according to the protocol 
delivered with the growth medium (Provitro GmbH, 2012, Zdrenka et al, 2012). 
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Fig. 13 HUEPC cells grown as a monolayer in a 75 cm² flask 
3.1.3 HepG2 cells 
HepG2 cells (Fig. 14) originate from a hepatocellular carcinoma of a 15 year old male 
Caucasian. They were obtained from ATCC (HB 8065; ATCC, Manassas, VA, USA) 
and cultured in Earle’s minimal essential medium (MEM) enriched with 10% FBS, 
0.5% Gentamycin, 1% L - glutamine, 1% non essential amino acids (NEAA) and 1% 
sodium pyruvate. The cells were incubated at 37 °C and 5% CO2 atmosphere in 
75 cm² flasks. They are adherent and generally grow in a monolayer, but as soon as 
HepG2 cells are confluent they build up multilayer (Zdrenka et al., 2012). 
Fig. 14 HepG2 cells grown as a monolayer in a 75 cm² flask 
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3.2 Handling of the cell lines 
3.2.1 Culture conditions and subculture 
All cell lines were grown under typical cell culture conditions (37 °C, 5% CO2, 
humidified incubator) and medium was replaced every 2 – 3 days. Cells were grown 
to 75 - 80% confluence. For subculture the cells were washed with phosphate 
buffered saline (PBS) and T24 and HepG2 cells were detached using 0.25% trypsine 
containing 0.1% 2-[2-[bis(carboxymethyl]amino]ethyl-(carboymethyl)amino]acetic 
acid (EDTA) and finally split into ¼ and transferred into new flasks (Zdrenka et al., 
2012). 
3.2.2 Cell exposure 
Except for the chronic exposure experiments, the cells were seeded into cell culture 
devices according to the experimental purpose and incubated over night. Medium 
was then replaced by fresh culture medium containing the desired arsenic compound 
and concentration (exposure medium) and the cells were then incubated under cell 
culture conditions (Ch. 3.2.1). 
For the chronic exposure experiments, 300,000 T24 cells were seeded into 75 cm² 
flasks and fed with 25 ml medium containing 50, 75, or 100 nM MMA(III), 
respectively. T24 cells fed with medium without any arsenic compound served as 
negative control. Once a week the cells were subcultured and fed with fresh 
exposure medium and 4 days later the exposure medium was replaced again. For 
cell detachment 0.25% trypsin without EDTA was used to prevent the complexation 
of arsenic (Zdrenka et al., 2012). 
3.3 Applied methods 
3.3.1 Determination of intracellular arsenic metabolism 
Several studies report that humans, who are exposed to arsenic contaminated 
drinking water excrete many different arsenic metabolites such as MMA(V), DMA(V), 
and DMMTA(V). (Aposhian, 2000; Fillol, 2010). In vivo experiments showed that 
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DMA(V) caused bladder cancer in rats after exposure for a long time (Wei et al., 
1999). Moreover, thiolated arsenicals (DMMTA(V)) could be detected in the urine of 
DMA(V) exposed rats (Yoshida et al., 1998). It still remains unknown, which arsenic 
species are responsible for the development of bladder cancer. Therefore, a new 
methodology for intracellular arsenic speciation in vitro was established and the 
arsenic metabolism in T24 cells was compared to that in HepG2 cells. 
3.3.1.1 Cell exposure and sample preparation using Precellys®24 tissue 
homogeniser 
Assay Principle: 
Methylating HepG2 cells and non-methylating T24 cells were treated with 5 µM 
MMA(III) for various time periods. An exhaustive cell-washing process to remove all 
extracellular arsenic by dilution, complexation or covalent binding had to be explored 
to ensure that only arsenic originating form intracellular sources was detected. 
Therefore, the dilution ability was tested by repeated washing with PBS, and the 
complex formation of EDTA with the arsenic was investigated. None of those 
washing processes led to in satisfying results, as there were still considerable 
amounts of arsenic left. Finally, 2,3-bis(sulfanyl)propane-1-sulfonic acid (DMPS, 
Fig. 15), generally applied for the cure of heavy metal poisoning, was used for the 
removal of extracellular arsenic by covalently binding it to its sulfhydryl groups 
(Hippler et al., 2011). 
SH 
HS> ,SO3H 
Fig. 15 Structure of DMPS (2,3-bis(sulfanyl)propane-1-sulfonic acid) 
Furthermore, a suitable cell lysis method had to be explored. Therefore, freeze and 
thaw was tested, which did not lead to a complete cell lysis. In contrast, osmotic 
pressure resulted in a complete cell lysis, but the dilution effect was of a big 
disadvantage, because of the detection limits of the arsenic speciation and 
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quantification methodology. Finally, mechanical lysis using the Precellys®24 tissue 
homogeniser (Fig. 16) was examined (Hippler et al., 2011). 
A ^ J t B 
C 
Fig. 16 Precellys®24 tissue homogeniser 
The homogenizer (Pequlab Biotechnologie GmbH) (A) was used for mechanical lysis. The 
applied devices (C) contained ceramic beads (B) with a diameter of 1.4 mm. (Peqlab 
Biotechnologie GmbH, 2012) 
The system is based on the destruction of cells and tissues by mechanical 
homogenisation using ceramic beads and shaking the samples with 6500 rpm. 
Subsequent centrifugation separated the non-soluble cell components from the 
soluble fraction (Hippler et al., 2011). 
The non-soluble fraction consisted of membranes and other solid cellular structures. 
They were enzymatically digested using Proteinase K and the conjugated arsenic 
was released by oxidation with H2O2 (hydrogen peroxide) (Naranmandura et al., 
2006; Hippler et al., 2011). 
Methodology: 
Cells were seeded into 150 cm² flasks and grown to confluence before experiments 
were performed. Both cell lines (T24 and HepG2) were incubated for 5 min up to 24 h 
in fresh growth medium containing 5 µM MMA(III) (exposure medium). The negative 
control consisted of cells incubated in fresh medium without any arsenic compound 
and subsequently they were handled the same way as the exposed cells. 
Additionally, a second negative control was trypsinised for cell counting. 
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After incubation the exposure medium was withdrawn and stored at -80°C. Cells 
were washed with 10 ml PBS and 10 ml Ampuwa (sterile, deionised water). For the 
next washing step 10 ml 0.1 mM DMPS were used to remove traces of extracellular 
uncombined arsenic ions. The last washing step with 10 ml PBS was carried out to 
remove the residues of DMPS before lysis (Fig. 17). All washing solutions were 
retained and stored at -80°C until arsenic speciation analysis (Hippler et al., 2011). 
Fig. 17 Washing process prior to the intracellular arsenic speciation and quantification 
Exhaustive cell washing ensures the removal of all extracellular arsenic residues after cell 
exposure (Hippler et al., 2011, modified) 
Cell lysis was performed using the Precellys®24 tissue homogeniser as a tool for 
mechanical lysis. Therefore, the cells were first detached from the culture flasks 
using a cell scraper and transferred to 0.5 ml tubes containing ceramic beads with a 
diameter of 1.4 mm. Exhaustive homogenisation was obtained within three intervals 
of 20 s and 6500 rpm. Final centrifugation using a miniSpin plus centrifuge at 
14.000 x g assured a complete separation of the cell lysates from membranes and 
other solid, insoluble cellular structures. This non-soluble fraction of each sample was 
then enzymatically digested using Proteinase K until the pellet was dissolved. Further 
oxidation with H2O2 (30%) assured the release of arsenic from peptides and other 
cellular molecules (Hippler et al., 2011). 
3.3.1.2 Intracellular arsenic speciation and quantification using HPLC-ICP/MS 
At this point I want to express my gratitude to my colleague and project partner J. 
Hippler from the Institute of Environmental Analytical Chemistry (University of 
Duisburg-Essen, Germany) under the head of Prof. Dr. Hirner, who kindly performed 
the experiments of the intracellular arsenic speciation and quantification and provided 
the data for the present study. 
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Assay Principle: 
The High Performance Liquid Chromatography (HPLC) is based on the separation of 
a mixture of compounds by interaction of the analytes with the stationary phases. A 
pump moves the mobile phase and the analytes through the column. Depending on 
the type of column the adherence of the analytes differs, and in consequence there 
are analyte-specific retention times. By comparing with standard solutions or using 
data bases the analytes can be identified. Identification of the analytes can further be 
determined be coupling the HPLC with a detector such as an UV detector or a mass 
spectrometer (MS). 
Fig. 18 HPLC-ICP/MS Coupling 
(Chen et al., 2005) 
Using inductively coupled plasma mass spectrometry reveals the advantage of highly 
sensitive multi element analyses for a large number of samples and is often applied 
in the trace analysis of heavy metals such as mercury, lead, or cadmium. A plasma 
serves as an ionisation source and produces the ions, which are then recognised by 
the detector (m/z). Using ICP/MS most of the elements achieve detection limits in the 
magnitude of ng/l. 
By coupling the ICP/MS with analytical separation methods such as HPLC, the 
system can be used for species analysis (Ammann, 2007). 
The cell lysates and the digestion products of the non-soluble fraction were analysed 
by using HPLC-ICP/MS technique. The total and relative amount of the different 
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intracellular detected arsenic species and their development over time gives an 
interesting hint to the ability of intracellular biotransformation. 
Methodology: 
After exposure, lysis, and centrifugation all solutions and samples were stored at -
80°C and thawed immediately before HPLC-ICP/MS analysis. The injected sample 
volume onto the HPLC-column was dependent on the expected arsenic content of 
the samples and counted 1 to 25 µl. 
A multi-As species standard was used for quantification and contained 2 pg to 200 pg 
As(III), MMA(III), DMA(V), MMA(V), DMA(III), and As(V). Transient signals for As at 
m/z 75 in non-collision cell mode at dwell times of 100 ms were monitored and 
revealed the peak areas for arsenic quantification. External calibration resulted in an 
excellent linearity (e.g. MMA(V): r² = 0.9999; DMA(V): r² = 0.999). The limits of 
detection were calculated and revealed values of approximately 3 pg As, whereas the 
exact values varied slightly depending on the arsenic species. The conditions chosen 
for HPLC and ICP/MS are presented in (Tab. 3). To proof the reliability of the results, 
two replicate experiments were conducted (Hippler et al., 2011, as cited in Zdrenka et 
al., 2012). 
Tab. 3 Conditions chosen for the HPLC and ICP/MS 
(Hippler et al., 2011, modified, as cited in Zdrenka et al., 2012) 
HPLC conditions 
HPLC Column Phenomenex Luna 3µ 
C1 8(2) 100 
Column temperature 30 °C 
Eluent flow rate 0.5 ml min -1 
Injection volume 1 - 25µl 
Eluent: 
Malonic acid 2 mM 
Tetrabutylammonium hydroxide 6 mM 
(TBAH) 
Methanol 5 v/v% 
Water 95 v / v % 
pH 6.0 
ICP/MS conditions 
Forward power (RF) 1580 W 
Plasma gas rate (cool gas flow) 15 L Argon min -1 
Carrier gas flow rate ~ 0.8 L min-1 
Make-up gas flow rate ~ 0.25 L min -1 
Sample depth 5.7 mm 
Spray chamber Quarz, cooled, 2 °C 
Isotopes monitored 75As, 35Cl, 77(40Ar37Cl)34S, 71Ga, 
73Ge, 115In, 103Rh 
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3.3.2 Genotoxicity 
3.3.2.1 Alkaline Comet Assay 
Assay principle: 
The Alkaline Comet Assay detects single and double strand breaks of the DNA by 
single cell electrophoresis. Hereby, the alkaline milieu rewinds the DNA and 
separates the strands. Because of the agarose density only small fragments of DNA 
can move in the electric field, whereas unbroken DNA stays densely bundled 
together (Fig. 19). 
A ' " » « • • B 
Fig. 19 Image analysis of the Alkaline Comet Assay 
(A) Negative control: the DNA is densely bundled together, (B) positive control: the fragments 
of the damaged DNA moved in the electric field during electrophoresis 
After staining the gels with a fluorescence dye intercalating into the DNA, image 
analysis can be performed. Hereby, several parameters such as tail length, tail 
fluorescence intensity etc. can be measured. Finally, the Olive Tail Moment can be 
calculated, which is defined as the product of the percentage of DNA in the tail 
multiplied by the tail length (Olive et al., 1991). 
Methodology (T24 and HepG2 cells): 
T24 and HepG2 cells were seeded with a density of 100,000 cells/2 ml medium into 
each well of a 24-well-plate and incubated over night. For exposure the cell culture 
medium was replaced by 2 ml of the exposure medium containing the arsenic 
compounds As(III), As(V), MMA(III), MMA(V), DMA(V) and TMAO in different 
concentrations. The negative control consisted of untreated cells, and positive control 
cells were exposed to 1 mg/ml ENU (N-ethyl-nitroso urea). For exposure to the 
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volatile DMA(III) 1,000,000 cells/10 ml medium were seeded into 25 cm² cell culture 
flasks with vent caps. 
After incubation for 30 min and 60 min the exposure media were removed and the 
cells were trypsinised as described elsewhere (Ch. 3.2.1). The cells were 
resuspended in PBS and 5,000 cells were seeded into each agarose gel consisting of 
0.79% low melting point agarose in PBS. The gels were solidified on ice and the cells 
were lysed overnight. 
For electrophoresis the gels were washed with Ampuwa and incubated in 4°C cold 
electrophoresis solution at pH 13 for 15 min (T24) or 20 min (HepG2), respectively. 
After electrophoresis for 30 min (T24) or 20 min (HepG2), respectively, the gels were 
washed with Ampuwa and neutralised to pH 7.5. Subsequently, the gels were 
washed with Ampuwa again and incubated in 100% ethanol to remove the water 
residues. Finally, the gels were dried overnight at 4°C. 
Methodology (HUEPC cells): 
According to limited cell number HUEPC cells were seeded with a density of 
15,000 cells/160 µl medium into each well of a 96-well-plate and incubated overnight. 
For exposure cell culture medium was replaced by 200 µl of the exposure medium 
containing the arsenic compounds As(III), As(V), MMA(III), MMA(V), DMA(V) and 
TMAO in different concentrations. The negative control consisted of untreated cells, 
and the positive control cells were exposed to 0.1 mg/ml ENU. 
After incubation for 30 min exposure media were removed and the cells were 
detached as described above. The cells were resuspended in 20 µl PBS and seeded 
into each agarose gel consisting of 0.79% low melting point agarose in PBS. The 
gels were solidified on ice and the cells were lysed overnight. 
For electrophoresis the gels were washed with Ampuwa and incubated in 4 °C cold 
electrophoresis solution at pH 13 for 15 min. After electrophoresis for 30 min the gels 
were washed with Ampuwa and neutralised to pH 7.5. Subsequently, the gels were 
washed with Ampuwa again and incubated in 100% ethanol to remove the water 
residues. Finally, the gels were now dried overnight at 4°C. 
Image analysis was performed with Comet Assay IV Software (Perceptive 
Instruments Ltd., Haverhill, UK) using a fluorescence microscope and a digital 
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camera. Therefore, the cells were stained with SYBR GREEN and 50 cells/gel were 
evaluated. Statistical analysis was performed using Microsoft Excel and Graph Pad 
Prism. The experiments were performed in triplicate, but due to limited cell counts, 
HUEPC cells could be examined only once. 
3.3.3 Intracellular COX-2 quantification 
3.3.3.1 Cell lysis and sample preparation 
Assay Principle: 
The CytoBuster Protein Extraction Reagent is a mixture of detergents optimised for 
efficient extraction of soluble proteins from mammalian cells. The non-ionic 
composition of CytoBuster enables isolation of functionally active proteins. No further 
treatment such as sonication or freeze and thaw is needed (MerckKGaA, 2012). 
Methodology: 
T24 cells derived from the chronic treatment (Ch. 3.2.2) were seeded with 
900,000 cells/150 cm² flask and grown to confluence for one week. In between, the 
cells were fed with fresh exposure media once. The exposure media always 
contained the same arsenic concentrations as during the chronic exposure before. 
After one week of incubation the exposure media were removed and the cells were 
washed twice with 10 ml PBS. Subsequently, the cells were lysed with 1.5 ml 
CytoBuster. The detergent was incubated for 5-10 min at room temperature and the 
cells were detached using a cells craper. The total cell lysate was then brought into 
reaction tubes and the samples were centrifuged at 14,000 x g and room temperature 
for 30 min. Finally, the supernatant was aliquoted and stored at -80°C. 
3.3.3.2 BCA (bicinchoninic acid) Assay 
Assay Principle: 
The BCA (bicinchoninic acid) Assay is generally determined for the quantitative 
analysis of proteins in complex samples such as cell lysates (Lottspeich & Engels, 
2006). It is based on the Biuret Reaction and the selective complex formation of 
bicinchoninic acid and Copper(I)-Ions (Cu+). The first step of the reaction is the 
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reduction of Cu2 + (originated from a CuSO4-solution) by Cysteine-, Tyrosine- and 
Tryptohane residues, as well as by the peptide bonds. The resulting Cu+ forms a 
stable complex together with the BCA (Fig. 20), which can be quantitatively 
measured using a spectrophotometer at λ = 562 nm. This highly sensitive alternative 
to the Lowry-Assay was first published by Smith et al. (1985). 
-OOC. COO-
Protein + Cu OH
 -
Cu 2 BCA Cu + 
-OOC COO-
^ ^ 
Fig. 20 The BCA (bicinchoninic acid) Assay 
The BCA Assay is a combination of Biuret Reaction and the selective complex formation of Cu+ 
and BCA (Lottspeich & Engels, 2006). 
Methodology: 
For the quantitative analysis of the total protein content in the cell lysates the BCA 
Assay was applied. The chemicals were obtained from BioRad and the test was 
performed according to the provided protocol (BioRadLaboratories GmbH, 2012). 
The samples had to be pre-diluted to a final concentration of 5%, and 5 µl each were 
added to a microtiter plate (Nunc Maxisorb). Additionally, a dilution series of BSA 
(bovine serum albumin) served as a standard for quantification. 25 µl of solution A’ 
(1 ml solution A + 20 µl solution S; solution A: alkaline copper(II)-tartrat solution; 
solution S is necessary in the presence of detergents) were added, as well as 200 µl 
of solution B (Folin Reagent). After incubation for 15 min the absorbance was 
measured using a plate reader. 
The analysis was performed in triplicates, and mean and standard deviation were 
evaluated. According to the standard curve the total protein concentration in the 
samples was calculated. 
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3.3.3.3 ELISA (enzyme-linked immunosorbent assay) 
Assay Principle: 
The ELISA is a largely known method for the quantitative analysis of biomolecules 
such as proteins. The principle is a ‘sandwich-formation’ of antibodies and the protein 
of interest (Fig. 21). Therefore, a microtiter plate is coated with an antibody that 
selectively binds the molecule of interest. After transferring the samples into the 
plate, a primary antibody is applied, that covers the bound protein. A secondary 
antibody conjugated with an enzyme binds now to the primary antibody and catalyses 
the colouric reaction of the applied substrate. The final addition of acid denaturises 
the enzyme and stops the reaction. The amount of the coloured reaction product can 
be quantitatively measured using a photometer (plate reader). The absorbance is 
directly proportional to the protein concentration in the analysed samples. 
TMB 
secondary antibody: 
goat anti-mouse IgG HRP conjugate 
detection antibody: 
monoclonal anti-COX-2 antibody 
COX-2 
capture antibody: 
plate rabbit anti-human COX-2polyclonal antibody 
Fig. 21 Schematic illustration of the COX-2 ELISA 
Methodology: 
The COX-2 ELISA kit was obtained from Calbiochem (Merck KGaA, Darmstadt, 
Germany) and the experiment was performed according to the available protocol. 
100 µl of the samples and the standards were transferred into the pre-coated 
microtiter plate and incubated for 90 min. After removing the supernatant the wells 
were washed three times with the wash buffer using an automated ELISA Washer. 
Subsequently, 100 µl of the primary antibody were added to each well. After 
incubation for 90 min the wells were washed again, and 100 µl of the secondary 
antibody with the HRP-conjugate (Horseradish peroxidase) were incubated for 
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another 60 min. After the final washing step 100 µl of the TMB substrate (3,3 ,5,5 -
tetramethylbenzidine) were added. The reaction was observed by measuring the 
absorbance of the standard curve at 360 nm. When the perfect absorbance was 
reached, the reaction was stopped by addition of 100 µl of the Stop-Solution (1 M 
H2SO4). Finally, the absorbance was measured at 450 nm. 
The analysis was performed in duplicates and the mean and standard deviation were 
evaluated. According to the standard curve the COX-2 concentration in the samples 
was calculated. Finally, the COX-2 concentration was divided by the total protein 
concentration and the results received were given in µg COX-2/mg total protein. 
3.3.4 miRNA analysis 
At this point I want to express my gratitude to my colleagues and project partners Dr. 
D. G. Weber and Dr. O. Bryk from the Institute for Prevention and Occupational 
Medicine of the German Social Accident Insurance (Institute of the Ruhr-University 
Bochum, Germany) under the head of Dr. G. Johnen, who kindly performed the 
experiments of the miRNA analysis and provided the data for the present study. 
3.3.4.1 Cell lysis and miRNA isolation 
Assay Principle: 
MiRNA isolation was performed by using the RNeasy Plus Mini Kit. Genomic DNA is 
easily removed without the need of DNase and highly purified miRNAs can be 
obtained from 1 Mio cells/sample. Fig. 22 schematically presents the isolation 
process (QIAGEN, 2012). 
53 
Material and Methods 
Fig. 22 Procedure of miRNA isolation using the RNeasy Plus Minikit 
(QIAGEN, 2012) 
Methodology: 
T24 cells obtained from the chronic treatment (Ch. 3.2.2) were harvested every 4 
weeks. After trypsinisation, cells were resuspended in RNAlater and aliquoted into 
1 Mio cell samples. The cells were stored at -20°C until analysis. 
The miRNA isolation was performed by using the RNeasy Plus Mini Kit. The following 
procedure was conducted according to the user manual (QIAGEN, 2012), but with 
few minor modifications. The cells were centrifuged for 10 min at 400 x g and 4 °C. 
The supernatant was removed and the pellet was resuspended in 350 µl RLT+ buffer 
and 10 µl mercaptoethanol. The homogenised lysate was then transferred to a gDNA 
Eliminator spin column placed in a 2 ml collection tube and centrifuged for 1 min at 
8,000 x g. After mixture of 350 µl ethanol (80%) with the flow-through a maximum 
volume of 700 µl was transferred to a RNeasy spin column placed in a 2 ml collection 
tube and again centrifuged for 1 min at 8,000 x g. Subsequently, the flow-through 
was mixed with a 1.4 times volume of ethanol absolute and transferred to an RNeasy 
Mini spin column placed in a 2 ml collection tube and centrifuged for 1 min at 
8,000 x g once more. The desired miRNA was then fixed on the column and purified 
by washing with 500 µl RPE and 500 µl ethanol (80%). Finally, the desired miRNA 
was eluated with 50 μl RNase-free water. 
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3.3.4.2 Reverse Transcription 
Assay Principle: 
To amplify miRNAs they first have to be converted into DNA, because during RCR 
specific DNA dependent DNA polymerases are used, which are not able to amplify 
RNA. Hence, reverse transcription (Fig. 23) must be determined to produce a cDNA, 
which is complementary to the desired miRNA. 
Fig. 23 Principle of the reverse transcription 
(Life Technologies Corporation, 2012) 
Hereby, RNA dependent DNA polymerases are used, which are enzymes obtained 
from retroviruses. The resulting cDNA then serves as the parent material for the 
following PCR to finally amplify the sample. 
Methodology: 
Briefly, a mastermix of a stem-loop Reverse Transcription Primer, Reverse 
Transcription Buffer, dNTPs (2’-desoxynucleotide-5’-phosphates), MultiScribe 
Reverse Transcriptase, RNase inhibitor, and Nuclease-free water was mixed and 
aliquoted according to the sample quantity. 10 µl of the mastermix were added to 5 µl 
of the samples (template), and applied to the reverse transcription. Therefore, the 
thermocycler was run with one cycle only: 30 min at 16°C, 30 min at 42°C, and 5 min 
at 85°C. Finally, the samples were cooled down to 4°C. 
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3.3.4.3 Quantitative PCR (TaqMan assay) 
Assay Principle: 
The PCR (polymerase chain reaction) was originally developed in 1984 by scientists 
of the Cetus Corporation (Lexikon der Biochemie, 1999). It is determined to amplify a 
DNA fragment, which is located between two regions of a known nucleotidase-
sequence within a complex DNA matrix. The source is not necessarily the isolated 
target gene, but also a complex DNA extract originated from a cell lysate can serve 
as raw material. 
The first step of a PCR is always the denaturation of the target material to receive 
single strands. Therefore, the mixture is heated up to 92 - 96°C for 60 s, followed by 
a cool down to 55 - 60°C for 30 s. The primer now hybridise via hydrogen bonds to 
their complementary sequence of the target DNA. The primers are 20 - 25 nucleotide 
long, synthetically produced oligonucleotides, which are complementary to the 
flanked sequences of the target gene. They serve as the point of initialisation for the 
polymerase and are elongated towards the 3’ -» 5’ direction during the third and last 
step of the PCR. Generally, the Taq-DNA-Polymerase isolated from the bacterium 
Thermus aquaticus is applied (Saiki et al.,1988), as it survives the heat during the 
denaturation step. This is prerequisite for the automatisation of the PCR. The Taq-
Polymerase connects the complementary dNTPs to the 3’-hydroxy-ends of the new 
strand. For this reaction a temperature of 72°C for 1 - 3 min is required, depending 
on the length of the amplificated matrix. The whole process is repeated a numerous 
times, whereas every repetition doubles the material. 
TaqMan Assay 
The TaqMan Assay is a real time PCR for the quantitative analysis of the target DNA 
matrix with its detection limits in the order of magnitude of femto- and attograms 
(Lottspeich & Engels, 2006). The amplification products are already measured during 
the PCR (homogenous quantitative analysis) without the removal of the reaction 
educts and the addition of detection reagents. This closed system prevents a sample 
contamination. 
For the detection a probe is applied, which adheres to the target sequence during the 
amplification. Such a probe is generally a combination of a fluorescence dye 
(reporter) and a quencher, whereas the latter absorbs the emitted fluorescence light 
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from the dye. Following hybridisation to the target molecule, the probe is splitted by 
the 5’-3’-exonuclease activity of the Taq-Polymerase and a fluorescent nucleotide is 
released (Fig. 24). 
The fluorescence can be quantitatively detected and directly correlated with the 
amount of amplificated hybrid complexes. The quantity is given as the cT-value, 
which indicates the amount of necessary PCR cycles to exceed a threshold. Plotting 
the cT-values half-logarithmic against the amount of copies in the raw material, a 
linear connection is resulted. Using a calibration with external standards or the co-
amplification with internal standards, the number of copies of the analysed samples 
can be determined. 
Fig. 24 Principle of the TaqMan Assay 
(Life Technologies Corporation, 2012) 
Methodology: 
Briefly, a mastermix containing TaqMan Assay Solution, TaqMan Buffer, and 
Nuclease-free water was prepared and transferred to optical 8-Tube-stripes (15 µl). 
5 µl of the samples (template) were added to each tube, whereas two replicates of 
each sample were prepared. Finally, the samples were loaded into the real-time PCR 
device and the PCR was started with 10 min at 95°C. Subsequently, 40 cycles were 
run with 15 s at 95°C and 1 min at 60°C. 
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For the quantification of miRNA changes in the T24 cells, the results were normalised 
according to the Ct-Method of Livak & Schmittgen (2001) (Equation 3): 
(3) Ct = (CtmiRNA - CtRNU) sample - (CtmiRNA - CtRNU) control 
whereas CtRNU is the mean value of the small nuclear RNAs RNU44 and RNU48, 
which were selected for the normalisation as they exhibited stable expression 
patterns throughout the exposure to different concentrations of MMA(III). 
3.3.5 DNA methylation 
At this point I want to express my gratitude to my colleagues and project partners P. 
Rozynek and Y. von der Gathen from the Institute for Prevention and Occupational 
Medicine of the German Social Accident Insurance (Institute of the Ruhr-University 
Bochum, Germany) under the head of Dr. G. Johnen, who kindly performed the 
experiments of DNA methylation analysis and provided the data for the present 
study. 
3.3.5.1 Cell lysis and DNA isolation 
Assay Principle: 
Cell lysis is a mandatory step in DNA isolation procedures and can be performed with 
detergents such as the ATL buffer. In addition, cellular proteins have to be broken 
down to avoid DNA degradation caused by DNAses. For this purpose the Proteinase 
K, a serin protease isolated from the fungus Engyodontium album (formerly 
Tritirachium album) (Ebeling et al., 1974), is generally added to the samples. After 
incubation and degradation of the samples, DNA isolation can easily be performed by 
using the QIAcube. This device enables fully automated sample preparation of up to 
12 samples per run. In this studythe QIAamp DNA Mini QIAcube Kit was applied. It 
simplifies DNA isolation from human tissue samples with fast spin-column 
procedures. No phenol-chloroform extraction is required, as the DNA binds 
specifically to the QIAamp silica-gel membrane while contaminants pass through. 
PCR inhibitors, such as divalent cations and proteins, are completely removed in two 
58 
Material and Methods 
wash steps. Pure DNA is eluted and genomic DNA sized up to 50 kb ready to be 
used in PCR (QIAGEN, 2012) is yielded. 
Fig.25 QIAcube for automated DNA isolation procedures 
(QIAGEN, 2012) 
Methodology: 
T24 cells obtained from the chronic treatment were harvested every 4 weeks 
(Ch. 3.2.2). After trypsinisation, cells were resuspended in PBS and stored at -20 °C 
until analysis. 
Samples of 2 Mio cells were centrifuged for 1 min at 11,000 rpm and incubated with 
180 µl Buffer ATL and Proteinase K at 56 °C. As soon as the samles were no longer 
viscid, DNA isolation was performed using the QiaCube in combination with the 
QIAamp DNA Mini QIAcube Kit. The settings used were those, suggested by the 
supplier (QIAGEN, 2012). The final elution volume was set at 200 µl. Using the 
NanoDrop the DNA concentration was determined at OD 260 nm. 
3.3.5.2 Bisulfite sequencing 
Assay Principle: 
The methodology of bisulfite sequencing allows the detection of DNA methylation in a 
given substrate. The treatment with bisulfite (sodiumhydrogensulfite) converts 
unmethylated cytosines into uracil (Fig. 26), whereas methylated cytosines are 
protected from this reaction. After amplification by PCR and sequencing, the 
methylated cytosines will be sequenced as cytosines and unmethylated cytosines 
appear as thymines. 
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Fig. 26 Bisulfite conversion reaction 
(Schaefer et al., 2009) 
The QIAGEN EpiTect Bisulfite Kit exhibits the advantage of a fast procedure as 
automated conversion and purification of bisulfite-converted DNA is possible on the 
QIAcube (Fig. 27). After bisulfite modification the converted single-stranded DNA 
binds to the membrane of an EpiTect spin column. The membrane-bound DNA is 
washed and desulfonated, and purified converted DNA is eluted from the spin column 
(QIAGEN, 2012). 
Fig. 27 Procedure of bisulfite conversion using the QIAGEN Epitect Bisulfite Kit 
(QIAGEN, 2012) 
The principle of pyrosequencing can be divided into 5 steps (Fig. 28). In a first step a 
sequencing primer is hybridised to a single-stranded PCR amplicon that serves as a 
template, followed by incubation with the enzymes, DNA polymerase, adenosine 
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triphosphate (ATP) sulfurylase, luciferase, and apyrase as well as the substrates, 
adenosine 5' phosphosulfate (APS), and luciferin. Subsequently, the first dNTP is 
added to the reaction. If the dNTP is complementary to the base in the template 
strand, the DNA polymerase catalyses its incorporation. Each incorporation event is 
accompanied by the release of pyrophosphates in equimolar quantities to the amount 
of incorporated nucleotides. 
Fig. 28 The 5 steps of the pyrosequencing reaction 
(QIAGEN, 2012) 
ATP sulfurylase converts the pyrophosphates to ATP in the presence of adenosine 
APS. This ATP drives the luciferase-mediated conversion of luciferin to oxyluciferin 
that generates visible light in amounts proportional to the amount of ATP. The light 
produced in the luciferase-catalysed reaction is detected by a chip and seen as a 
peak in the pyrogram. The height of each peak is proportional to the number of 
nucleotides incorporated. The apyrase continuously degrades unincorporated 
nucleotides and ATP. When degradation is complete, another nucleotide is added. 
Finally, the addition of dNTPs is performed sequentially. Hereby, desoxyadenosine 
alfa-thio triphosphate (dATP·S) is used as a substitute for the natural 
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desoxyadenosine triphosphate (dATP), since it is efficiently used by the DNA 
polymerase, but not recognized by the luciferase. As the process continues, the 
complementary DNA strand is built up and the nucleotide sequence is determined 
from the signal peaks in the pyrogram (QIAGEN, 2012). 
Methodology: 
For the bisulfite modification the QIAGEN Epitect Bisulfite Kit was used exactly 
according to the suppliers protocol (QIAGEN, 2012). Following bisulfite modification 
and purification of the converted DNA, an assay-specific PCR was performed by 
using the AmpliTaq Gold DNA Polymerase and a reverse-primer, which is 5’-
biotinylated. Denaturation was achieved at 95°C for 20 s, followed by the annealing 
at 50 - 60°C for 20 s. Elongation of the strands was accomplished at 72°C for 20 s. 
50 PCR cycles were needed to ensure that most of the primers (especially the 
biotinylated ones) are consumed to minimise the background noise for the following 
pyrosequencing step. After the last cycle, the samples were first kept at 72°C for 
5 min before they were cooled down to 8°C. 
After success monitoring via agarose gel electrophoresis, the amplicons were 
denaturated and single strands were obtained by using the Biotage Sample-Prep 
Workstation according to the supplier’s protocol (QIAGEN, 2012). Pyrosequencing 
was determined using the Biotage Pyrosequencer PSQ 96MA and the PyroMark 
Gold reagents. The assay is designed for the detection of 5 - 15 CpGs per promoter 
region and analyses the methylation of every single CpG. 
3.3.6 In vitro mammalian cell transformation test 
Assay Principle: 
The ability of contact inhibition is one of the manifold mechanisms to prevent 
inappropriate cell proliferation and can easily be observed in two-dimensional cell 
cultures, which stop further proliferation as soon as a confluent cell monolayer is built 
up (Hanahan & Weinberg, 2011). In neoplasias, cells lose the ability of contact 
inhibition. There are simple in vitro experiments to assay this phenomenon. Cells 
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grown to confluence in general stop proliferation, but after transformation and a loss 
of contact inhibition they continue proliferation and form colonies. 
E»i'!liig£S 
— «>»».— — - . — — — « « » » * _ 
Fig. 29 Cell culture experiment to assay the loss of contact inhibition in vitro 
(blue: confluent cell monolayer, red: colonies built up after loss of contact inhibition). 
This method is, among others, mentioned in the EU Method B.21 and can be found in 
Dir 88/303/EEC (OJ L 133 1988). However, the guideline emphasises that the 
available methods for the detection of phenotypical changes alone have not been 
established to create a mechanistic link with cancer, but nevertheless, they might be 
capable of detecting tumour promoters. 
Methodology: 
T24 cells obtained from the chronic exposure (Ch. 3.2.2) were grown to confluence in 
12.5 cm² flasks and fed twice a week with 12.5 ml fresh medium containing 50, 75, or 
100 nM MMA(III), respectively. UROtsa cells fed with medium without any arsenic 
compound served as negative control. Image analysis was performed subsequently 
after 2 weeks of incubation using an inverted microscope combined with a Leica 
digital camera. 
3.3.7 Colony formation assay 
Assay Principle: 
When a normal cell is transformed into a cancer cell it loses its restraint to grow 
adherent in monolayers. After cell transformation, which is a step towards 
malignancy, the cells gain the ability to grow anchorage-independent in soft agar and 
form colonies. With help of the colony formation assay (Bredfeldt et al., 2006) the 
development of an anchorage-independent growth after chronic arsenic exposure 
can be determined (Zdrenka et al., 2012). Therefore, T24 cells obtained from the 
chronic exposure experiment were seeded into soft agar and cultured for two weeks. 
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With the loss of the anchorage dependent growth the cells are able to proliferate and 
build cell colonies, otherwise the cells underlie apoptosis. To avoid false positive 
effects because of the high passages two controls were included into the assay: the 
untreated negative control cultured under the same conditions like the treated cells, 
as well as untreated cells of a young passage. 
This method is, among others, mentioned in the EU Method B.21 and can be found in 
Dir 88/303/EEC (OJ L 133 1988). However, the guideline emphasises that the 
available methods for the detection of phenotypical changes alone have not been 
established to create a mechanistic link with cancer, but nevertheless, they might be 
capable of detecting tumour promoters. 
Methodology: 
The colony formation assay was prepared in a 24-well plate. First, 500 µL of a base 
agar containing 0.6% low melting point (LMP) agarose in cell culture medium were 
added to each well, solidified at room temperature, and sterilised under UV light for at 
least 4 hours. 
T24 cells derived from the chronic exposure experiment (Ch. 3.2.2) were seeded with 
a density of 10,000 cells/500 µL top agar (0.3% LMP agarose in cell culture medium) 
into each well. Additional wells were prepared without cells containing only base and 
top agar for background detection. The cells were fed with 250 µL of fresh cell culture 
medium every 3 – 4 days, and image analysis was performed subsequently after 
2 weeks of incubation using an inverted microscope combined with a Leica digital 
camera (Zdrenka et al., 2012). 
3.3.8 Cellular migration and invasion 
Assay Principle: 
The ability of invasion is a particular characteristic of malignant transformed cells. 
The cells are now able to detach from the parent tissue and exhibit protease activity 
to move actively through a biological layer. After migration through the body 
circulation they exhibit the skill, to attach and integrate into a new tissue. The ability 
of invasion provides the basis for the metastasing properties of tumours. 
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For the chronic low-dose exposure it was interesting to determine, whether the 
chronic treatment with MMA(III) can cause such changes. Therefore, the 
xCELLigence DP system (Roche Applied Science, Mannheim, Germany) (Fig. 30) 
with its CIM-Plates (Fig. 31) was used. 
Fig. 30 xCELLigence DP System with control unit and analyser 
(Roche Diagnostics GmbH, 2009) 
These devices consist of a two-chamber-system separated with a microporous 
membrane. The membrane is combined with a gold electrode on the lower side. The 
cells are seeded into the upper chamber, whereas the lower chamber is filled with 
cell culture medium only. For simulating a biological layer both sides of the 
membrane were coated with collagen, since collagen IV is the major component of 
the basement membrane (Du et al., 2009). 
Fig. 31 xCELLigence CIM-Plate system for invasion analysis 
(Bird & Kirstein, 2009, modified) 
The cells, which gained the ability of invasion, can now move through the collagen 
layer and pass the microporous membrane, but only the cells which then adhere at 
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the lower side of the membrane at the electrode are detected. Particles, cell 
fragments, and cells, which cannot attach, will not be detected. 
Attached cells are detected because they cause a relative change in the measured 
electrical impedance, which is displayed via the dimensionless parameter termed Cell 
Index (CI). In the absence of cells or when the cells are not well adhered on the 
electrodes, the CI is zero. In contrast, the attachment of cells under the same 
physiological conditions results in an CI above zero, whereas the CI is directly 
proportional to the cell count and cell adhesion (Fig. 32; Abassi, 2008). 
Fig. 32 Principle of the measurement of the Cell Index using the xCELLigence system 
(Abassi, 2008) 
The measurement was conducted by using the provided software. The advantage of 
this system is not only the guarantee, that only actively invading cells are detected, 
but also that this method is not an endpoint assay. During the whole experiment the 
system measures label-free in arbitrary intervals, so that a time dependent 
development can be observed. 
Methodology: 
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For the detection of invasion the xCELLigence DP system was conducted. Therefore, 
CIM-Plates were coated with 50 µl of 0.02% collagen on each side of the 
microporous membrane for 1 h. After removing the collagen residues the CIM-Plates 
were dried for approximately 1 h at room temperature under the laminar flow. In 
between T24 cells originated from the chronic exposure were trypsinised as 
described elsewhere (Ch. 3.2.2) and brought to a concentration of 1.5 Mio cells/ml. 
For the detection of migration uncoated CIM-Plates were conducted. 
160 µl of the pre-warmed cell culture medium were added to each well of the lower 
chamber and 100 µl were added to each well of the upper chamber. The CIM-Plates 
were then placed into the xCELLigence device and the background was measured. 
Now 100 µl of the prepared cell suspensions were added (duplicate wells), and the 
CIM-Plates were placed into the xCELLigence device again. The measurement was 
performed for 24 h with intervals of 15 min (Zdrenka et a., 2012). 
3.4 Statistics 
All experiments were performed in triplicate, unless stated otherwise. The statistical 
evaluation for the Alkaline Comet Assay was performed using GraphPad Prism 
(GraphPad Software, Inc., CA, USA). The mean values of the detected Olive Tail 
Moments are presented in bar graphs with the standard error of mean (SEM). For 
statistical analysis the non-parametric Mann-Whitney-Test was applied, which 
approximates the Gaussian distribution for more than 20 random samples and 
compares each test group to the untreated control group. Probability values (p) are 
given as follows: 
p > 0.05 non-significant, p 0.05 *, p 0.01 **, p 0.001 *** 
The quantification of miRNAs was determined using the Ct-Method. With 2- Ct 
the relative quantities (RQ) of samples of the treated cells were compared to those of 
the untreated control cells. Significance levels according to Mattie et al. (2006) were 
set at RQ < 0,5 (decrease) and RQ > 2,0 (increase). 
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4 Results 
In this study several endpoints in vitro were analysed to gain further knowledge about 
the processes ongoing during arsenic-induced bladder carcinogenesis. First, the 
intracellular metabolism of MMA(III), one of the most important metabolites during 
arsenic intoxication, was determined in human urothelial cells (T24) and compared to 
that of hepatocytes (HepG2). Furthermore, acute genotoxic effects of the arsenic 
species As(III), MMA(III), DMA(III), As(V), MMA(V), DMA(V), and TMAO were 
analysed using the Alkaline Comet Assay. A dose-response relationship was 
examined, as well as the impact of the exposure duration. Additionally, genotoxicity in 
T24 cells was compared to that in HepG2 cells, which are known to exhibit metabolic 
properties, and primary human uroepithelial cells (HUEPC). 
Moreover, possible effects resulting from chronic low-dose exposure to MMA(III) 
were analysed. Those included epigenetic events such as the regulation status of 
COX-2 protein, miRNA analysis, DNA methylation patterns (both global and specific 
promoter methylation), as well as phenotypic alterations such as the loss of contact 
inhibition, anchorage-independent growth, and migrating and invading properties. 
The study addresses some of the most important effects during carcinogenesis and 
reveals a strong overview over molecular effects following arsenic exposure. 
4.1 Intracellular arsenic speciation and quantification 
At this point I want to express my gratitude to my colleague and project partner J. 
Hippler from the Institute of Environmental Analytical Chemistry (University of 
Duisburg-Essen, Germany) under the head of Prof. Dr. Hirner, who kindly performed 
the experiments of the intracellular arsenic speciation and quantification using HPLC-
ICP/MS and provided the data for the present study. 
First data were already published in Hippler et al. (2011), and further results were 
presented and discussed in Zdrenka et al. (2012), wherefrom the respective 
information was recited in the following chapter. 
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Results of the intracellular arsenic speciation and quantification 
Using HPLC-ICP/MS analysis enabled the detection of more than 99.99% of the total 
arsenic in the non-soluble fraction of both cell lines, and only 0.003% and 0.01% of 
the total arsenic in the soluble fractions of T24 cells and HepG2 cells, respectively. 
While in the non-soluble fraction of T24 cells the arsenic content consisted only of a 
monomethylated species, in HepG2 cells a time dependent occurrence of a 
dimethylated arsenic species additionally to monomethylated arsenic was observed 
(Fig. 33). The differentiation between trivalent and pentavalent arsenic metabolites 
was impossible due to their oxidative release from the cellular structures (Zdrenka et 
al., 2012). 
(A) non-soluble fraction of HepG2 cells 
(B) non-soluble fraction of T24 cells 
Fig. 33 Quantification of the metabolites in the non-soluble fraction after exposure of 
HepG2 (A) and T24 (B) cells to 5 µM MMA(III) 
The analysis was performed using HPLC-ICP/MS technique (Zdrenka et al., 2012). Since this 
experiment was conducted once only, no statistical analysis was performed 
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In the soluble fractions of both HepG2 and T24 cells only pentavalent arsenic species 
were detected (Fig. 34). In HepG2 cells a time dependent increase and decrease of 
MMA(V) was observed. Additionally, the increase of DMA(V) by time was discovered. 
In contrast, in T24 cells only MMA(V) but no DMA(V) was detected. The occurrence 
of MMA(III) after 18 and 24 hours of exposure is believed to be the result of cytotoxic 
effects and due to membrane damage (Zdrenka et al., 2012). 
(A) soluble fraction of HepG2 cells 
(B) soluble fraction of T24 cells 
Fig. 34 Quantification of the metabolites in the soluble fraction after exposure of HepG2 (A) and 
T24 cells (B) to 5 µM MMA(III) 
The analysis was performed using HPLC-ICP/MS technique (Zdrenka et al., 2012). Since this 
experiment was conducted once only, no statistical analysis was performed. 
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4.2 Alkaline Comet Assay 
First data were already presented and discussed in Zdrenka et al. (2012), wherefrom 
the respective information was recited in the following chapter. 
The Alkaline Comet Assay was conducted to examine the genotoxic effects of 
different arsenic metabolites. Testing the trivalent species revealed significant single 
and double strand breaks in T24 cells already after 30 min of exposure (Fig. 35). 
(A) Alkaline Comet Assay – T24 cells – As(III) (B) Alkaline Comet Assay – T24 cells – MMA(III) 
(C) Alkaline Comet Assay – T24 cells – DMA(III) 
Fig. 35 DNA damage in T24 cells after 30 and 60 min of treatment with trivalent arsenic species 
The Alkaline Comet Assay was conducted to assay single and double strand breaks of the DNA 
after 30 exposure As(III) (A), MMA(III) (B), and DMA(III) (C). The DNA damage is given in the 
Olive Tail Momen 
(mean ± SEM with p > 0,05: non-significant, p 0,05: *, p 0,01: **, p 0,001: ***, n = 150 cells). 
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It seems that genotoxicity decreases with longer exposure time. This effect is 
misleading due to the occurrence of first cytotoxic effects already at the 
concentrations chosen. Microscopic evaluation revealed cells with decreased size 
and altered appearance, their number increasing proportional to the exposure 
concentration. It is assumed that the cells, which suffered severe damage, adhered 
only very loosely, and hence, these cells were lost during sample preparation, e.g. 
during removal of the exposure medium, cell washing, or trypsination. However, 
testing up to cytotoxic concentrations is in compliance with methods recommended 
for regulatory purposes (European Union [EU], 2008). 
Although biotransformation was initially discussed to serve as a detoxification 
process, MMA(III) still is highly genotoxic and DMA(III) even exhibits the most 
genotoxic effects. In contrast, pentavalent arsenic species did not show any 
genotoxic effect except for As(V) at very high concentrations (Fig. 36) (Zdrenka et al., 
2012). 
Alkaline Comet Assay - T24 cells – 30 min 
Fig. 36 DNA damage in T24 cells after 30 min of treatment with pentavalent arsenic species 
The Alkaline Comet Assay was conducted to assay single and double strand breaks of the DNA 
after exposure to As(V), MMA(V), DMA(V) and TMAO. The DNA damage is given in the Olive Tail 
Moment 
(mean ± SEM with p > 0,05: non-significant, p 0,05: *, p 0,01: **, p 0,001: ***; n = 150) 
(Zdrenka et al., 2012, modified) 
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Elongation of the exposure time up to 60 min did not reveal significant differences in 
genotoxicity except for As(V), which seemed to cause no DNA damage any more (for 
details please refer to Appendix 7.2, Tab. 10). Slight cytotoxicity was observed during 
microscopic evaluation, and hence, this effect is considered to be preparation based. 
A comparison of MMA(III)-induced genotoxicity in T24, HepG2, and HUEPC cells 
revealed that T24 cells were least susceptible of all. In contrast, HUEPC cells 
exhibited the strongest sensitivity against DNA breakage after 30 min of exposure 
(Fig. 37). In addition, notably reduced cell numbers were observed in treated HUEPC 
cells. The numbers given in the respective columns represent the number of 
evaluated cells of each sample. In both T24 and HepG2 samples more than 150 cells 
were evaluable, whereas in HUEPC cells only 6 (50 µM MMA(III)) up to 41 cells 
(0.5 µM MMA(III)) could be analysed, highlighting the strong cytotoxicity observed in 
HUEPC cells. This notice is in concordance with the observations and results 
presented above. 
Alkaline Comet Assay - MMA(III) - 30 min 
ct. 
Fig. 37 DNA damage in T24, HepG2, and HUEPC cells after 30 min of treatment with MMA(III) 
The Alkaline Comet Assay was conducted to assay single and double strand breaks of the DNA 
in T24, HepG2, and HUEPC cells after exposure to MMA(III). The DNA damage is given in the 
Olive Tail Moment (mean ± SEM with p > 0,05: non-significant, p 0,05: *, p 0,01: **, p 0,001: 
***, the numbers of evaluated cells are given in the columns.) 
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4.3 COX-2 activation 
Among acute cytotoxic and genotoxic effects, especially at high doses, arsenic also 
exhibits tumour-promoting activities after chronic low-dose exposure. As one of the 
manifold molecular markers during carcinogenesis, mRNA and protein levels of COX-
2 (official gene name PTGS2), were measured in this study. 
Fig. 38 presents COX-2 protein levels in T24 cells after short-term exposure up to 
1 week. MMA(III) induces distinct decreased COX-2 protein levels as compared to 
the concurrent untreated negative control at both concentrations of 75 and 100 nM 
after 1 h of exposure, whereas the levels normalised again within 24 h. Already after 
1 week of exposure elevated COX-2 protein levels were detected in both 75 and 
100 nM MMA(III)-treated cells. 
COX-2 Protein – T24 cells – exposure up to 1 week 
Fig. 38 COX-2 protein levels in T24 cells 
The ELISA assay was conducted to analyse the COX-2 protein levels in T24 cells after 
exposure to 75 and 100 nM MMA(III) for 1 h, 24 h, and 1 week, respectively. Values are given as 
COX-2 ratio in treated cells as compared to the untreated negative control. Since this 
experiment was conducted once only, no statistical analysis was performed. 
Chronic low-dose exposure of T24 cells to 75 and 100 nM MMA(III) revealed similar 
results (Fig. 39). Elevated COX-2 protein levels were observed for more than 75 
weeks, whereas 75 nM caused an even more distinct increase than 100 nM MMA(III). 
Nevertheless, fluctuations were observed at both concentrations. In contrast, analysis 
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of the COX-2 mRNA levels did not reveal such distinct effects. Up to 32 weeks of 
exposure mRNA levels fluctuate in both untreated control and 100 nM MMA(III)-
treated cells, finally leading to a relatively constant level slightly below the value from 
the beginning of the study (Fig. 40). 
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Fig. 39 COX-2 protein levels in T24 cells after chronic low-dose exposure with 75 and 100 nM 
MMA(III) 
Values are given as COX-2 ratio in treated cells as compared to the concurrent untreated 
negative control. Since this experiment was conducted once only, no statistical analysis was 
performed. 
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Fig. 40 COX-2 mRNA in T24 cells during chronic low-dose exposure to MMA(III) in comparison 
to concurrent untreated control cells. 
Ct values were normalised to GAPDH. Since this experiment was conducted once only, no 
statistical analysis was performed. 
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4.4 miRNA analysis 
At this point I want to express my gratitude to my colleagues and project partners Dr. 
D. G. Weber and Dr. O. Bryk from the Institute for Prevention and Occupational 
Medicine of the German Social Accident Insurance (Institute of the Ruhr-University 
Bochum, Germany) under the head of Dr. G. Johnen, who kindly performed the 
experiments of the miRNA analysis and provided the data for the present study. 
Results of the miRNA analysis 
Altered miRNA levels were reported for several cancer diseases as they are involved 
in the regulation of the EMT and other processes: they are known as molecular 
modulators and were described as essential components of fundamental signal 
transduction of carcinogenesis (Dalmay & Edwards, 2006; Sotiropoulou et al., 2009). 
In this study miRNA analysis was performed using the TaqMan assay. 33 miRNAs 
were analysed in T24 cells after exposure to 100 nM MMA(III) for 10, 15, 19, 24, 28, 
32, 36, 40, 44, 48, 52, and 56 weeks, respectively. The selected miRNAs were 
namely miR-let-7f, -7g, miR-15a, -16, 17, -18a, -19a, -19b, -20A, -26b, -30a, -92a, -
96, -98, -122, -126, -128a, -140, -142, -144, -155, -182, -190, and -199a. 
The following miRNAs showed significant expression alterations after arsenic 
axposure as compared to the concurrent negative controls: miR-15a, -19a, -19b, -
30a-3p, -126, -128a, and -182 for at least 3 time points, whereas miR-let-7f, -7g, miR-
16, -17, -18a, -20a, -26b, -92a, -96, -98,and -140-5p were significantly altered at only 
one or two time points. The remaining miRNAs (miR-122, -142-5p, -144, -155, -190, -
199a-5p) were either unchanged or not detectable. The results are given in Tab. 4. 
The latter 9 miRNAs of Tab. 4 were recently associated with bladder cancer (Catto et 
al., 2009; Dyrskjot et al., 2009; Ichimi et al., 2009; Lin et al., 2009; Veerla et al., 
2009), and hence, they were analysed for all exposure concentrations (50, 75, and 
10 nM) of MMA(III) from week 10 up to week 56. They all showed significantly altered 
expression patterns in treated cells for at least two time points or for at least two 
arsenic concentrations. 
It is notable that from about week 36 on a global decrease of miRNAs occurs, 
whereas few of them even stay at the lower level up to study termination. Among 
those are miR-139 and miR-146a, as well as miR-200a and -429. This result was not 
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only observed at 100 nM MMA(III), but also at 50 and 75 nM MMA(III) and 50 nM 
As(III). Fig. 41 shows exemplarily the course of miR-429, the values are presented as 
relative changes to the untreated control. Although a first increase of miR-429 was 
observed, a distinct decrease of miR-429 over time is also notable from week 19 
onwards. 
Tab. 4 Altered expression of 33 selected miRNAs in T24 cells during chronic low-dose 
exposure to 100 nM MMA(III) for up to 56 weeks 
A red fiels symbolises a statistically significant decrease (RQ < 0,5), anda green field shows a 
statistically significant increase (RQ > 2,0) of expression patterns of treated cells in 
comparison to untreated cells. A white field symbolises a steady expression, whereas a grey 
field was used when the respective miRNA was not detectable. 
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Fig. 41 Altered miR-429 expression in T24 cells after arsenic exposure up to 56 weeks 
Given are the relative changes in treated cells as compared to the concurrently untreated 
negative controls of the same passage. Since this experiment was conducted once only, no 
statistical analysis was performed. 
4.5 DNA Methylation 
At this point I want to express my gratitude to my colleagues and project partners P. 
Rozynek and Y. von der Gathen from the Institute for Prevention and Occupational 
Medicine of the German Social Accident Insurance (Institute of the Ruhr-University 
Bochum, Germany) under the head of Dr. G. Johnen, who kindly performed the 
experiments of the DNA Methylation analysis and provided the data for the present 
study. 
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Results of the DNA Methylation analysis 
Altered DNA methylation patterns were commonly reported in various cancer 
diseases. These alterations include both global DNA hypomethylation as well as 
promoter hypo and hypermethylation. While global DNA hypomethylation leads to 
genomic instability, promoter hypomethylation can result in oncogene activation and 
promoter hypermethylation might lead to the inactivation of tumour suppressor 
genes. Since DNA methylation is such an unique mechanism of epigenetic 
regulation, whose alteration can have fatal consequences such as cancer 
development, the study addresses DNA methylation analysis of several genes known 
to be involved in carcinogenesis. 
As a first step, a baseline was established for the methylation status of T24 cells. 
Therefore, a change in the methylation status of T24 cells in contrast to non-
tumorigenic urothelial cells was noted. T24 cells showed a decreased methylation of 
LINE1 (45% instead of approx. 75%), whereas the following genes, which are usually 
unmethylated in primary urothelial cells, showed a distinct increase of DNA 
methylation: DAPK1 (20%), RAR ß (60%), CDH1 (22%), and RASSF1 (90%). In 
contrast, FHIT, MGMT, and SOCS3 did not show any altered promoter methylation 
patterns. These alterations were considered to be the result of the immortalization of 
this cell line. 
When the T24 cells were cultured for 68 weeks without arsenic treatment, their 
methylation patterns were observed to be stable in the seven genes described above 
(Fig. 42 to Fig. 47). At the same time, the treated cells showed none or only minor 
alterations (Fig. 42 to Fig. 45). Only for C1QTNF6 (Fig. 46) and CDH1 (Fig. 47) an 
increase of methylation over time form 22% to 35% was observed, whereas this 
development only started at approx. week 36 of exposure. This observation is in 
accordance with the fact that expression of miRNAs, which are known to be 
responsible for the suppression of metastasis and invasion, were decreased at the 
same time. 
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Fig. 42 Methylation pattern of LINE1 in cultured T24 cells with and without (control) chronic 
low-dose treatment to 100 nM MMA(III) 
Since this experiment was conducted once only, no statistical analysis was performed. 
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Fig. 43 Methylation pattern of MGMT in cultured T24 cells with and without (control) chronic 
low-dose treatment to 100 nM MMA(III) 
Since this experiment was conducted once only, no statistical analysis was performed. 
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DNA Methylation of RAR ß 
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Fig. 44 Methylation pattern of RAR ß in cultured T24 cells with and without (control) chronic 
low-dose treatment to 100 nM MMA(III) 
Since this experiment was conducted once only, no statistical analysis was performed. 
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Fig. 45 Methylation pattern of RASSF1 in cultured T24 cells with and without (control) chronic 
low-dose treatment to 100 nM MMA(III) 
Since this experiment was conducted once only, no statistical analysis was performed. 
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DNA Methylation of C1QTNF6 
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Fig. 46 Methylation pattern of C1QTNF6 in cultured T24 cells with and without (control) chronic 
low-dose treatment to 100 nM MMA(III) 
Since this experiment was conducted once only, no statistical analysis was performed. 
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Fig. 47 Methylation pattern of CDH1 in cultured T24 cells with and without (control) chronic 
low-dose treatment to 100 nM MMA(III) 
Since this experiment was conducted once only, no statistical analysis was performed. 
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The results observed for 100 nM MMA(III) treatment were similar to those seen in 
T24 cells treated with 75 nM MMA(III). Fig. 48 shows the methylation patterns of 
CDH1, MGMT, and LINE1 in untreated T24 cells in comparison to those in T24 cells 
after exposure to 100 nM and 75 nM MMA(III). 
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Fig. 48 Comparison of the methylation pattern of CDH1, MGMT, and LINE1 in cultured T24 cells 
without treatment (control) and after chronic low-dose exposure to 75 and 100 nM MMA(III) 
Since this experiment was conducted once only, no statistical analysis was performed. 
In addition to the genes mentioned above, two more relevant genes discussed in the 
current literature were analysed. Methylation of KRT7 und G0S2 during arsenic 
exposure was reported to increase with time (Jensen et al. 2009). However, this 
effect was not observed under the conditions of this study (data not shown). 
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4.6 In vitro Mammalian Cell Transformation Test 
The in vitro Mammalian Cell Transformation Test was determined to assay the loss of 
contact inhibition and morphological changes in chronically treated T24 cells as 
commonly observed phenotypic alterations during carcinogenesis. Although this cell 
line is known to be tumorigen, it still shows contact inhibition when cultured in vitro 
(Fig. 49). The aim of this test was to detect MMA(III) as a possible tumour promoter. 
T24 cells were cultured for 92 weeks and treated twice a week with fresh exposure 
medium containing 50 nM, 75 nM and 100 nM MMA(III), respectively. Untreated T24 
cells of the same passage served as negative control. A confluent monolayer of cells 
from each exposure group was incubated for another 2 weeks and subsequently 
visually evaluated for treatment related effects (Fig. 49). 
It is obvious that chronic exposure to MMA(III) at environmentally relevant doses 
revealed distinct effects on T24 cells as compared to concurrently untreated negative 
control cells. Morphological changes have developed at all doses, including 
misshapen and over-sized cells, whereas cells treated with 50 and 75 nM MMA(III) 
exhibited the strongest effects. Moreover, distinct increases in colony formation due 
to the loss of contact were observed at both 50 and 75 nM doses. Such treated T24 
cells formed colonies with a diameter of more than 200 µm. However, only few barely 
perceptible colonies were built up after treatment with 100 nM MMA(III). 
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Fig. 49 In vitro Mammalian Cell Transformation Test with T24 cells after chronic exposure to 
MMA(II) 
The in vitro Mammalian Cell Transformation Test was conducted for the analysis of 
morphological changes and the loss of contact inhibition after chronic treatment of T24 cells 
with 50 nM (A+B), 75 nM (C+D), or 100 nM (E+F) MMA(III), respectively, for 92 weeks. The 
concurrent negative control (G+H) consisted of untreated T24 cells of the same passage. Given 
are two pictures of parallel treated samples. 
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4.7 Colony Formation Assay 
The Colony Formation Assay was determined to assay the loss of anchorage 
dependent growth. Therefore, T24 cells were cultured for 93 weeks and treated twice 
a week with fresh exposure medium containing 50 nM, 75 nM and 100 nM MMA(III), 
respectively. Untreated T24 cells of the same passage served as concurrent negative 
control. The cells were bedded into soft agar and incubated for two weeks. Although 
T24 cells are tumorigen, they cannot be cultured in soft agar, which was proven by 
the negative control. In contrast, after chronic exposure to MMA(III) T24 cells 
exhibited an anchorage-independent growth and formed notable colonies (Fig. 50). 
The colonies observed are tumour-like, and especially at a concentration of 75 nM 
clearly defined colonies were observed. The colonies formed of T24 cells treated with 
50 and 100 nM MMA(III), respectively, were smaller in size than those of 75 nM-
treated cells (Zdrenka et al., 2012). 
(A) 
(B) 
89 
Results 
(C) 
(D) 
Fig. 50 Colony Formation Assay with T24 cells after chronic exposure to MMA(II) 
The Colony Formation Assay was conducted for the analysis of an anchorage-independent 
growth after chronic treatment of T24 cells with 50 nM (A), 75 nM (B), or 100 nM (C) MMA(III), 
respectively, for 93 weeks. The concurrent negative control (D) consisted of untreated T24 cells 
of the same passage. Given are two pictures of parallel treated samples (Zdrenka et al. ,2012). 
4.8 Cellular migration and invasion 
First data were already presented and discussed in Zdrenka et al. (2012), wherefrom 
the respective information was recited in the following chapter. 
To estimate the increase of malignancy of chronically arsenic-exposed human 
urothelial cells, their altered motility and invasiveness were examined. The 
xCELLigence system was conducted to assay the migration and invasion of T24 cells 
after 92 weeks of exposure to MMA(III). Hereby the cells moved through a 
microporous membrane and attached at the opposite side on the electrodes. For the 
analysis of the invasiveness the membranes and electrodes were coated with 
collagen, a typical extracellular matrix. The results show, that after exposure to 75 
and 100 nM MMA(III) for 92 weeks the motility of T24 cells was increased in 
comparison to the concurrently untreated control of the same passage. Only the 
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exposure to 50 nM MMA(III) did not lead to an increase of migrated cells (Fig. 51) 
(Zdrenka et al., 2012). 
(A) 
(B) 
Fig. 51 Migration (A) and Invasion (B) of T24 cells after chronic exposure to MMA(II) 
The xCELLigence system was conducted for the analysis of the ability of migration and 
invasion after chronic treatment of T24 cells with 50, 75, or 100 nM MMA(III), respectively, for 92 
week. CIM-Plates were coated with collagen for invation experiments (B) to simulate a 
biological matrix (Zdrenka et al. ,2012). Since this experiment was conducted once only, no 
statistical analysis was performed. 
The examination of the invasion led to similar results. After coating the plate surface 
with collagen all samples exhibited an increased invasion property as compared to 
the concurrently untreated control. In both migration and invasion assays the cells 
treated with 100 nM MMA(III) exhibited the strongest effects, leading to the 
assumption of a dose-dependent manner (Zdrenka et al, 2012). 
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5 Discussion 
Arsenic is one of the most harmful toxins in drinking water worldwide. At many places 
on earth the arsenic concentrations found are 10 µg/l and above, clearly exceeding 
the tolerable value recommended by the WHO (WHO, 2001). Moreover, human 
exposure in daily life also occurs via food (fish, rice, etc.) and smoke, as well as 
occupationally (Food Standards Agency of th UK, 2004; Lozna & Biernat, 2008; 
Meharg et al., 2008; Signes-Pasto et al., 2009; Sun et al., 2009). Hence, at many 
places on earth millions of people are at risk of arsenic-induced diseases such as 
cancer. Several kinds of arsenic-induced cancer diseases have already been 
reported, including skin, lung, kidney, and bladder cancer (Chiou et al., 1995; Tseng, 
2007; Chen et al., 2010; Ren et al., 2011). 
After oral uptake, arsenic might be subjected to the first-pass effect, which is a well-
known metabolic pathway observed for several xenobiotics, and which is of great 
importance in the assessment of drug-metabolism. Orally uptaken xenobiotics are 
resorbed through the intestinal mucosa into the circulation, and then transported 
through the portal vein (Vena portae hepatis) to the liver where they finally will be 
subjected to hepatic metabolism (Forth et al., 2009). In the case of arsenic 
compounds, fast hepatic metabolism of inorganic arsenic will result in well-
characterised methylated species, which are then systemically available. Hence, the 
present work focussed especially on methylated metabolites such as MMA(III), as 
these are known to be of high importance regarding systemic toxicity and 
carcinogenicity as compared to the parent inorganic species (As(III) or As(V)). 
In the present study the cellular uptake and biotransformation of arsenic species in 
non-methylating human urothelial cells (T24) and methylating human hepatic cells 
(HepG2) was investigated by using HPLC-ICP / MS technique. The induced 
genotoxic effects of several arsenic species (namely As(III), As(V), MMA(III), 
MMA(V), DMA(III), DMA(V), and TMAO) in T24 cells were measured by means of the 
Alkaline Comet Assay, and the effects on malignant cell behaviour after chronic 
arsenic treatment was assayed, using the following in vitro approaches: the in vitro 
Mammalian Cell Transformation Test, the Colony Formation Assay, and the Migration 
and Invasion Assay. Some of the key processes altered in T24 cells by chronic 
arsenic exposure were analysed this study; the endpoints addressed were: 
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alterations in COX-2 activation, miRNA expression, and DNA methylation patterns. 
The present work aims to analyse the basic key events during the development of 
arsenic-induced bladder cancer in vitro. 
5.1 Intracellular arsenic speciation and quantification 
At this point I want to express my gratitude to my colleague and project partner J. 
Hippler from the Institute of Environmental Analytical Chemistry (University of 
Duisburg-Essen, Germany) under the head of Prof. Dr. Hirner, who kindly performed 
the experiments of the intracellular arsenic speciation and quantification using HPLC-
ICP/MS and provided the data for the present study. 
First data were already published in Hippler et al. (2011), and further results were 
presented and discussed in Zdrenka et al. (2012), wherefrom the respective 
information was recited in the following chapter. 
Discussion of the intracellular arsenic speciation and quantification 
The data presented here demonstrate that MMA(III) is rapidly taken up by human 
urothelial cells (T24) and human hepatic cells (HepG2). MMA(III) is known to be an 
important arsenic metabolite due to its high toxicity. Additionally, many studies report 
monomethylated and dimethylated arsenic species as the main metabolites in the 
urine (Aposhian et al., 2000; Fillol et al., 2010, as cited in Zdrenka et al., 2012). The 
use of an improved isolation method and HPLC-ICP/MS technique (Hippler et al., 
2011) enabled the analysis of fast MMA(III) association to large membrane 
structures, high-molecular-weight proteins, and other insoluble cell components, and 
furthermore, the recovery of unbound pentavalent arsenic metabolites in the soluble 
fractions; these were found to amount to only 0.003% of the total intracellular arsenic 
in T24 cells and 0.01% in HepG2 cells. Furthermore, differentiation between the 
various methylated metabolites and their oxidation state in complex cellular matrices 
was possible (Zdrenka et al., 2012). 
The results also revealed a fast cellular uptake of MMA(III) for both the T24 and 
HepG2 cell lines, followed by rapid oxidation to MMA(V) already within 5 min, which 
further increased with time (Fig. 34). Additionally, in HepG2 cells a time dependent 
methylation to DMA(V) was observed. These findings appear to be in contrast to the 
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reductive intracellular milieu (Du et al., 2009, Hippler et al., 2011, as cited in Zdrenka 
et al., 2012) due to glutathione concentrations up to millimolar ranges (Anderson, 
1998, Hippler et al., 2011, as cited in Zdrenka et al., 2012). However, taking different 
cell compartments and specific metabolic effects of arsenic into account could 
provide a possible explanation. It is largely known from the literature that in contrast 
to their pentavalent analogues, trivalent arsenicals bind to proteins (Styblo & 
Thomas, 1997b; Yan et al., 2009, Hippler et al., 2011, as cited in Zdrenka et al., 
2012). This leads to the assumption that MMA(III) rapidly binds to proteins after 
uptake, which is in compliance with the detection of more than 99.99% of the total 
arsenic in the non-soluble fraction in both cell lines (Fig. 33 and Fig. 34). A fast 
subsequent degradation of at least part of the arsenic-conjugated or arsenic-inhibited 
proteins can be presumed. Protein degradation is predominantly mediated by the 
proteasomes but can also take place in lysosomes, especially during turnover of 
membrane proteins (Clague & Urbé, 2010, Hippler et al., 2011, as cited in Zdrenka et 
al., 2012). An increased turnover of arsenic-bound proteins is in agreement with the 
evidence of the catabolism of arsenic-induced improperly folded or damaged proteins 
via the ubiquitin-dependent protein degradation pathway in zebrafish liver (Lam et al., 
2006, Hippler et al., 2011, as cited in Zdrenka et al., 2012). Several studies report 
that protein ubiquitination not only targets protein degradation using the proteasome 
pathway but also the lysosomal pathway (Marques et al., 2004; Barriere et al.; 2007, 
Shenoy et al, 2008; Arancibia-Cárcamo et al, 2009, Hippler et al., 2011, as cited in 
Zdrenka et al., 2012). The lysosomes are known to exhibit cellular oxidative activities 
(Chen, 2002, Hippler et al., 2011, as cited in Zdrenka et al., 2012) and during 
oxidative stress large amounts of hydrogen peroxide enter the lysosome, leading to 
the formation of hydroxyl radicals and lysosomal destabilisation (Terman et al., 2006, 
Hippler et al., 2011, as cited in Zdrenka et al., 2012). In addition, the lysosome is an 
important organelle in autophagy, helping the cells to remove toxic aggregation-prone 
proteins and even damaged organelles that are incompatible with the unfolding 
mechanism of the proteasome (Yang et al., 2008; Clague & Urbé, 2010; Mehrpour et 
al., 2010, Hippler et al., 2011, as cited in Zdrenka et al., 2012). The increase of 
protein catabolism, the elimination of excess or damaged organelles by autophagy, 
and the sequestering of toxicants is ubiquitous and believed to be a kind of “first-
response reaction” to delay apoptosis (Kundu & Thompson, 2008; Yang et al., 2008, 
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Hippler et al., 2011, as cited in Zdrenka et al., 2012). In the early stage of cell death 
autophagy was reported to be activated in HL60 cells soon after exposure to As2O3 
to maintain cell survival under stress conditions (Yang et al., 2008, Hippler et al., 
2011, as cited in Zdrenka et al., 2012). 
Summarising all these data, it can be concluded from the results that MMA(III) is 
immediately taken up and rapidly bound to proteins and other cellular structures, 
followed by first, the generally accepted methylation to dimethylarsinic in HepG2 cells 
only, and second, the degradation of affected proteins and cellular structures in the 
lysosomes in both HepG2 and T24 cells (Fig. 52) (Hippler et al., 2011, as cited in 
Zdrenka et al., 2012). During oxidative degradation in the lysosomes arsenic is 
released as MMA(V) and DMA(V), which are either excreted from the cell or reduced 
by antioxidants in the cytosol. The reduced species MMA(III) and DMA(III) can then 
re-associate with proteins and cellular structures. In HepG2 cells most of the 
incorporated MMA(III) is methylated and oxidised to DMA(V) after passing this cycle; 
in T24 cells the cycle is limited to oxidation and reduction, and finally excretion, due 
to the fact that urothelial cells are non methylating (Hippler et al., 2011, as cited in 
Zdrenka et al., 2012). 
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Fig. 52 Proposed arsenic cycle in HepG2 (A) and T24 cells (B) after exposure to MMA(III) 
(Hippler et al., 2011 (modified), Zdrenka et al. 2012) 
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5.2 Arsenic-induced genotoxicity 
Results on arsenic-induced genotoxicity were already presented and discussed in 
Zdrenka et al. (2012), wherefrom the respective information was recited in the 
following chapter. 
Especially the trivalent arsenicals are known to exhibit strong genotoxic effects (Dopp 
et al., 2010a, as cited in Zdrenka et al., 2012). These effects can either be detected 
as DNA damage using the Micronucleus Test or the Comet Assay (Dopp et al., 2008, 
as cited in Zdrenka et al., 2012), as oxidative damage by assaying the amount of 8-
oxo-dG (8-oxo-2'-deoxyguanosine) or in form of chromosomal aberrations (Dopp et 
al., 2004, as cited in Zdrenka et al., 2012). In this study the Alkaline Comet Assay 
was utilised to analyse single and double strand breaks of the DNA in cells treated 
with As(III), As(V), MMA(III), MMA(V), DMA(III), DMA(V), and TMAO, respectively. 
Significant genotoxic effects of all tested trivalent arsenic compounds (As(III), 
MMA(III) and DMA(III)) and the pentavalent arsenate were detected in T24 cells 
already after 30 min of exposure (Fig. 35 and Fig. 36). These results are in 
compliance with the findings of previous studies using several mammalian cell types 
(Schwerdtle et al., 2003; Raisuddin & Jha, 2004; Dopp et al., 2005, as cited in 
Zdrenka et al., 2012). Moreover, the data presented in Fig. 37 show that the degree 
of genotoxicity is also dependent on the cell type and/or tissue tested. In fact, as 
shown in Fig. 37, immortalised cell lines such as T24 cell line, which already have 
undergone cell transformation to some degree, seem to be less susceptible to the 
genotoxic potential of arsenic compounds when compared to primary cells, such as 
HUEPC cells. Furthermore, the comparison of both cell lines (T24 and HepG2), 
clearly reveals that the kind of tissue the cells were originally derived from, is of great 
importance regarding the outcome of genotoxic effects. The results of the 
experiments conducted within the present work revealed that HepG2 cells, which 
originate from liver tissue, showed a greater susceptibility toward arsenic-induced 
genotoxicity when compared to the urothelial T24 cells. This was assumed to be 
related to the different metabolic capacity of the cell types, as was highlighted by the 
experiments dealing with the intracellular arsenic speciation. This emphasises, how 
important the knowledge of the tissue-dependent arsenic biotransformation as shown 
in Fig. 52 is, as the genotoxic effect of arsenic metabolites is not only dependent on 
its oxidative state, but also on the state of methylation (Hirner & Rettenmeier, 2010; 
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Dopp et al., 2010b, as cited in Zdrenka et al., 2012). Wnek et al. (2009, as cited in 
Zdrenka et al., 2012) reported that in UROtsa cells DNA damage caused by MMA(III) 
does not only result from acute treatment with high doses, but also from chronic 
exposure to low levels of MMA(III) over 12 – 52 weeks. The incidence of single- and 
double-strand breaks is significantly decreased after the removal of MMA(III) for 
2 weeks, but still remains significantly above the untreated control. In parallel, the 
relative poly (ADP-ribose) polymerase (PARP) activity was noticed to be significantly 
reduced during this chronic exposure, and increased again after removal of MMA(III). 
Trivalent arsenic species are known to attach to zinc binding structures generally 
found in DNA repair enzymes and transcription factors, leading to alteration or 
inhibition of these proteins (Kitchin & Wallace, 2008). Together with the findings of Hu 
et al. (1998, as cited in Zdrenka et al., 2012) it is likely that DNA repair is inhibited by 
both, direct protein interaction and altered signal transduction or gene expression 
(Zdrenka et al., 2012). 
Owing to all these facts, not only DNA damage itself plays a pivotal role in arsenic-
induced carcinogenesic, but also inorganic arsenic and its metabolites are of 
importance in their function as potent epigenetic modulators, leading to (tissue 
specific) altered cellular functions, malignant transformation, and finally tumour 
development. 
5.3 DNA Methylation during arsenic-induced malignancy 
At this point I want to express my gratitude to my colleagues and project partners P. 
Rozynek and Y. von der Gathen from the Institute for Prevention and Occupational 
Medicine of the German Social Accident Insurance (Institute of the Ruhr-University 
Bochum, Germany) under the head of Dr. G. Johnen, who kindly performed the 
experiments of the DNA Methylation analysis and provided the data for the present 
study. 
Discussion of the DNA Methylation during arsenic-induced malignancy 
Many studies report arsenic-induced aberrant DNA methylation patterns, resulting in 
changes in the promoter activity that lead to altered gene expression (Sutherland & 
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Costa, 2003; Jensen et al., 2009; Smeester et al., 2011; Ren et al.; 2011). Aberrant 
DNA methylation patterns might be the result of arsenic-induced altered global 
histone modification, finally leading to the silencing of tumour suppressor genes 
(Zhou et al., 2008). Within a further experiment conducted within the present work, 
T24 cells were chronically treated with MMA(III) at low doses up to 100 nM. Six 
genes known to be involved in carcinogenesis (LINE1, MGMT, RAR ß, RASSF1, 
C1QTNF6, and CDH1) were exemplarily analysed for the development of their 
methylation status. In fact, global DNA hypomethylation could be correlated with 
chromosomal instability (Matsuzaki et al., 2005), and further, hypomethylation of 
LINE1 in particular was found to be associated with the initiation of the clonal 
expansion of premalignant cells in early stages of cancer development (Wilhelm et 
al., 2010, Zeimet et al., 2010). Therefore, the methylation status of LINE1 was first 
examined. In the experiment of the present work, the methylation status in T24 cells 
treated with 75 and 100 nM MMA(III) and in concurrently untreated control cells was 
found to be stable, without any treatment-related effects observed. In fact, 
fluctuations detected throughout the experiment were similar for both controls and 
treated cells as shown in Fig. 42 and Fig. 48. Hence, MMA(III)-induced effects on 
global DNA methylation, in particular on LINE1 hypomethylation, were not observed 
in T24 cells under the conditions of the test. It is quite clear that the LINE1 
methylation status observed in untreated T24 control cells does not represents the 
status of “normal” urothelial cells, as the T24 cell line used in the present work is 
already a transformed tumour cell line (Johnen et al., 2013). A further influence of 
arsenic exposure on LINE1 methylation in existing urothelial tumour tissue seems in 
light of the present result unlikely. 
Few data are available that human exposure to arsenic, e.g. via contaminated 
drinking water, leads to global DNA hypomethylation (Ren et al., 2011). Especially, 
the hypomethylation of LINE1 was observed in subjects suffering from bladder 
cancer, indicating a strong correlation between the risk of non-invasive bladder 
cancer and LINE1 hypomethylation. In contrast, no such strong correlation could be 
evidenced for invasive bladder cancer. Rent et al. (2011) suggested that LINE1 is an 
independent risk factor for bladder cancer and might be suitable as a biomarker. 
Nevertheless, a dose-response relationship between LINE1 methylation extent and 
the risk of bladder cancer could not yet be observed (Wilhelm et al., 2010). Thus, 
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further studies still are needed to assay whether LINE1 methylation patterns are 
directly targeted by arsenic. Altered global DNA methylation levels in general have 
already been correlated with the arsenic metabolism as both systems use the same 
methyl donor SAM (S-adenosyl-methionine). SAM is known to transfer methyl groups 
to DNA methyltransferases and to AS3MT (arsenic (+3 oxidation state) 
methyltransferase) (Ren et al., 2011, as cited in Zdrenka et al., 2012). Further studies 
are needed to prove this, for example by comparing methylation patterns in cells with 
and without metabolic capacities. Hepatic cells could be used as a kind of positive 
control as they are known to be methylating, while uothelial cells such as UROtsa 
and T24 cells lack methylation abilities. The clonal UROtsa/F35 cell line (actually 
T24/F35 cell line according to Johnen et al. (2013)) is known to express rat AS3MT, 
and therefore exhibited methylating properties (Hester et al., 2009) and might 
therefore serve as a link between both hepatic and urothelial cell lines. 
Besides global DNA hypomethylation, promoter hypermethylation was also observed 
in human skin and bladder cancer, in animals in vivo, as well as in human and animal 
cell lines in vitro (Ren et al., 2011). In a further experiment reported in the present 
work, RASSF1 was analysed for MMA(III)-induced inactivation due to promoter 
hypomethylation. Its transcript RASSF1A was reported to exhibit tumour suppressive 
properties by preventing cell proliferation as a result of the inhibition of cell cycle 
progression through G1 into S, and the induction of cell death (Dammann et al., 
2005; Burbee et al., 2011). Promoter hypermethylation of RASSF1A was observed in 
patients suffering from bladder cancer after arsenic exposure, and RASSF1A was 
further associated with invasive bladder cancer, which is the more advanced and 
fatal form of this disease (Dulaimi et al., 2004; Dammann et al., 2005); furthermore, a 
correlation between arsenic exposure, RASSF1A promoter methylation, and bladder 
cancer occurrence was also reported by Marsit et al. (2006b). Moreover, arsenic 
exposure resulted in promoter hypermethylation of RASSF1A in A/J mice and was 
associated with the development of lung cancer (Ren et al., 2011). In the present 
work chronic treatment of T24 cells with 75 and 100 nM MMA(III) did not alter 
promoter methylation of RASSF1 as compared to the concurrently untreated control 
(Fig. 45 and Fig. 48). Furthermore, no distinct fluctuations were observed in the 
methylation status of this promoter in neither of the test groups except for the 75 nM 
MMA(III)-treated culture after 40 weeks of exposure. Nevertheless, this observation 
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was considered to be an outlier value without any biologically relevance rather than a 
treatment related effect, since it was reversible and only seen at the time point and 
test concentration mentioned above. At a first glance the data indicate that the loss of 
the tumour suppressive properties of RASSF1 transcripts as one of the key events 
during arsenic-induced malignant transformation could not be confirmed under the 
conditions of this test. In light of the fact that methylation of the RASSF1 promoter 
region of untreated T24 cells showed already a methylation baseline of approximately 
90%, a further methylation seems unlikely and therefore the use of the T24 cell line in 
this experiment is questionable. It should be noted at this point that the study was 
initially based on the mistaken assumption that the cell line used was UROtsa. Based 
on the results observed in the present work, the identy of the cell line was challenged 
and only recent data gave proof that the cell line tested was actually T24. Futher 
work is necessary to repeat the experiment with well characterised urothelial cells 
(Johnen et al., 2013) and re-evaluate the data presented here. 
Aberrant MGMT promoter methylation leads to decreased defence abilities of the cell 
against genotoxicity. O6-methylguanine-DNA methyltransferase (MGMT) transfers 
the alkyl groups from the O6-position of guanine on itself. Since the protein is not 
regenerated after the reaction but degraded, this protein is not a true enzyme (Ekim 
et al., 2011, Pegg, 2011), and depletion of its functionality might lead to a dramatic 
accumulation of genetic damages. The experiments of the present work investigated 
the increase in MGMT promoter methylation in T24 cells following chronic treatment 
with MMA(III) for up to 80 weeks. Although T24 cells are tumour cells, the level of 
MGMT promoter methylation is low (approximately 4%) and comparable to normal 
urothelial cells (approximately 2%). In contrast, MGMT promoter methylation of 
hepatoma cells (HepG2) is more than 15 times higher (approximately 62%) (Johnen 
et al., 2013). As a result of the experiment conducted in the present study, no 
increase in MGMT could be observed (Fig. 43) after chronic MMA(III) exposure, 
leading to the conclusion that under the in vitro test conditions used, MMA(III) had no 
impact on the expression of MGMT. Further studies investigating arsenic-induced 
decrease of MGMT-functionality are deemed necessary, especialy in light of the 
genotoxic properties observed for arsenic compounds. 
RAR ß is known as a nuclear receptor and a transcriptional factor, and together with 
its isoforms it was reported to be closely linked to cancer due to tumour suppressive 
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properties (Lei & Thé, 2003). Altered methylation patterns of RAR ß have also been 
detected in bladder cancer (Chan et al., 2002; Hoque et al., 2006; Negraes et al., 
2008). However, no changes in the promoter methylation of RAR ß were observed in 
T24 cells during chronic low-dose exposure with MMA(III) up to more than 80 weeks 
as compared to concurrently non-treated control cells (Fig. 44). However, the base-
line methylation patterns of RAR ß in untreated T24 control cells is already 
approximately 60%, but aggressive cancer cell lines like HeLa show methylation 
paterns of 98% (Johnen et al., 2013). Thus, a further influence of arsenic exposure 
on RAR ß methylation in existing urothelial tumour tissue seems in light of the 
present result unlikely. 
Recently, the expression of C1QTNF6 was detected in hepatocellular cancer tissue, 
and interestingly, no C1QTNF6 protein was found in non-cancerous liver tissues. 
Moreover, its possible role in tumour angiogenesis in this cancer type was discussed 
(Takeuchi et al., 2011). Furthermore, endocrine actions, and anti-inflammatory 
functions of C1QTNF6 were reported (Wong et al., 2008; Kim et al., 2010). However, 
the pathologic role as well as the expression status of this protein in carcinogenis still 
remains unclear and needs further clarification and investigations. Therefore, the 
methylation pattern of the gene coding C1QTNF6 was analysed in the present work 
in order to identify a possible influence of C1QTNF6 protein expression on the 
progression of T24 cells during long-term exposure to MMA(III) (Fig. 46). For this 
purpose, DNA methylation was examined in T24 cells treated with 100 nM MMA (III) 
over a period of 84 weeks. The results revealed an increase of methylation in the 
treated cells when compared to the concurrently untreated control cells from week 36 
onward. Starting from week 64, the increase became even more distinct, until an 
approx. 3.5 fold higher methylation status in week 84. Since hypermethylation leads 
to decreased protein expression, the biological consequence and the influence on 
the tumour progression remains unclear. It is unlikely, that the observed effect has a 
tumour promotive function, but a tumour protective function is even more 
questionable. Further research is urgently needed to clarify the role of C1QTNF6 
protein and its expression in progression in arsenic-exposed T24 cells in vitro as a 
model for arsenic-induced bladder cancer. 
The methylation status of CDH1, coding the cell adhesion protein E-cadherin, was 
reported not to be a suitable biomarker to differentiate between benign and malignant 
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tumours, as both show similar methylation patterns (Pu et al., 2006). Nevertheless, 
promoter hypermethylation of CDH1 was often found in epithelial tumours, resulting 
in the loss of inhibition of cell invasion (Yoshiura et al., 1995; Conacci-Sorrell et al., 
2002). In the present work, promoter methylation of CDH1 was investigated in T24 
cells after chronic treatment to 75 and 100 nM MMA(III). After 8 weeks of exposure 
the DNA methylation level of control cells was clearly higher than that of both treated 
cultures (Fig. 47 and Fig. 48), but intersecting at week 24 for the 75 nM culture and at 
week 36 for the 100 nM culture. From this time point on a time dependent decrease 
of CDH1 methylation in control cells and increase in treated cells was observed, 
leading to an even more distinct difference when comparing both control and treated 
cells. Due to the fact that such a clear difference in the promoter methylation was 
observed, a biological relevance may be assumed. Furthermore, this result is in 
compliance with the results received from the cellular migration and invasion assay, 
showing a distinct dose-dependent and treatment-related increase in cellular 
migration and invasion (Fig. 51). Hence, it can be assumed that promoter 
hypermethylation of CDH1 is one of the key events during MMA(III)-induced 
progression of T24 cells in vitro, leading to increased cellular motility and 
invasiveness. However, to prove this hypothesis, further experiments are neccessary, 
where hypermethylation of CDH1 is artificially suppresed. If progression would be 
hereby prohibited, srong evidence would be given that the hypothesis would be true. 
Summarising all the data received for DNA methylation, it seems that this epigenetic 
process might only be affected to a minor degree by chronic arsenic exposure of T24 
cells. However, further experiments analysing more genes known to be involved in 
carcinogenesis are needed to confirm this. Since the T24 cell line is tumourigen, the 
DNA methylation patterns have already distinctly changed, so that those prominent 
genes, which are generally analysed for the detection of tumourigenesis, have 
already undergone modifications. Typical examples in this study were LINE1 and 
RASSF1. During baseline establishment a change in the methylation status of T24 
cells in contrast to “normal untransformed” urothelial cells was noted. T24 cells 
showed a decreased methylation of LINE1 (45% in T24 cells versus 75% in normal 
urothelial cells), whereas the following genes, which are usually unmethylated in 
primary urothelial cells, showed a distinct increase of DNA methylation: DAPK1 
(20%), RAR ß (60%), CDH1 (22%), and RASSF1 (90%). It is assumed that due to 
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this altered background the changes in methylation resulting from arsenic treatment 
may have been superimposed. However, at study initiation, the cell line used was 
expected to be UROtsa, which is non-tumorigenic. But this cell line was generated by 
immortalisation with SV40, which also revealed changes to the genetic background 
and led to altered DNA methylation patterns too. Tab. 5 shows the DNA methylation 
of selected genes in different cell lines and normal urothelial cells from healthy 
patients, representing the difference in continous cell lines and primary cultures. The 
challenge for the further research will be to establish a continuous urothelial cell line 
exhibiting less altered epigenetic background changes. Primary cell cultures are not 
considered suitable for the purpose of such methylation studies, due to their short 
lifetime. 
Tab. 5 DNA methylation in different cell lines 
1)
 UROtsa: urothelial cell line provided by A. Fabrarius, University of Heidelberg, Germany 
2)
 T24 cell line used in the present work (provided as UROtsa cell line by M. Styblo, University 
of North Carolina, USA) 
3)
 T24: transitional cell carcinoma of urinary bladder, available at ATCC (American Type Culture 
Collection) 
4) 
5) 
HepG2: hepatocellular carcinoma, available at ATCC 
HeLa S3: cervix carcinoma, available at DSMZ (German Collection of Microorganisms and 
Cell Cultures) 
6)
 Urotheal urine: mean of results obtained from four healthy persons 
(Johnen et al., 2013, modified) 
Cell line 
UROtsa 1) 
T24 2) 
T24 3) 
(ACC 376) 
HepG2 4) 
(HB-8065) 
HeLa S3 5) 
(CCL-2.2) 
Urothel urine 6) 
Gene promoter region (% methylation) 
LINE1 
56 
46 
47 
54 
69 
69 
RAR ß 
96 
64 
50 
5 
98 
2 
RASSF1 
1 
91 
93 
89 
3 
2 
CDH1 
2 
23 
83 
7 
97 
3 
C1QTNF6 
12 
9 
18 
31 
7 
18 
MGMT 
1 
4 
1 
62 
2 
2 
5.4 The role of miRNAs in arsenic-induced carcinogenesis 
At this point I want to express my gratitude to my colleagues and project partners Dr. 
D. G. Weber and Dr. O. Bryk from the Institute for Prevention and Occupational 
Medicine of the German Social Accident Insurance (Institute of the Ruhr-University 
Bochum, Germany) under the head of Dr. G. Johnen, who kindly performed the 
experiments of the miRNA analysis and provided the data for the present study. 
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Discussion of the role of miRNAs in arsenic-induced carcinogenesis 
In tumour tissue the regulation via miRNAs is of great relevance. Among classically 
known cancer genes, miRNAs are known as molecular modulators, and were 
described as essential components of fundamental signal transduction of 
carcinogenesis (Dalmay & Edwards, 2006; Sotiropoulou et al., 2009). Comparable to 
protein-coding genes miRNAs can also be downregulated by DNA hypermethylation 
in the promoter regions of cancer cells (Zimbardi et al., 2012). Many miRNAs 
possess tumour suppressive functionality and can depress proliferation. Altered 
miRNA profiles in bladder cancer tissues were recently reported (Catto et al., 2009; 
Dyrskjot et al., 2009; Ichimi et al., 2009; Lin et al., 2009; Veerla et al., 2009; Hanke et 
al., 2010). Nevertheless, only little information is available on the effect of arsenic 
treatment on miRNA profiles, especially in bladder cancer. To gain more information 
on the regulatory impact of miRNAs in arsenic-induced bladder cancer, an 
expression profile of 33 miRNAs associated with cancer was analysed. T24 cells 
derived from the chronic treatment with 100 nM MMA(III) and concurrently untreated 
control cells were harvested every 4 weeks starting from week 10 up to week 56 of 
exposure. Although the expression profile revealed various fluctuations of the 
analysed miRNAs throughout the study period, there were few miRNAs showing 
distinct trends in their profiles (Tab. 4). These were namely miR-139-5p, miR-146a, 
miR-149, miR-200a, and miR-429, which were only recently associated with bladder 
cancer in particular (Catto et al., 2009; Dyrskjot et al., 2009; Ichimi et al., 2009; Lin et 
al., 2009; Veerla et al., 2009). In the present study miR-139-5p was significantly 
decreased at six time points from week 32 onwards, whereas 2 and 4 time points 
were hereby in direct succession. MiR-139-5p was recently reported to be 
downregulated in various kinds of cancer diseases, including basal cell carcinoma 
(Sand et al., 2012), ovarian cancer (Miles et al., 2012), and clear cell renal cell 
carcinoma (Wu et al., 2012). Especially in the latter carcinoma, miR-139-5p was 
associated with metastasis and poor prognosis. Additionally, miR139 was detected to 
be decreased in bladder tumours (Ichimi et al., 2009), possibly targeting CXCR4 and 
resulting in metastasis. CXCR4 was described to be increased in invasive bladder 
tumours (Dalmay & Edwards 2006; Retz et al. 2005). In the present work, miR-200a 
was also found to be significantly decreased in 100 nM MMA(III)-treated T24 cells as 
compared to concurrently untreated control cells at week 19, 28, and continuously 
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from week 36 onward. MiR-200-miRNAs inhibit the expression of the proteins Zeb1 
and Zeb2, which suppress the transcription of CDH1. Decreased levels of miR-200-
miRNAs were correlated with progression in breast cancer, and further with the poor 
prognosis of ovarian carcinoma (Gregory et al., 2008; Hu et al., 2009). The findings 
match with the results from the present work, since enhanced migration and invasion 
of treated cells were also observed, indicating an even more malignant phenotype 
with properties required for metastasis (Fig. 51). As in case of miR-200a this would 
mean that the synthesis of the E-cadherin protein could have been depressed via two 
independent routes: first, as a secondary effect of the decrease of members of the 
miR-200-miRNA family, and second, as a result of CDH1 hypermethylation as 
described earlier (Fig. 47 and Fig. 48). 
MiR-146a was detected to play a role in suppression of metastasis in breast cancer 
(Hurst et al., 2009), among others, by decreasing protein levels of MMP9, which is 
important for the invasion of tumour cells (Bhaumik et al., 2008). ROCK1 was 
identified to be a target of miR-146a in prostate carcinoma cell lines, as well as 
CXCR4 in leukemia cells (Labbaye et al., 2008; Lin et al., 2008). In this study miR-
146a expression was significantly and continuously decreased from week 32 of 
exposure until the end of the study, giving further evidence that alteration of miRNAs 
expression profiles may contribute to tumour progression in MMA(III)-treated T24 
cells. In contrast, miR-149 was observed to be increased during the study at weeks 
10, 24, 32, and 40-52. Zhaohui et al. (2011) reported the miR-149 mediated 
promotion of proliferation of nasopharyngeal carcinoma cell lines, as well as an 
increase in their mobility and invasion. Furthermore, miR-149 was reported to 
downregulate the expression of E-cadherin. The authors conclude that miR-149 
might be involved in the invasion and metastasis continuously through the regulation 
of the epithelial-mesenchymal transition (EMT). Regulation of EMT through miRNAs 
was further discussed for the miR-200-miRNAs (miR-200a, -200b, -200c, -141, -429) 
in combination with miR-205. As described earlier, significant changes in the 
expression of miR-200a were observed. Furthermore, miR-205 was clearly increased 
at 4 time points throughout the study (week 19 36, 52, and 56), even though 
fluctuations were observed; in addition, miR-429 expression was also altered 
throughout the study period. After first fluctuations (decrease at weeks 10 and 28 and 
increase at weeks 15 and 24), a continuous decrease was detected from week 36 
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onward, suggesting the hypothesis of a compensatory mechanism at the beginning, 
which finally failed, leading to the further development of a malignant phenotype. 
Since the development of the expression profile of miR-429 led to the hypothesis of a 
compensation process during malignancy, the analysis was repeated and the 
expression profile was not only measured for 100 nM MMA(III) exposure, but also for 
50 and 75 nM MMA(III), as well as 50 nM As(III) (Fig. 41). In all treatment groups a 
strong increase of miR-429 was observed after 15 weeks of exposure, followed by a 
strong and more or less steady decrease far below the control values and the values 
obtained in the treated groups at test beginning. The increase was the strongest at 
50 nM MMA(III) and moderate at 75 nM MMA(III), whereas at 100 nM MMA(III) the 
increase was no more statistically significant. In the case of As(III), the weakest 
increase of miR-429 was observed. The analogue trend, the dose dependency, and 
the fact that both MMA(III) and As(III) were affected from the increase, enhance the 
hypothesis that a compensatory mechanism had occurred, but finally failed. 
Summarising all the data derived from the miRNA analysis, some evidence is given 
that altered miRNA profiles play a pivotal role in arsenic-induced progression of T24 
cells in vitro. Nevertheless, care has to be taken when the relevance of altered 
miRNA profiles is interpreted in carcinogenesis, as their expression patterns are 
highly specific for cell-type and cellular differentiation status. This is further 
highlighted by the findings of Johnen et al. (2013), who compared the miRNA 
expression in different cell lines (Fig. 53). 
Altered expression patterns are not conclusively the reason for malignant 
transformation, but a consequence of genetic and epigenetic changes that result in 
the loss of the normal cell identity accompanied by malignant transformation (Kent & 
Mendell, 2006). Further in vivo experiments are necessary to confirm the results of 
the present work, and to clarify the regulatory impact of miRNA expression in arsenic-
induced bladder cancer in humans. 
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Fig. 53 Comparison of miRNA expression in different cell lines. 
Normalized levels of miR-141 (yellow), miR-200a (red), miR-200b (green), miR-200c (blue), and 
miR-429 (orange) were determined in HeLa 1), T24 2), T24 3), UROtsa 4), RT4 6), and HUEPC 5). 
Expression levels were determined by Real-Time 22 PCR. RNU44 and RNA48 were used for 
normalization. The y axis was adapted to better accommodate the genes with low expression 
levels. (Johnen et al., 2013, modified) 
1)
 HeLa S3 (DSMZ); 2) T24 (ATCC); 3) T24 cell line used in the present work (provided as UROtsa) 
(Styblo, University of North Carolina, USA); 4) UROtsa (Fabrarius, University of Heidelberg, 
Germany); 5) HUEPC (Provitro GmbH); 6) RT4 (well differentiated transitional papillary tumour of 
urinary bladder) (ATCC) 
5.5 Arsenic-induced COX-2 protein activation 
The COX-2 protein is known to exhibit pro-carcinogenic properties (Vane et al., 
1998). It was reported to suppress apoptosis, promotes proliferation, and is involved 
in many processes during the development of various cancer diseases including 
bladder cancer, and moreover, malignant transformation of human urothelial cells 
(UROtsa) as a consequence of chronic low-dose treatment (Eblin et al., 2007). COX-
2 protein was described to be an essential factor for the survival of human and 
mammalian cells under stress conditions, as it protects the cells from stress-induced 
apoptosis, for example caused by DNA damaging agents (Chai et al., 2007). The 
induction, expression, and activity of COX-2 was reported to be one essential step in 
the development of colon cancer due to the decrease of apoptosis and the survival of 
the epithelial cells beyond normal lifetimes, allowing the development of a malignant 
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phenotype. Therefore, COX-2 activity is correlated with the progression of pre-
cancerous epithelial cells to fully malignant phenotypes (Vane et al., 1998). In 
general, there is no COX-2 activity in the tissues, but a single stimulus enhances the 
protein level for only a few hours (Vane et al., 1998). In the present study the 
occurrence of COX-2 protein in T24 cells was investigated after arsenic exposure in 
comparison to concurrently untreated control cells. Treatment with 75 and 100 nM 
MMA(III) for up to 1 week resulted in first a distinct decrease in intracellular COX-2 
protein after 1 h, which normalised to control values again within 24 h (Fig. 38). 
Already after 1 week of exposure to both 75 and 100 nM MMA(III), elevated COX-2 
protein levels as compared to untreated controls were observed. The effects detected 
showed a dose-response, with 100 nM treatment resulting in a slightly stronger 
decrease within 1 h and a slightly stronger increase after 1 week of exposure as 
compared to 75 nM treatment. Chronic exposure of T24 cells to MMA(III) revealed 
more or less continuously elevated COX-2 protein levels in treated cells as compared 
to concurrent control cells (Fig. 39). Fluctuations were observed for both exposure 
concentrations, whereas, in contrast to the short-term treatment, the increase of 
COX-2 protein was stronger in 75 nM-treated cells than in those treated with 100 nM. 
While 100 nM MMA(III)-treated cells showed lower COX-2 protein content than the 
control cells during weeks 25 - 33 of exposure, and the values were comparable to 
those of the control cells again from week 60 to week 65, treatment with 75 nM 
MMA(III) never resulted in values below those of the control cells and only at week 
28, a COX-2 protein level comparable to that of the control was noticed. The 
fluctuations suggest that there could be a compensatory processe occurring to 
prevent the development of cell malignancy. To investigate the regulation of the 
COX-2 protein expression, the respective mRNA level was also analysed during the 
chronic low-dose exposure to MMA(III) (Fig. 40). The mRNA levels detected in 
100 nM-treated and untreated cells ran inversely proportional. Fluctuations such as 
those seen from the protein content were not observed for the mRNA level from week 
32 onward. While COX-2 protein expression in exposed cells was elevated as 
compared to the control between week 40 and week 56, the mRNA level of 100 nM-
treated cells was decreased at the same time. Hence, it can be concluded, that the 
regulation of the COX-2 protein content in the cells is not induced by the existing 
amount of the respective mRNA. Interestingly, the trend of the COX-2 mRNA 
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observed in 100 nM MMA(III)-treated cells matches with the trend of the miR-26a and 
miR-26b (Fig. 54). This result is in compliance with the findings of Ji et al. (2012), 
showing that the expression levels of COX-2 mRNA and miR-26b were inversively 
correlated in carcinoma cells of nasopharyngeal epithelia (CNE cells). 
Fig. 54 COX-2 mRNA (normalised) and miR-26a- and miR-26b- expression (normalised) in 
UROtsa cells after exposure to 100 nM MMA(III) for 24 - 56 weeks 
The authors suggest that COX-2 mRNA contains a binding site for miR-26b, which is 
suspected to regulate the COX-2 protein expression by directly interacting with the 
mRNA. The authors further suggested mRNA cleavage as a possible mechanism. 
This assumption could not be confirmed in the present study. While direct interaction 
between miR-26a and miR-26b with the COX-2 mRNA can be assumed (Fig. 54), it is 
unlikely that this alone leads to direct regulation of the COX-2 protein synthesis, since 
the mRNA level and the protein level could not be directly correlated with each other 
(Fig. 39 and Fig. 40). It might be possible that further events occur during the chronic 
treatment with MMA(III), which influence the COX-2 protein expression by interfering 
with the regulatory effect of miR-26a and miR-26b. Moreover, it is generally known 
that several backup systems exist to prevent aberrant cell proliferation and malignant 
transformation. It is likely that exposure to MMA(III) induces deregulatory and, in 
addition, compensatory processes, finally leading to an imbalance, which would also 
explain the strong fluctuations observed for COX-2 mRNA and protein level, as well 
as for the miRNA levels. It is possible that with longer exposure times this imbalance 
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would increase, finally leading to a failure of the compensatory system and maybe 
revealing a clear inverse connection between the miRNAs, the COX-2 mRNA, and 
the respective protein level. Nevertheless, further experiments with longer exposure 
durations are necessary to confirm this hypothesis. 
5.6 Arsenic-induced tumour progression 
The processes described above are by far not expected to be the only ones ongoing 
in urothelial cells during arsenic-induced malignant transformation. But these 
processes are believed to be part of the key events occurring during tumour 
development and progression. To prove direct correlation of those mechanisms with 
the development of tumour progression of T24 cells as a result of arsenic exposure, 
further experiments were carried out to analyse malignant phenotypical alterations. 
T24 cells derived from the chronic low-dose exposure to MMA(III) were included into 
several tests, investigating effects such as altered morphology, growth inhibition, 
anchorage-independent growth, motility, and invasiveness. 
At first, the in vitro Mammalian Cell Transformation Test was carried out. This test 
analyses the possible loss of contact inhibition during tumour progression and is 
mentioned in the EU method B.21 for testing mutagenicity of chemicals. T24 cells 
derived from the long-term exposure to 50, 75, and 100 nM MMA(III) were seeded to 
confluence. The non-tumourigenic variant of T24 cells normally grow in a monolayer, 
and hence, if no tumour progression had occurred yet, the cells would have stopped 
proliferating (Gildea et al., 2000). This behaviour physiologically preserves the normal 
organ shapes in organisms. In this study, untreated control cells showed the more or 
less physiologic behaviour, supporting the assumption that the T24 cell line 
contaminating the UROtsa stock used in our laboratory is the non-tumourigenic 
variant. However, chronic exposure to MMA(III) led to a loss of this preventive 
contact inhibition and revealed cells growing in three-dimensional layers (Fig. 49). 
Within two weeks of incubation the cells formed colonies with a diameter of more 
than 200 µm. Moreover, the treated cultures included big and misshapen cells. The 
observations were strongest for the 75 nM-treated culture, but also 50 nM-exposed 
cells exhibited altered morphology and colonial growth. At 100 nM MMA(III) 
treatment, the cells built up only few and barely perceptible colonies, but misshapen 
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cells were still recognisable. The fact that untreated control cells of the same 
passage did not exhibit such an altered phenotype, clearly indicates that the effects 
observed are treatment-related and suggest that MMA(III) treatment induces tumour 
progression. Altered morphology of urothelial cells as a result of long-term low-dose 
treatment with arsenic was also reported for the untransformed cell line UROtsa 
(Bredtfeld et al., 2006); and the detected loss of contact inhibition matches with the 
findings that the expression of the cell surface protein E-cadherin was affected by 
arsenic treatment (induced by CDH1 promoter hypermethylation (Fig. 47 and Fig. 48) 
and altered expression profiles of the miR-200 family miRNAs (Tab. 4 and Fig. 41). 
E-cadherin is normally connected with cell surface receptors such as the EGFR, 
enhancing cell-cell attachments and, moreover, disabling growth factors to bind to 
their respective receptors. This connection is carried out by the protein Merlin, which 
is a gene product of NF2 (Okada et al., 2005, Curto et al., 2007, Hanahan & 
Weinberg, 2001). Further experiments analysing e.g. promoter hypermethylation of 
NF2 or the expression profiles of Merlin might give further insights into the 
mechanism of arsenic-induced tumour progression, in particular, into the mechanism 
underlying the loss of contact inhibition. 
The results observed in the in vitro Mammalian Cell Transformation Test are similar 
to those observed in the Colony Formation Assay. This assay aims to detect 
anchorage-independent growth by bedding the cells into soft agar. Adherent growing 
cells, such as the non-tumourigenic variant of T24 cells, suffer apoptosis, if they fail 
to attach to a surface (Gildea et al., 2000). This effect was shown for the untreated 
control cells, which failed to grow under these conditions (Fig. 50 D). In contrast, T24 
cells treated with MMA(III) for 93 weeks clearly exhibited distinct growth abilities in 
soft agar, confirming the loss of anchorage dependent growth (Fig. 50 A-C). This 
phenotype was also noted for the tumourigenic T24T cell line (Gildea et al., 2000). It 
can therefore be assumed that under the conditions of this study, MMA(III)-treatment 
caused tumour progression in human bladder cells in vitro. 
The observation of anchorage independent growth might indicate that those cells in 
vivo would not underlie elimination by apoptosis, as soon as they are released from 
their respective tumour tissue. As a consequence, the cells should now be able to 
circulate in the organism once they have entered the blood stream. Hence, the ability 
of anchorage-independent growth is one essential step in the development of 
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metastasis. Moreover, only a few of the MMA(III)-treated T24 cells surviving in soft 
agar in this study grew separately; tumour-like colony formation was the predominant 
observation. This effect was observed over all three MMA(III) concentrations tested, 
but treatment with 75 nM MMA(III) exhibited the biggest and most dense colonies. 
This finding matches with the fact that COX-2 activation was stronger in 75 nM-
treated cells than those exposed to 100 nM MMA(III), since elevated COX-2 protein 
expression was reported to be important for sustaining anchorage-independent 
growth (Eblin et al., 2009). The results not only suggest that the MMA(III) treated 
cells underwent tumour progression to develop the ability to form primary tumours, 
but might also gain properties to form metastases. Bredtfeld et al. (2006) observed 
anchorage-independent growth of UROtsa cells exposed to 50 nM MMA(III) for 24 
and 52 weeks. Moreover, xenograft implantation of these cells into SCID mice 
exhibited the formation of moderately differentiated cell carcinomas (Bredfeldt et al., 
2006). Since UROtsa cells were described as generally non-tumourigenic (Petzold et 
al., 1995; Sens et al., 2004; Bredtfeld et al, 2006), the results clearly prove arsenic-
induced malignant transformation. The tumourigenic T24T cell line was also shown to 
form tumours when injected into SCID mice (Gildea et al., 2000). Consequently, 
implantation of T24 cells derived from the long-term exposure to 50, 75, and 100 nM 
MMA(III) of this study into SCID mice should lead to similar results, but possibly 
giving further information on dose dependency, which was not investigated by 
Bredfeldt et al. (2006). It would be interesting to see, if MMA(III) treatment also 
reveals strongest tumourigenic effect at 75 nM like in the Colony Formation Assay in 
soft agar. 
Metastasis is a later stage in carcinogenesis that in most cases is the immediate 
cause of cancer-related death. In order to metastasise tumour cells have to increase 
their motility and must be able to invade through tissues and the walls of blood and 
lymphatic vessels, which is essential for the extra- and intravasation process (Fidler, 
2003, Fig. 10). In this study the motility and the invasive potential of T24 cells derived 
from the chronic low-dose exposure were investigated using the xCELLigence 
system. The cells were seeded into devices consisting of two chambers separated by 
a microporous membrane. Cells migrating through this membrane were detected 
using impedance measurement. Values revealed from concurrently untreated control 
cells were compared to those of cells treated with MMA(III). The results show that 
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untreated T24 cells exhibit a certain migration potential, which corresponds to the 
observations made by Gildea et al. (2000). However, motility of cells exposed to 75 
and 100 nM MMA(III) for more than 90 weeks was distinctly increased. Only the 
50 nM-treated cells exhibited decreased motility as compared to the control 
(Fig. 51 A). In further experiments the microporous membranes of the devices were 
coated with collagen on both sides as a simulation of extracellular matrix (Du et al., 
2009). Those cells, which gained proteolytic properties and the ability to pass the 
membrane and penetrate its coating, are supposed to be able to invade through 
tissues and the walls of blood and lymphatic vessels, and hence, are strongly 
malignant exhibiting metastatic potential. Untreated control cells of the T24 cell line 
exhibited invasive properties, which was also reported by Gildea et al. (2000), but 
after 92 weeks of exposure cells treated with MMA(III) showed a strong increase in 
invasion as compared to the untreated control cells (Fig. 51 B). While invasion of 50 
and 75 nM-treated cells increased only to a slight but still distinct degree, 100 nM-
treated cells invaded within the 20 h experiment duration 2.5 imes more than the 
control cells and approx. 2 times more than the 50 and 75 nM-treated cells. 
Moreover, invasion of 100 nM-treated cells was by far quicker than that of the control 
cells and the lower treatment doses, exhibiting a linearity and therefore a maximum 
velocity between 6 and 10 h experiment duration, finally leading to an experiment-
based saturated state. In contrast, the course of invasion of 50 and 75 nM-exposed 
cells was parallel to that of the untreated control cells, and none of these samples 
reached the saturated state. These findings support a dose-response relationship 
and suggest that the malignant effect increases with the exposure concentration. 
Nevertheless, when comparing all endpoints addressed in this study, the dose-
dependency is inconclusive. Among this, care must be taken when endpoints 
addressing malignancy are evaluated in T24 cells, since this cell line is already a 
cancer cell line. Nevertheless, the tumourigenic T24T cell line was reported not to 
exhibit increased invasive properties as compared to the non-tumourigenic variant 
T24. As an increase was observed in T24 cells after chronic MMA(III) treatment, it 
can be assumed that the phenotype resulting from arsenic exposure might be even 
more malignant than that presented by the T24T cell line. A further uncertainity is 
given by the fact that the experiment with chronic MMA(III) exposure was carried out 
only once owed to the huge experimental effort. Thus, for further certainity, the 
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experiments described here should be repeated and the results should be evaluated 
again. Moreover, experiments should additionally be carried out with the normal 
untransformed UROtsa cell line. Since the methods applied analysing phenotypical 
alterations after chronic arsenic exposure revealed positive results, it can be 
expected that similar (or even worse) effects will be observed when testing UROtsa. 
Unfortunately, there is too little information given in the scientific literature, supporting 
or negating the hypothesis of dose-dependent malignant transformation of arsenic-
treated T24 or UROtsa cells. Nevertheless, few data is available for 50 nM MMA(III) 
and 1 µM As(III) in comparison to 1 µM Cd(II). Jensen et al. (2009) summarised the 
phenotypic alterations of UROtsa cells observed during development of malignancy 
after chronic low-dose exposure to MMA(III) (Tab. 6). 
Tab. 6 Summary of arsenic exposure conditions and selected effects on UROtsa cells as a 
result of various recent studies 
Cell line name, the treatment metal, concentration (exposure), and duration of treatment for 
each cell line are shown. In addition, the phenotypic properties of each cell line including 
increased growth rate relative to UROtsa (hyperproliferation), anchorage-independent growth 
(AIG), and ability of each cell line to form tumours when injected subcutaneously into 
immunocompromised mice are described. The reference cites previous publications 
describing part or all of the information presented for a given cell line. (Jensen et al., 2009, 
modified) (NA = not applicable; ND = not determined) 
Cell Line 
UROtsa 
URO-MSC12 
URO-MSC24 
URO-MSC36 
URO-MSC52 
URO-MSC24 + 
URO-MSC24 + 
URO-MSC52 + 
URO-MSC52 + 
URO-ASSC 
URO-CDSC 
3mo 
6mo 
3mo 
6mo 
Treatment 
None 
MMA (III) 
MMA (III) 
MMA (III) 
MMA (III) 
MMA (III) 
MMA (III) 
MMA (III) 
MMA (III) 
As (III) 
Cd (II) 
Exposure 
None 
50 nM 
50 nM 
50 nM 
50 nM 
50 nM 
50 nM 
50 nM 
50 nM 
l j i M 
l j i M 
Duration 
None 
12 weeks 
24 weeks 
36 weeks 
52 weeks 
24 weeks 
24 weeks 
52 weeks 
52 weeks 
52 weeks 
52 weeks 
Hyperproliferation 
NA 
Yes 
Yes 
Yes 
Yes 
ND 
ND 
ND 
ND 
Yes 
Yes 
AIG 
No 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Tumors in mice 
No 
No 
No 
ND 
Yes 
ND 
ND 
Yes 
Yes 
Yes 
Yes 
5.7 Conclusion 
In conclusion, further studies are necessary to gain more information on the impact of 
the exposure concentrations. Since arsenic is not only carcinogenic at low doses, it 
also exhibits cytotoxic effects at higher concentrations, leading to strong systemic 
toxicity in vivo. It is therefore likely, that at one point the exposure concentration 
exceeds the “tolerance level”, finally suppressing carcinogenicity due to the 
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predominance of acute toxicity. More studies, both in vitro and in vivo, have to 
investigate a possible cut-off value for carcinogenesis. In addition, more 
epidemiologic information is needed about human exposure and the concurrent 
health hazard. Nevertheless, elimination of human arsenic contamination should be 
the ambitious aim by e.g., applying clean water technologies, minimising 
occupational exposure, and avoiding contaminated food. 
Fig. 55 summarises the molecular mechanisms of MMA(III)-induced toxicity and 
malignancy in T24 cells in vitro after chronic low-dose exposure. This extended 
model proposes the fast cellular uptake and subsequent conjugation of MMA(III) to 
proteins and other cellular structures in addition to the immediate occurrence of 
genotoxicity. It can be hypothesised that, as a “first-response” to such a cellular 
stress, cellular autophagy is activated, preventing cell death and, as a side effect, 
causing a kind of “cellular cycling” of MMA(III). In addition, the affection of cellular 
structures by MMA(III) leads to epigenetic alterations, which can be manifested and 
might become inheritable because of the prevented cell death. As a consequence, 
malignant transformation and progression can occur, leading to pre-neoplastic cells. 
This finally might reveal the development of cancer in vivo (Hippler et al., 2011; 
Zdrenka et al., 2012). 
Because this highly hypothetic model is based on few endpoints addressed in in vitro 
research using urothelial carcinoma cells, further experimens should be conducted to 
verify the results observed. It is likely that few effects such as increased DNA 
methylation of RASSF1 resulting from chronic exposure to MMA(III) are invisible, 
because a maximum alteration is already present in the cancer cell line tested. 
However, in case of the positive tests, it can be expected that the effects observed 
would be even worse with normal, untransformed cells, since arsenic exposure 
increased the malignant potential of an already malignant cell line. However, care 
must be taken when interpreting the results obtained from the present study: owing 
the huge experimental effort necessary for chronic treatment of cell cultures and 
continous sampling of these during that exposure time, the experiment was 
conducted with one culture per test concentration only. Thus, an experimental design 
should be developed, in which more cultures of the same treatment group can be run 
in parallel. 
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Among good quality data obtained from in vitro tests, there is still an urgent need for 
further in vivo studies. While in vitro assays give important data for the investigation 
of molecular mechanisms, there is lack of information concerning the defence of a 
whole organism against cancer, including among others, toxicokinetic and 
toxicodynamic of the carcinogen, immune response, and tumour growth restriction 
because of limited blood supply. Only in vivo studies have the power to correlate the 
mechanism observed on single cell basis in vitro with a realistic carcinogenic 
potential. Nevertheless, in vitro research enables researchers to investigate specific 
targets in animal experiments without being lost in the complexity of a whole 
organism. Determining in vitro tests as a first step enables researchers to define a 
concrete question for the subsequent in vivo experiment, and hence, decreasing 
animal numbers in terms of animal welfare. 
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Fig. 55 Proposed molecular mechanisms of MMA(lll)-induced toxicity and malignancy in UROtsa cells after chronic low-dose 
exposure 
(Zdrenkaetal., 2012) 
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7 Annex 
7.1 Instruments, chemicals and reagents 
Laboratory equipment used in this study 
> Water-Jacked Incubator 
> Microscope Labovert FS 
> Digital camera for the Microscope Labovert FS 
> Fluorescence microscope DMLS 
> Digital camera for the fluorescence microscope 
> Centrifuge MiniSpin plus 
> Centrifuge Microfuge 22R Cent 
> HPLC 1100 
> HPLC Coloumn Luna, 3µ C18(2), 150 x 4,6 mm, max. 
pressure 400 bar 
> SecurityGuard Cartride Kit Cartridge: C18; 
4 x 3.0 mm 
> ICP/MS 7500a 
> Precellys 24 Tissue Homogenisator 
> QIAcube 
> NanoDrop ND-2000 
> Sample-Prep Workstation 
> Pyrosequencer PSQ 96MA 
> GENios Plate Reader 
> xCELLigence DP System 
Forma Scientific (Marietta, USA) 
Leica Microsystems GmbH (Wetzlar, Germany) 
Leica Microsystems GmbH (Wetzlar, Germany) 
Leica Microsystems GmbH (Wetzlar, Germany) 
Leica Microsystems GmbH (Wetzlar, Germany) 
Eppendorf (Hamburg, Germany) 
Beckmann Coulter (Krefeld, Germany) 
Agilent Technologies (Waldbronn; Germany) 
Phenomenex (Aschaffenburg, Germany) 
Phenomenex (Aschaffenburg, Germany) 
Agilent Technologies (Waldbronn; Germany) 
PEQLAB Biotechnologie (Erlangen, Germany) 
QIAGEN (Hilden, Germany) 
PEQLAB Biotechnologie (Erlangen, Germany) 
QIAGEN (Hilden, Germany) 
QIAGEN (Hilden, Germany) 
Tecan (Crailsheim, Germany) 
Roche Applied Science (Mannheim, Germany) 
Materials used in this study 
> Cell culture flasks 
> Cell Culture Multiwell Plate, 24 well 
> Microplate, 96 well 
> Cellscraper 
> Pipetus 
> Serological Pipettes 
> Eppendorf Research Pipettes 
> Eppendorf Research Multichannel-Pipettes 
> Universal pipette tips 
> Reaction tubes 
> PS tubes screw cap 
> Precellys Homogenisation kit (0,5 ml tubes, ceramic 
1,4 mm) 
> Injection filters 4 mm (0,2 / 0,45 µm) 
> GelBond Film 
> Chamber Slides 
> Immuno 96 MicroWell Solid PlatesMaxiSorp 
> CIM-Plates for xCELLigence DP System 
TPP (Trasadingen, Switzerland) 
Greiner Bio-One (Frickenhausen, Germany) 
Greiner Bio-One (Frickenhausen, Germany) 
Greiner Bio-One (Frickenhausen, Germany) 
Hirschmann Laborgeräte GmbH & Co. KG 
(Eberstadt, Germany) 
Greiner Bio-One (Frickenhausen, Germany) 
Eppendorf AG (Hamburg, Germany) 
Eppendorf AG (Hamburg, Germany) 
Greiner Bio-One (Frickenhausen, Germany) 
Greiner Bio-One (Frickenhausen, Germany) 
Greiner Bio-One (Frickenhausen, Germany) 
PEQLAB Biotechnologie (Erlangen, Germany) 
Phenomenex (Aschaffenburg, Germany) 
Lonza Group Ltd (Basel, Switzerland) 
Nunc GmbH &. Co. KG (Langenselbold, Germany) 
Nunc GmbH &. Co. KG (Langenselbold, Germany) 
Roche Applied Science (Mannheim, Germany) 
Cell lines and primary cells used in this study 
> UROtsa cells (actually T24 cells) 
> HepG2 cells 
> HUEPC 
Prof. M. Styblo (University of North Dakota, USA) 
ATCC (Manassas, VA, USA) 
Provitro GmbH (Berlin, Germany) 
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As(III), sodium arsenite, 98% 
As(V), disodium arsenate heptahydrate, 98% 
MMA(III), monomethylarsonic iodide, 98% 
MMA(V), disodium monomethylarsonic acid, 98% 
DMA(III) dimethylarsinc iodide, >99% 
DMA(V) cacodylic acid, 99.5% 
MEM (Earle’s Minimal Essential Medium) 
serum-free urothelial cell growth medium 
FBS (fetal bovine serum) 
L-Glutamin 
NEAA (not essential amino acids) 
Sodium pyruvate 
Gentamycin 
Amphotericin B 
PBS (phosphate buffered saline) 
Trypsin 
Trypsin / EDTA 
Ampuwa (pure water) 
DMPS (2,3-bis(sulfanyl)propan-1-sulfonic acid) 
Proteinase K 
H202, 30% 
Methanol, 99% 
Tetrabutylammoniumhydroxide, 99.9% 
Malonic acid, > 99% 
Acetonitrile, > 99 % 
THF (Tetrahydrofurane) 
TFA (Trifluor acetic acid) 
Pure water derived from the pure water device 
PURELAB ultra 18,2 MO * cm 
ENU (N-ethyl-nitroso urea) 
LMP (low melting point) Agarose 
Trizma HCI ( 2-Amino-2-(hydroxymethyl)-1,3-
propanediol) 
NaOH (sodium hydroxide) 
EDTA (Ethylenediaminetetraacetic acid) 
NaCl (sodium chloride) 
N-Lauroylsarcosine sodium salt 
DMSO (dimethyl sulfoxide) 
Triton-X 
Glacial acetic acid 
HCl (hydrochloric acid ), 37% 
SYBR Green 
Buffer ATL 
Proteinase K 
QIAamp DNA Mini QIAcube Kit 
Epitect Bisulfite Kit 
AmpliTaq Gold 
RNAIater 
RNeasy Plus Mini Kit 
TaqMan MicroRNA Reverse Transcription Kit 
TaqMan MicroRNA Assay 
RNase-free, sterile-filtered water 
CytoBuster 
DC Protein Assay Reagents Package 
Protein Standard II, bovine serum albumin 
COX-2 ELISA kit 
Collagen 
Fluka (Seelze, Germany) 
Sigma-Aldrich (Taufkirchen, Germany) 
Argus Chemicals (Vernio, Italy) 
Tri-Chemical Laboratories Inc (Yamanashi, Japan) 
Synthesis according to Styblo et al. (1997) 
Strem (Kehl, Gemany) 
cc-Pro (Oberdorla, Germany) 
Provitro GmbH (Berlin, Germany) 
GIBCO Invitrogen (Darmstadt, Germany) 
Sigma (Oberhaching, Germany) 
cc-Pro (Oberdorla, Germany) 
cc-Pro (Oberdorla, Germany) 
cc-Pro (Oberdorla, Germany) 
cc-Pro (Oberdorla, Germany) 
Gibco Invitrogen (Darmstadt , Germany) 
cc-Pro (Oberdorla, Germany) 
cc-Pro (Oberdorla, Germany) 
Fresenius Kabi GmbH (Bad Homburg, Germany) 
Alfa Aesar (Karlsruhe, Germany) 
Sigma-Aldrich (Steinheim, Germany) 
Merck (Darmstadt, Germany) 
Merck (Darmstadt, Germany) 
Sigma-Aldrich (Steinheim, Germany) 
Merck-Schuchhardt (Hohenbrunn, Germany) 
Merck-Schuchhardt (Hohenbrunn, Germany) 
Fisher Scientific (Schwerte, Germany) 
Fisher Scientific (Schwerte, Germany) 
Elga Labwater (Celle, Germany) 
Sigma-Aldrich (Steinheim, Germany) 
Invitrogen (Darmstadt, Germany) 
Sigma-Aldrich (Steinheim, Germany) 
Sigma-Aldrich (Steinheim, Germany) 
Sigma-Aldrich (Steinheim, Germany) 
Sigma-Aldrich (Steinheim, Germany) 
Sigma-Aldrich (Steinheim, Germany) 
Sigma-Aldrich (Steinheim, Germany) 
Merck (Darmstadt, Germany) 
Sigma-Aldrich (Steinheim, Germany) 
Merck (Darmstadt, Germany) 
Invitrogen (Darmstadt, Germany) 
QIAGEN (Hilden, Germany) 
QIAGEN (Hilden, Germany) 
QIAGEN (Hilden, Germany) 
QIAGEN (Hilden, Germany) 
Life TechnologiesCorporation (Carlsbad, CA, USA) 
Life TechnologiesCorporation (Carlsbad, CA, USA) 
QIAGEN (Hilden, Germany) 
Life TechnologiesCorporation (Carlsbad, CA, USA) 
Life TechnologiesCorporation (Carlsbad, CA, USA) 
Life TechnologiesCorporation (Carlsbad, CA, USA) 
Merck (Darmstadt, Germany) 
BioRad Laboratories GmbH (Munich, Germany) 
BioRad (Munich, Germany) 
Merck (Darmstadt, Germany) 
SERVA Electrophoresis GmbH (Heidelberg, 
Germany) 
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Solutios prepared in this study(Comet Assay) 
> Tris solution 
> NaOH solution 
> EDTA solution 
> Lysis solution I 
> Lysis solution II 
> Neutralisation solution 
> 50x TAE buffer 
> 1x TAE buffer 
> SYBR-Green stain solution 
> Electrophoresis solution 
1 M Trizma HCl in Ampuwa 
2 M NaOH in Ampuwa 
0.5 M and 1 M EDTA in Ampuwa 
-> adjust to pH 8 by using NaOH solution 
- 10 mL Tris solution (1 M) 
- 146.1 g NaCl 
- 100 mL EDTA (1 M) 
- 10 g N-Laurylsarcosine sodium salt 
-> fill up to 1000 ml with Ampuwa and heat up to 
100 °C 
- 100 mL DMSO 
- 10 mL Triton-X 
-> storage under protection from light 
- 200 mL Tris solution 
- 300 mL Ampuwa 
-> adjust to pH 7.5 by using NaOH solution 
- 242 g Trizma 
- 57.1 mL Glacial acetic acid 
- 100 mL EDTA (0.5 M, pH 8) 
-> fill up to 1000 ml with Ampuwa 
-> dilute 50x TAE buffer 1:50 
- 20 µl SYBR-Green stock solution 
- 35 ml 1x TAE buffer 
-* storage under protection from light 
- 75 ml 2 M NaOH 
- 1 ml 0.5 M EDTA 
- 0.79 g Trizma 
-> fill up to 500 ml with Ampuwa and adjust to pH 
12.7 by using HCl 
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7.2 Supplementary results 
7.2.1 Chromatograms of the intracellular arsenic speciation and quantification 
Fig. 56 Chromatograms of the intracellular arsenic speciation and quantification in the soluble 
fractions of (left) HepG2 cells and (right) of T24 cells 
(Hippler et al., 2011) 
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Fig. 57 Chromatograms of the intracellular arsenic speciation and quantification in the non-
soluble fractions of (left) HepG2 cells and (right) T24 cells. 
7.2.2 Data table of genotoxicity 
Tab. 7 Results of the Alkaline Comet Assay with HUEPC cells (30 min of exposure) 
DNA damage caused by MMA(III) was investigated by using the Alkaline Comet Assay after 30 min 
of exposure in HUEPC cells (mean ± standard error). Significance was tested by using the non-
parametric Man Whitney Test with ns = no significant increase, * = p-value 0.05, ** = p-
value 0.01, 
*** = p-value 0.001, ct. = cytotoxic. 
negative control 
0.5 µM 
5 µM 
50 µM 
ENU 0.1 mg / ml 
MMA(III) 
0.748 ± 0.169 
0.896 ± 0.243 ns 
1.486 ± 0.365 * 
2.283 ± 1.406 ct. 
1.996 ± 0.346 ** 
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Tab. 8 Results of the Alkaline Comet Assay with HepG2 cells (30 min of exposure) 
DNA damage caused by inorganic and methylated arsenic compounds was investigated by using 
the Alkaline Comet Assay after 30 min of exposure in HepG2 cells (mean ± standard error). 
Significance was tested by using the non-parametric Man Whitney Test with ns = no significant 
increase, 
* = p-value 0.05, ** = p-value 0.01, *** = p-value 0.001, ct. = cytotoxic. 
negative 
control 
0.1 µM 
0.5 µM 
1 µM 
5 µM 
10 µM 
50 µM 
ENU 
0.1 mg/ml 
As(III) 
0.321 ± 
0.059 
0.346 ± 
0.045 ns 
0.285 ± 
0.045 ns 
0.188 ± 
0.030 ns 
0.304 ± 
0.046 ns 
0.192 ± 
0.017 ns 
0.495 ± 
0.058 ** 
2.034 ± 
0.201 *** 
As(V) 
0.229 ± 
0.035 
0.206 ± 
0.029 ns 
0.360 ± 
0.062 ns 
0.205 ± 
0.024 ns 
0.175 ± 
0.018 ns 
0.200 ± 
0.022 ns 
0.201 ± 
0.023 ns 
2.124 ± 
0.197 *** 
MMA(III) 
0.322 ± 
0.067 
0.256 ± 
0.034 ns 
0.342 ± 
0.067 ns 
0.234 ± 
0.028 ns 
0.330 ± 
0.050 *** 
0.652 ± 
0.066 *** 
0.438 ± 
0.037 *** 
2.088 ± 
0.199 *** 
MMA(V) 
0.207 ± 
0.036 
0.340 ± 
0.050 ** 
0.153 ± 
0.015 ns 
0.192 ± 
0.020 ns 
0.142 ± 
0.014 ns 
0.157 ± 
0.014 ns 
0.144 ± 
0.014 ns 
1.872 ± 
0.208 *** 
DMA(V) 
0.159 ± 
0.016 
0.166 ± 
0.018 ns 
0.125 ± 
0.015 ns 
0.188 ± 
0.020 ns 
0.122 ± 
0.013 ns 
0.152 ± 
0.017 ns 
0.163 ± 
0.020 ns 
1.871 ± 
0.209 *** 
TMAO 
0.299 ± 
0.037 
0.230 ± 
0.032 ns 
0.330 ± 
0.060 * 
0.278 ± 
0.043 ns 
0.346 ± 
0.060 ns 
0.215 ± 
0.028 ns 
0.398 ± 
0.074 ns 
1.912 ± 
0.207 *** 
Tab. 9 Results of the Alkaline Comet Assay with T24 cells (30 min of exposure) 
DNA damage caused by inorganic and methylated arsenic compounds was investigated by using 
the Alkaline Comet Assay after 30 min of exposure caused (mean ± standard error of mean). 
Significance was tested by using the non-parametric Man Whitney Test with ns = no significant 
increase, * = p-value 0.05, 
** = p-value 0.01, *** = p-value 0.001, ct. = cytotoxic, – = not tested. 
negative 
control 
0.001 µM 
0.005 µM 
0.01 µM 
0.05 µM 
0.1 µM 
0.5 µM 
1 µM 
5 µM 
10 µM 
50 µM 
ENU 
0.1 mg/ml 
As(III) 
0.073 ± 
0.009 
0.290 ± 
0.032 *** 
0.272 ± 
0.036 *** 
0.244 ± 
0.033 *** 
0.256 ± 
0.029 *** 
0.423 ± 
0.044 *** 
0.282 ± 
0.027 *** 
0.949 ± 
0.049 *** 
As(V) 
0.093 ± 
0.011 
0.120 ± 
0.016 ns 
0.129 ± 
0.016 ns 
0.142 ± 
0.019 ns 
0.138 ± 
0.016 ns 
0.127 ± 
0.014 ns 
0.344 ± 
0.037 *** 
0.984 ± 
0.041 *** 
MMA(III) 
0.099 ± 
0.010 
0.103 ± 
0.013 ns 
0.154 ± 
0.020 ns 
0.184 ± 
0.025 ns 
0.129 ± 
0.017 ns 
0.255 ± 
0.025 *** 
0.550 ± 
0.037 *** 
1.116 ± 
0.045 *** 
MMA(V) 
0.080 ± 
0.008 
0.104 ± 
0.011 ns 
0.098 ± 
0.011 ns 
0.081 ± 
0.010 ns 
0.084 ± 
0.011 ns 
0.092 ± 
0.010 ns 
0.103 ± 
0.011 ns 
0.932 ± 
0.045 *** 
DMA(III) 
0.231 ± 
0.023 
0.282 ± 
0.025 ns 
0.339 ± 
0.027 *** 
0.357 ± 
0.027 *** 
0.395 ± 
0.024 *** 
0.669 ± 
0.034 *** 
ct. 
ct. 
DMA(V) 
0.085 ± 
0.009 
0.110 ± 
0.011 ns 
0.069 ± 
0.009 ns 
0.085 ± 
0.010 ns 
0.064 ± 
0.008 ns 
0.099 ± 
0.012 ns 
0.090 ± 
0.011 ns 
1.044 ± 
0.039 *** 
TMAO 
0.064 ± 
0.008 
0.091 ± 
0.009 ns 
0.094 ± 
0.011 ns 
0.084 ± 
0.010 ns 
0.084 ± 
0.009 ns 
0.070 ± 
0.009 ns 
0.107 ± 
0.017 ns 
1.267 ± 
0.058 *** 
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Tab. 10 Results of the Alkaline Comet Assay with T24 cells (60 min of exposure) 
DNA damage caused by inorganic and methylated arsenic compounds was investigated by using 
the Alkaline Comet Assay after 60 min of exposure in T24 cells (mean ± standard error). 
Significance was tested by using the non-parametric Man Whitney Test with ns = no significant 
increase, 
* = p-value 0.05, ** = p-value 0.01, *** = p-value 0.001, ct. = cytotoxic, – = not tested. 
negative 
control 
0.001 µM 
0.005 µM 
0.01 µM 
0.05 µM 
0.1 µM 
0.5 µM 
1 µM 
5 µM 
10 µM 
50 µM 
ENU 
0.1 mg/ml 
As(III) 
0.105 ± 
0.011 
0.150 ± 
0.017 ns 
0.181 ± 
0.019 * 
0.187 ± 
0.020 ** 
0.186 ± 
0.017 ** 
0.165 ± 
0.014 ** 
0.182 ± 
0.014 *** 
1.054 ± 
0.047 *** 
As(V) 
0.111 ± 
0.012 
0.169 ± 
0.017 * 
0.158 ± 
0.016 ns 
0.136 ± 
0.018 ns 
0.184 ± 
0.018 ** 
0.179 ± 
0.016 *** 
0.168 ± 
0.015 ** 
0.956 ± 
0.041 *** 
MMA(III) 
0.145 ± 
0.017 
0.133 ± 
0.012 ns 
0.121 ± 
0.011 ns 
0.147 ± 
0.017 ns 
0.132 ± 
0.013 ns 
0.350 ± 
0.038 *** 
0.560 ± 
0.034 *** 
1.236 ± 
0.075 *** 
MMA(V) 
0.106 ± 
0.012 
0.139 ± 
0.014 ns 
0.185 ± 
0.018 *** 
0.156 ± 
0.014 * 
0.116 ± 
0.011 ns 
0.123 ± 
0.015 ns 
0.141 ± 
0.014 ns 
1.199 ± 
0.060 *** 
DMA(III) 
0.158 ± 
0.016 
0.210 ± 
0.019 * 
0.167 ± 
0.017 ns 
0.222 ± 
0.018 ** 
0.559 ± 
0.031 *** 
1.078 ± 
0.189 ct. 
ct. 
ct. 
DMA(V) 
0.130 ± 
0.014 
0.151 ± 
0.014 ns 
0.165 ± 
0.015 * 
0.153 ± 
0.015 ns 
0.155 ± 
0.014 ns 
0.155 ± 
0.015 ns 
0.161 ± 
0.014 ns 
1.311 ± 
0.077 *** 
TMAO 
0.122 ± 
0.015 
0.119 ± 
0.012 ns 
0.105 ± 
0.011 ns 
0.120 ± 
0.011 ns 
0.138 ± 
0.015 ns 
0.124 ± 
0.012 ns 
0.132 ± 
0.014 ns 
1.536 ± 
0.066 *** 
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7.3 Supplementary material 
7.3.1 Curriculum Vitae 
The CV is not included in the online version for reasons of data protection. 
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